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Receptor tyrosine kinases 
Receptor tyrosine kinases (RTKs) are transmembrane proteins that are involved in the 
development and progression of cancer. They consist of an extracellular domain that can 
bind ligands, such as growth factors, cytokines or hormones, and an intracellular kinase 
domain that can activate several intracellular signaling pathways (Figure 1A). RTKs exist 
as inactive monomers and dimerization of two receptors is required for signaling activity. 
Upon binding of a ligand, the conformation of the receptor changes and dimerization 
can occur between two molecules of the same receptor (homodimerization) or between 
two different receptors (heterodimerization). After dimerization, the cytoplasmic kinase 
domain of the receptor becomes phosphorylated which will result in the recruitment 
of different intracellular signaling molecules. Subsequently, signaling pathways that are 
involved in tumor cell proliferation, differentiation, motility, and apoptosis will become 
activated.(1-4) 
Figure 1. A: schematic view of a RTK. B: Schematic view of different ways to inhibit RTKs.
Signaling through RTKs can be inhibited in several ways (Figure 1B). First of all, monoclonal 
antibodies (mAbs) can bind ligands, thereby preventing them from activating the receptor. 
Second, mAbs can be directed against the extracellular domain of the receptor (ligand 
binding site or the dimerization site), thereby hindering ligand binding and/or dimerization 
and subsequent activation. Finally, small molecules (tyrosine kinase inhibitors (TKIs)) can 
be used to target the intracellular domain of RTKs. They prevent the phosphorylation of 
the tyrosine residues and subsequent activation of signaling pathways. Currently, several 
mAbs and TKIs targeting RTKs are being used to treat cancer patients.(1-4) 
RTKs can be classified into 20 subfamilies, which contain a total of 58 different RTKs.(5) 
The most well known are the epidermal growth factor receptor (EGFR or ERBB), fibroblast 
growth factor receptor (FGFR), insulin-like growth factor receptor (IGFR and IR), platelet-
derived growth factor receptor (PDGFR) and the vascular endothelial growth factor 
receptor (VEGFR) family. In this thesis we will focus on the IGFR, EGFR, and VEGFR families 
(Table 1). 
IGFR family
The IGFR family consists of three receptors: IGF-1R, IGF-2R and IR. Of these receptors, 
A B
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IGF-1R plays the most prominent role in cancer development and progression. IGF-1R 
is expressed on many different cancer types, including breast cancer, colorectal cancer, 
prostate cancer, and sarcomas. It is involved in proliferation, apoptosis, angiogenesis and, 
tumor invasion. Upon binding of the growth factors IGF-1 and IGF-2, the MAPK and PI3K/
AKT pathway become activated.(2) Furthermore, IGF-1R induces hypoxia-inducible factor 
1α (HIF-1α) protein synthesis, which induces expression of vascular endothelial growth 
factor (VEGF), a central mediator of angiogenesis.(6) In addition, data suggest that IGF-
1R expression may be related to resistance to cytotoxic, anti-estrogen, HER2, and EGFR-
targeted therapy.(7-10) 
Table 1. Overview of receptor tyrosine kinases (RTKs)
Receptor 
family
Receptor 
members
Ligands Kinase activity Examples of therapeutic 
agents
IGFR (2) IR IGF-2, insulin Active kinase BMS-754807
IGF-1R IGF-1, IGF-2 Active kinase R1507, figitumumab, 
AMG479, BMS-754807
IGF-2R IGF-2 No kinase activity None
EGFR (4) EGFR (HER1) AR, EGF, TGFα, 
EPGN, EPR, 
BTC, HBEGF
Active kinase Cetuximab, 
panitumumab, erlotinib, 
gefitinib, lapatinib
ERBB2 
(HER2)
Unknown Active kinase Trastuzumab, 
pertuzumab, lapatinib
ERBB3 
(HER3)
NRG1 and 
NRG2
No kinase activity AMG888, MM-121, 
pertuzumab, AZD8931, 
lapatinib
ERBB4 
(HER4)
NRG1, NRG2, 
NRG3, NRG4, 
HBEGF, BTC, 
EPR
Active kinase lapatinib
VEGFR (11) VEGFR1 PlGF, VEGF-A 
VEGF-B
Little kinase activity Sorafenib, sunitinib, 
bevacizumab (anti-
VEGF-A)
VEGFR2 VEGF-A, 
VEGF-C, 
VEGF-D
Active kinase Sorafenib, sunitinib, 
bevacizumab (anti-
VEGF-A)
VEGFR3 VEGF-C, 
VEGF-D
Active kinase Sorafenib, sunitinib
AR, amphiregulin; EGF, epidermal growth factor; TGFα, transforming growth factor-α; EPGN, epigen; EPR, 
epiregulin; BTC, β-cellulin; HBEGF, heparin-binding EGF-like growth factor; NRG, neuregulin; IGF, insulin-like 
growth factor; PlGF, placenta growth factor
Phase I/II studies with anti-IGF-1R antibodies have shown the safety and tolerability of 
targeting IGF-1R. Furthermore, these studies demonstrated a wide range of responses, 
from progressive disease to near complete response.(12-14) Although these results 
seemed promising, larger randomized phase III trials failed to show a clear benefit from 
targeting IGF-1R in combination with conventional treatment strategies.(15-17) However, 
these trials were conducted in unselected patient populations. Since early phase trials 
have shown meaningful single-agent responses, it is of importance to be able to identify 
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those patient that potentially benefit from IGF-1R targeted therapy. This selection may 
be based on receptor expression since in vitro studies have shown that expression is 
necessary for antitumor activity of anti-IGF-1R antibodies.(18, 19)
EGFR family
The EGFR family consists of four receptors: EGFR, HER2, HER3 and HER4. Of these 
receptors, EGFR and HER2 are most widely studied for their role in cancer. Dimerization 
of HER2 or EGFR leads to activation of several downstream pathways, including PI3K-AKT 
and MAPK, resulting in increased tumor cell proliferation, migration and survival.(1, 4) 
HER2 is overexpressed in 20-30% of all breast carcinomas and in subsets of ovarian, lung, 
prostate, gastric, and esophageal cancers. Breast cancers that overexpress HER2 have 
been associated with aggressive tumor growth, high relapse rate and poor prognosis.(20) 
Furthermore, HER2 overexpressing tumors may be more resistant to endocrine therapy 
and chemotherapy.(21) Different therapeutic strategies have been developed to target 
HER2, including the mAb trastuzumab. Trastuzumab significantly improves survival of 
patients with HER2-positive advanced breast and gastric cancer, when combined with 
chemotherapy.(22-24) Next to HER2, several agents have been developed to target EGFR. 
For example, the mAb cetuximab is currently approved to treat patients with metastatic 
colorectal cancer and head and neck cancer.(25, 26) 
VEGFR family
The VEGFR family plays an important role in angiogenesis. Angiogenesis is defined as the 
growth of new blood vessels from pre-existing vessels and is an essential process if solid 
tumors are to grow beyond a few millimeters. It is an important target for cancer treatment. 
VEGF is a key mediator of angiogenesis and its function can be inhibited by the mAb 
bevacizumab. Targeting of VEGF affects tumor growth by several mechanisms, including 
inhibition of new vessel growth and induction of endothelial cell apoptosis. Moreover, it 
affects vessel function by inducing vasoconstriction and vessel normalization.(11, 27-29) 
Bevacizumab has been approved for treatment of metastatic colorectal cancer, metastatic 
renal cell carcinoma, glioblastoma, and non-small cell lung cancer.(30-34) 
Outline of thesis
Although numerous antibodies have been developed that target RTKs, the efficacy of 
these agents as monotherapy is often limited and it is difficult to predict on beforehand 
which patients will benefit from treatment. To optimize the use of mAbs for cancer 
therapy, accurate methods for patient selection and response monitoring are required to 
maximize the chances for effective treatment and to minimize the exposure of patients to 
ineffective treatment, with its associated unwanted side effects and financial burden to the 
health care system. Furthermore, a combination of the different antibodies may be used 
to further improve survival of cancer patients. Finding a rational to choose a particular 
combination of antibodies remains difficult. In addition, timing and sequencing of the 
different agents may be important, if not crucial. This thesis describes the development 
of new radiotracers that may have potential for patient selection. Furthermore, these 
radiotracers were used to study how different therapeutic agents interact and affect each 
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other’s tumor targeting. 
The first part of this thesis describes the development and characterization of new 
radiotracers to image IGF-1R expression in breast cancer. In chapter 3, the humanized 
mAb R1507, which is directed against the extracellular domain of IGF-1R, was radiolabeled 
indium-111 (111In) and zirconium-89  (89Zr). Both tracers could successfully visualize IGF-1R 
expressing breast cancer xenografts with immunoSPECT and immunoPET, respectively. 
In chapter 4 this imaging method was improved by using radiolabeled R1507 F(ab’)2 
fragments that allowed faster tumor targeting and revealed improved tumor-blood ratios. 
In chapter 5 and 6 the dynamics of IGF-1R expression during conventional breast cancer 
treatment were studied. In addition, the dynamics of IGF-1R expression of breast cancer 
xenografts were monitored by 111In-R1507 immunoSPECT. 
Chapter 7 describes the development of a new radiotracer to image HER2 expression. 
For this purpose, Affibody molecules directed against HER2 were radiolabeled with 
fluorine-18 (18F) using the novel Al18F technology. This tracer showed to be a promising 
new imaging agent for HER2-expressing tumors. 
Chapter 8 and 9 focus on the combination of bevacizumab and cetuximab treatment. 
Bevacizumab treatment significantly reduced the tumor targeting of anti-EGFR and anti-
IGF-1R antibodies, while cetuximab reduced the targeting of bevacizumab to tumors. 
Finally, the results obtained in these studies and the future perspectives are discussed in 
chapter 10. 
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Abstract
Breast cancer is a heterogeneous disease that can be subdivided into different groups, 
based on gene expression profiles or clinicopathological characteristics such as estrogen 
receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 
(HER2) expression. The expression of these receptors has both prognostic and predictive 
value. To improve breast cancer treatment, accurate methods for patient selection and 
response monitoring are required. One way to achieve this is by using molecular imaging, 
which can be used to measure the expression and accessibility of tumor-associated 
antigens in vivo, without the need of invasive biopsies. This review will focus on tumor-
receptor imaging for currently approved targeted therapies and discuss the potential 
role of molecular imaging in the development of new therapeutic agents in breast 
cancer. Progress has been made in radionuclide imaging of ER, PR, HER2 and epidermal 
growth factor receptor (EGFR) expression, which can be used for treatment selection and 
response prediction to endocrine and other targeted therapy. Moreover, clinical studies 
have shown the feasibility for molecular imaging of the angiogenic pathway exploiting 
the expression of antigens closely associated with angiogenesis, such as αvβ3 and VEGF. 
As proof of concept has been established, further research should be directed towards 
validation of the imaging methods and the impact on patient management.
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Introduction
Breast cancer is a heterogeneous disease that can be subdivided into different groups, 
based on gene expression profiles or clinicopathological characteristics such as ER, PR 
and HER2 expression. The expression of these receptors has prognostic value and can be 
used to predict response to treatment. For example, patients with ER positive tumors have 
a more favorable prognosis, and tumor growth can be inhibited effectively by endocrine 
treatment.(1) On the other hand, patients with triple negative breast tumors have a 
reduced survival rate and do not benefit from the currently available targeted therapies.
(2)
To improve the treatment of breast cancer with new targeted therapies, accurate methods 
for patient selection and response monitoring are required. This can be achieved by 
molecular imaging techniques. These techniques aim to visualize, characterize and 
measure biological processes at the molecular and cellular level in living subjects.(3) 
Molecular imaging overcomes some of the drawbacks of histopathological evaluation such 
as sampling errors in heterogeneous tumors and heterogeneous expression in multiple 
metastases in a single individual. Furthermore, it depicts the accessibility for targeting 
agents to interact with specific receptors on tumor cells. Several types of molecular 
imaging have been used, including ultrasound, magnetic resonance imaging (MRI), optical 
imaging, computed tomography (CT), and radionuclide imaging with positron emission 
tomography (PET) or single photon emission computed tomography (SPECT). This review 
is restricted to radionuclide imaging of breast cancer. The most commonly used PET tracer 
is [18F]fluorodeoxyglucose (FDG), which measures glucose metabolism and can be used 
for diagnosis, staging and monitoring of therapy response in breast cancer. The value of 
FDG-PET in breast cancer patients has been reviewed extensively elsewhere.(4, 5) This 
paper will focus on specific receptor imaging for currently approved targeted therapies 
in breast cancer patients and will discuss the potential role of molecular imaging in the 
development of new therapeutic agents. 
Tumor-receptor imaging for patient selection
Patient selection for targeted therapy is often based on receptor expression, for example 
endocrine therapy for ER positive tumors and trastuzumab for HER2 overexpressing 
tumors. In current clinical practice, expression of these receptors is determined on 
sections of tumor biopsies by immunohistochemical staining of protein expression or 
fluorescence in situ hybridization of mRNA expression. Receptor expression can also be 
measured in vivo with PET or SPECT using radiolabeled tracers with high affinity for these 
tumor-associated receptors. Molecular imaging techniques have several advantages. First, 
they allow measurement of receptor expression of whole tumors and their metastases, 
thereby avoiding misinterpretation due to intratumoral and interlesional heterogeneity. 
Second, such an imaging method allows monitoring of expression during the course of 
disease, without the need for repeated invasive biopsies. This is of clinical importance since 
receptor expression can change during the course of disease, due to disease progression 
and the effects of treatment. Third, in vivo imaging techniques also take accessibility of 
the target into account. Several factors may influence whether therapeutic agents will 
reach the tumor cells, such as blood vessel density, vascular permeability and intratumoral 
interstitial fluid pressure.(6, 7) If target accessibility is low, therapeutic agents cannot reach 
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the tumor and may be unexpectedly ineffective despite adequate expression of receptors 
on the tumor cells as determined by immunohistochemistry. 
Tumor-receptor imaging for response monitoring
In vivo imaging techniques can be used to identify responders and non-responders early 
after initiation of treatment, thereby minimizing adverse effects and treatment costs. 
Moreover, non-responders can be switched to a treatment more likely to be beneficial. 
One mechanism of action of therapeutic agents is binding and subsequent internalization 
and degradation of the receptor-ligand complex.(8, 9) Changes in receptor expression 
can therefore be used for early response monitoring. For example, changes in HER2 
expression during trastuzumab treatment of breast cancer xenografts can be measured 
non-invasively with radiolabeled anti-HER2 Affibody molecules.(10) Evaluating receptor 
down regulation with immunohistochemistry is cumbersome due to the need to take 
repeated biopsies, while in vivo imaging allows the noninvasive monitoring of receptor 
expression at multiple time points during the course of therapy. For this purpose, it is 
important to consider that the therapeutic agent itself cannot be used for response 
monitoring during therapy, because of the direct competitive effect of the treatment drug 
and the radiotracer for the same receptor binding site. Therefore, radiotracers are needed 
that recognize a distinct epitope on the receptor of interest (Figure 1).
Figure 1. Schematic overview of the competition between a radiotracer and therapeutic agent itself. A: 
Radiolabeled therapeutic antibodies target the receptor tyrosine kinase (RTK) expressed on the tumor cell 
membrane. B: The therapeutic dose of the unlabeled antibody has bound to the RTK and prevents binding of 
the radiolabeled antibody. C: A radiotracer recognizing a distinct epitope on the same RTK can still bind and can 
be used to image RTK expression with PET or SPECT. 
Tumor-receptor imaging and therapy resistance
Ultimately, most tumors will develop resistance to targeted therapy. One of the 
proposed mechanisms behind this process is upregulation of growth factor receptors. 
For example, trastuzumab resistance may emerge due to EGFR or HER3 upregulation 
and, subsequently, tumor cells may no longer depend on HER2 signaling for tumor 
cell proliferation.(11) Upregulation of these receptors can be measured by molecular 
imaging techniques and these upregulated receptors may be identified as new 
targets for further systemic treatment. In this way, molecular imaging may provide 
a rationale for the combination of a particular set of therapeutic agents, or a specific 
timing and sequence of different types of targeted agents in individual patients. 
Tumor-receptor imaging in clinical trials
In drug development there is a great need for biomarkers that can be used to monitor 
and predict response to new drugs. Tumor-receptor imaging can play an important 
A B C
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role in treatment with so-called targeted agents. For example, radiolabeled therapeutic 
antibodies, drugs such as taxanes or even tyrosine kinase inhibitors can be used to non-
invasively determine receptor expression and target accessibility of all tumor lesions. This 
may allow tailored patient selection for specific clinical trials. In addition, radiolabeled 
therapeutics can provide information about the pharmacokinetics, optimal dosing 
for tumor targeting and targeting of critical normal organs. This can be used to further 
optimize the dosing and timing of targeted treatment. Finally, tumor-receptor imaging 
can be used to identify responders and non-responders early after start of therapy.
Receptor imaging for approved targeted therapies
ER
In approximately 75% of all breast cancer patients, the tumors are hormone receptor 
positive.(12) The classical mechanism of ER activation involves direct binding of estrogen 
to ER, resulting in interaction with DNA to regulate transcription of genes involved in cell 
proliferation, apoptosis, migration and invasion. Estrogen can also bind ER located in 
extranuclear sites, such as the plasma membrane, where ER can directly activate growth 
factor receptors such as IGF-1R and HER2.(13)
Two classes of ER targeting agents are approved for treatment of patients with ER-positive 
breast cancer: classical anti-estrogens (e.g. tamoxifen en fulvestrant), which directly block 
ER activity in tumor cells, and aromatase inhibitors (e.g. anastrozole and letrozole), which 
inhibit the production of estradiol through the aromatase enzyme pathway. Hormone 
receptor expression is the most powerful predictor for response to endocrine therapy.(1) 
Currently, ER expression is routinely determined immunohistochemically in each newly 
diagnosed and recurrent breast cancer. However, up to 20% of all ER estimations may 
be inaccurate.(14) Furthermore, ER expression can be heterogeneous within a tumor and 
may very well change during the course of disease, particularly during tumor progression. 
Discordance in ER expression between the primary tumor and metastatic lesion has been 
described in several studies and ranges from 10 – 35%.(15-17) Therefore, a single biopsy 
may provide an incomplete assessment of ER expression. 
In vivo imaging methods have been developed to avoid misclassification of ER status due 
to intratumor and interlesional heterogeneity. The most widely studied PET tracer for in 
vivo imaging of ER expression is 16-α-[18F] fluoro-17-β-estradiol (18F-FES). This radiotracer 
was first reported in 1984 and has since been used in several preclinical and clinical 
imaging studies (Table 1).(18) 18F-FES has binding characteristics similar to estradiol and 
can be used to measure ER expression in vivo. 
18F-FES PET can visualize ER expression in primary and metastatic breast cancer (Figure 
2). The uptake of this tracer in tumor lesions correlates strongly with ER expression as 
measured by immunohistochemistry; the overall agreement between 18F-FES uptake and 
ER status is approximately 90%.(19-21, 25) Furthermore, 18F-FES PET is a sensitive method 
to identify heterogeneous ER expression, such as loss of ER expression at metastatic 
sites.(20, 24) Several groups have shown that 18F-FES uptake is predictive for response to 
endocrine therapy. 
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Table 1. Overview of clinical imaging studies
Target Tracer Patients (total number of patients) Refe-
rences
ER 18F-FES Primary and metastatic breast cancer 
(n=413)
(19-28)
Z-123I-MIVE Primary and metastatic breast cancer 
(n=72)
(29-32)
PR 18F-FENP and 18F-FFNP Primary breast cancer (n = 29) (33, 34)
HER2 111In- and 89Zr-
trastuzumab
Metastatic breast cancer and other 
malignancies (n=67)
(35-39)
111In- and 68Ga-ABY-002 Recurrent breast cancer (n=3) (40)
EGFR 111In-anti-EGFR-425 Glioma (n=28) (41)
111C-PD153035 and 
111C-erlotinib
Non-small cell lung cancer (n=35) (42-44)
Angiogenesis
    αvβ3
18F-galacto-RGD Various malignancies (n=104) (45-51)
99mTc-NC100692 Primary and metastatic breast cancer 
and metastatic lung cancer (n=41)
(52, 53)
18F-AH111585 Metastatic breast cancer (n=7) (54)
99mTc-3P4-RGD2 Solitary pulmonary nodules (n=21) (55)
    VEGF/VEGFR 123I-VEGF165 Gastrointestinal tumors (n=18) (56)
111In-bevacizumab Various malignancies (n=35) (57-59)
    ED-B domain
    fibronectin 
123I-L19(scFv)2 Various malignancies (n=20) (60)
Baseline 18F-FES uptake was higher in patients that responded to endocrine therapy 
and low or absent 18F-FES uptake predicted lack of response.(22-24, 26) Mortimer et 
al. have shown that the mean baseline standardized uptake value (SUV) of 18F-FES was 
significantly higher in patients that responded to tamoxifen treatment (SUV: 4.3 ± 2.4, n 
= 21) compared with non-responders (SUV: 1.8 ± 1.4, n = 19). The corresponding positive 
and negative predictive values (PPV and NPV) for response to tamoxifen using baseline 
18F-FES uptake (cut-off value SUV ≥ 2) were 79% and 88%, respectively.(23) In a second 
study the PPV and NPV for response to aromatase inhibitors and fulvestrant have been 
determined using the same cut-off value SUV ≥ 2. The PPV and NPV were only 50% (12 
of 24 patients responded) and 81% (5 of 27 patients responded). Of the 16 patients with 
a very low baseline 18F-FES uptake (SUV < 1.0), 15 patients did not respond to aromatase 
inhibitors.(26) The lower PPV and NPV found in this study may be explained by different 
patient populations. In the first study none of the patients received endocrine therapy 
before entering the study, while in the second study, 75% of the patients received prior 
endocrine therapy. Unfortunately, the NPVs of 18F-FES PET reported in these studies is not 
sufficiently high to deny patients at least temporary treatment with a potentially effective 
and cheap drug that does not exhibit major side effects.
Several studies have investigated the potential of 18F-FES PET for early response monitoring 
and have shown that endocrine therapy can cause a significant decrease in 18F-FES uptake 
(19, 22, 23, 27) Moreover, the degree of ER blockade (i.e. decrease in 18F-FES uptake) was 
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significantly higher in responders than non-responders.(22, 23) For example, Mortimer et 
al. have shown that 7 to 10 days after initiation of tamoxifen treatment the percentage 
decrease in SUV was 55% ± 14% for responders (n = 21), while the decrease was only 19% 
± 17% in non-responders (n = 19) (23). Linden et al. have used 18F-FES PET to study the 
pharmacodynamics of different types of endocrine therapy. They showed that receptor 
blocking agents (tamoxifen (n=5) and fulvestrant (n = 11)) induced a larger reduction in 
18F-FES uptake than aromatase inhibitors (n = 14). Moreover, receptor blockade was more 
complete with tamoxifen than with fulvestrant. These results show that 18F-FES PET can 
be used to measure the activity of different types endocrine therapy in vivo. However, the 
authors did not determine whether a larger reduction in 18F-FES uptake was also clinically 
relevant.(27)
Figure 2. Example of 18F-FES PET. A: Bonescan of patient showing suggestive lesion at L2 (arrowhead). Biopsy 
of this lesion did not show malignancy. B: Coronal and C: Sagittal images of 18F-FES PET showing 18F-FES uptake 
in vertebra L2 and multiple other bone metastases (arrowheads), as well as large locoregional recurrence in soft 
tissue (arrow). Only most intense lesions are  indicated (reprinted with permission) (28).
Recently, a study was published that assessed the value of 18F-FES PET in breast cancer 
patients presenting with a clinical dilemma despite complete standard work-up.(28) 
In total, 33 patients were referred for 18F-FES PET to evaluate 1) equivocal lesions on 
conventional work-up, 2) ER status in metastatic patients and 3) the origin of metastases. 
18F-FES PET was especially sensitive for the detection of bone metastases, while 
visualization of liver metastases was hampered by high physiologic background. 18F-FES 
PET improved diagnostic understanding in 88% of the patients and led to a therapy 
change in 48% of the patients. Therapy changes included initiation of endocrine therapy 
A B C
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instead of chemotherapy or wait-and-see policy, initiation of radiotherapy, administration 
of bisphosphonates, initiation of new line endocrine therapy and discontinuation of 
endocrine therapy or radiotherapy. This study showed that 18F-FES PET may be a valuable 
additional diagnostic tool when standard work-up is inconclusive and biopsies are not 
feasible. 
A second ER ligand used for molecular imaging of ER expression is Iodine-123 (123I)-labeled 
cis-11β-methoxy-17α-iodovinylestradiol (Z-123I-MIVE). Early studies have shown that it 
is feasible to visualize ER expressing tumors using Z-123I-MIVE for scintigraphic imaging 
and that uptake correlates with immunohistochemical analysis of ER expression (rate 
of agreement 82-100%).(29-31) Moreover, Rijks et al. have shown that 3 to 6 weeks of 
tamoxifen treatment almost completely blocked the tumor uptake of Z-123I-MIVE in 7 out 
of 9 patients (decrease tumor uptake 89% ± 10%). In 2 patients, tumor uptake increased 
by 50% and 400% and subsequent evaluation demonstrated progressive disease in both 
cases.(29) A larger study in 21 patients with primary breast cancer showed that tamoxifen 
treatment (3 to 8 weeks) caused complete blockade of Z-123I-MIVE tumor uptake in 17 
out of 21 patients, while 4 patients showed remaining or unchanged tumor uptake. 
The progression-free survival of patients showing complete receptor blockade was 
significantly longer (14 ± 2 months) compared with the other patients (2 ± 1 months).(32)
In summary, both ER ligands 18F-FES and Z-123I-MIVE have a high sensitivity and low or no 
false positivity for the detection of ER-positive breast cancer. Moreover, clinical studies 
have shown that both tracers can be used to predict and evaluate response to endocrine 
therapy and might be used to select patients for ER targeted therapy. However, it should 
be taken into account that the side effects of endocrine therapy are only modest and 
overtreatment might not be a clinically significant burden for the patient. Nevertheless, 
if non-responding patients can be identified early after start of treatment they can be 
switched to treatment from which they are more likely to benefit. A disadvantage of both 
radiotracers is the hepatic clearance, resulting in accumulation in liver, gall bladder and 
intestines. This limits the visualization of tumor lesions in these organs, while uptake 
in other tissue such as bone, lung and lymph nodes is not hampered.(28, 61) The main 
advantage of 18F-FES compared to Z-123I-MIVE is the higher resolution and sensitivity 
of PET, which allows the detection of small tumors. In addition, quantification is more 
accurate. On the other hand, the cost to develop SPECT tracers such as  Z-123I-MIVE are 
much lower and SPECT is more widely available than PET (Table 2). 
PR
The expression of PR is associated with ER.(62, 63) Over 50% of all ER-positive tumors 
express PR, while PR expression in ER-negative tumors is generally low.(64) It is unclear 
whether PR expression is an independent predictor for response to endocrine therapy. A 
large study reported that PR expression predicts response to adjuvant endocrine therapy, 
independent of ER expression,(65) while this was not confirmed in a meta-analysis.(1, 65) 
Although the precise role of PR in the management of breast cancer is still unclear, current 
guidelines recommend to routinely determine PR expression.(14)
To date, the development of radiotracers for PR has been less successful than for ER. 21-
[18F]fluoro-16-α-ethyl-19-norprogresterone ([18F]-FENP) is an example of a radiotracer 
used for PR imaging. However, progestins such as 18F-FENP have a relatively low affinity for 
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PR, and uptake in the tumor did not correlate with the level of PR expression. In humans, 
18F-FENP failed to visualize PR expressing tumors, probably due to the rapid clearance 
and degradation of the compound.(33, 66) Preclinical and clinical research to develop a 
suitable radiotracer for PR imaging is still ongoing. Recently, Dedashti et al. have tested a 
new tracer, 21-18F-fluoro-16a,17a-[(R)-(19-a-furylmethylidene)dioxy]-19-norpregn-4-ene-
3,20-dione (18F-FFNP), in breast cancer patients.(34, 67, 68) They reported a significant 
correlation between tumor/normal tissue ratio and PR status. However, no significant 
association was found between tumor SUVmax  and PR status. This may indicate that tumor 
uptake needs to be corrected for non-specific uptake in the contralateral breast. Further 
characterization of the specific and nonspecific uptake of this tracer is required.(34)
Table 2. The advantages and disadvantages of SPECT versus PET.
Advantages Disadvantages
PET •	 Higher resolution
•	 Higher sensitivity
•	 More accurate quantification
•	 High costs of tracer development
•	 More advanced radiolabeling
SPECT •	 Lower cost of tracer development
•	 Detection of multiple probes at the 
same time
•	 More widely available 
•	 Longer half-lives of isotopes
•	 Lower resolution
•	 Lower sensitivity
•	 Quantification more challenging 
(attenuation correction)
HER2
Human epidermal growth factor receptor 2 (HER2) is a member of the epidermal growth 
factor receptor (EGFR) family. Dimerization of HER2 with other members of the EGFR 
family leads to activation of several downstream pathways, including PI3K-AKT and 
MAPK, resulting in increased tumor cell proliferation, migration and survival.(69) HER2 
is overexpressed in 20-30% of all breast carcinomas and in subsets of ovarian, lung, 
prostate, gastric, and esophageal cancers.(70) Breast cancers that overexpress HER2 have 
been associated with aggressive tumor growth, high relapse rate and poor prognosis.
(70) Furthermore, HER2 overexpressing tumors may be more resistant to endocrine- and 
chemotherapy.(71)
Different therapeutic strategies have been developed to target HER2, including the 
monoclonal antibody trastuzumab and tyrosine kinase inhibitor lapatinib. Trastuzumab 
significantly improves survival of patients with HER2-positive advanced breast and gastric 
cancer, when combined with chemotherapy.(72-74) Lapatinib targets the intracellular 
domain of both HER2 and EGFR. The addition of lapatinib to capecitabine prolongs 
progression free survival of patients with advanced HER2-positive breast cancer.(75)
Currently, trastuzumab and lapatinib treatment are recommended only for the subgroup 
of breast cancer patients with HER2 overexpressing tumors.(76) Therefore, accurate 
assessment of HER2 expression is essential for appropriate patient selection. In current 
clinical practice, HER2 expression is determined on tumor biopsies by immunohistochemical 
staining of HER2 protein expression or fluorescence in situ hybridization (FISH) of HER2 
mRNA expression. Up to 20% of the current HER2 assessments may be inaccurate.(77, 78)
Furthermore, HER2 expression can differ between the primary tumor and metastases.(79, 
80) Therefore, in vivo imaging of HER2 expression may result in more accurate detection 
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of HER2 expression and would allow the monitoring of HER2 expression during the course 
of disease, without the need for repetitive invasive biopsies. 
Several approaches for in vivo imaging of HER2 expression have been developed, 
including radiolabeled antibodies, antibody fragments, Affibody molecules, diabodies, 
minibodies and peptides. For example, Indium-111 (111In)-labeled trastuzumab 
specifically accumulated in HER2-expressing breast tumors. Perik et al. have performed 
111In-trastuzumab SPECT in 15 patients with metastatic breast cancer diagnosed with a 
HER2 positive primary tumor. They showed that 45% of all known tumor lesions, detected 
by routine imaging techniques, were visualized and in 13 out of 15 patients new tumor 
lesions were identified.(36) More recently, trastuzumab was radiolabeled with the 
positron emitting radionuclide Zirconium-89 (89Zr). Fourteen patients with HER2 positive 
metastatic breast cancer underwent immunoPET imaging. Although the study was not 
designed as a head-to-head comparison with conventional staging modalities (CT, MRI 
and bone scans), the majority of tumor lesions were identified with 89Zr-trastuzumab PET. 
Furthermore, 89Zr-trastuzumab PET showed a high spatial resolution and good signal-to-
noise ratios, resulting in superior image quality compared with 111In-trastuzumab SPECT.
(36, 37, 39) Although most tumors lesions were visualized with 89Zr-trastuzumab PET, still 
in half of the patients, PET scans showed no uptake in one or more tumors lesions that were 
previously identified with conventional imaging. Future studies will have to determine 
not only the reason why these lesions were not visualized, but also the relevance of these 
findings. A potential explanation may be lack of HER2 expression of these metastatic 
lesions. Although all patients were diagnosed with at least one HER2-positive lesion, 
this was not evaluated for all tumor lesions since this would require multiple invasive 
biopsies.(79, 80) Other potential explanations may be that scans were performed under 
suboptimal imaging conditions and dosing, and timing or spatial resolution needs to be 
improved. Especially dosing plays an important role in HER2 imaging. Low doses (10 mg) 
of 89Zr-trastuzumab resulted in high accumulation in the liver and a pronounced intestinal 
excretion. As a result, 89Zr-trastuzumab cleared rapidly from blood, resulting in low tumor 
uptake. Higher doses of 89Zr-trastuzumab (50 mg) resulted in lower hepatic uptake and 
enhanced tumor targeting. The exact mechanism of this dose-dependent clearance and 
tumor targeting is unknown. A possible explanation may be the presence of high plasma 
levels of extracellular domains shed by HER2. After binding of trastuzumab to these 
domains, the complex is cleared via the liver and can no longer bind HER2 expressed on 
tumor lesions.(81)
A potential side effect of trastuzumab is cardiotoxicity, especially when combined with 
anthracyclines.(74) In a preliminary report, Behr et al. suggested that pretreatment 
scanning with a tracer dose of radiolabeled trastuzumab can predict cardiotoxicity. Seven 
women out of 20 women had scintigraphic evidence of cardiac uptake and 6 of them 
subsequently developed cardioxicity.(35) However, a second study in fifteen patients 
failed to confirm that cardiac uptake of radiolabeled trastuzumab was of value to predict 
trastuzumab-related cardiotoxicity.(36)
A disadvantage of trastuzumab-based tracers is that they cannot be used to monitor 
changes in HER2 expression during trastuzumab treatment, as the therapeutic doses of 
the unlabeled antibody compete with the tracer molecule for the same epitope on HER2. 
McLarty et al. have radiolabeled pertuzumab, a HER2 dimerization inhibitor that does 
not compete with trastuzumab for binding HER2, to monitor HER2 expression during 
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trastuzumab treatment in mice bearing breast cancer xenografts.(82) They showed that 
111In-pertuzumab SPECT was a sensitive method to detect early HER2 downregulation 
during trastuzumab therapy, suggesting that this technique has potential for early 
response monitoring during HER2-targeted treatment. 
Although studies with the antibodies trastuzumab and pertuzumab have shown 
encouraging results, their long circulatory half-life intrinsically results in slow tumor 
accumulation and slow clearance from the background. Therefore, other approaches 
to image HER2 expression have been considered. Trastuzumab F(ab’)2 fragments were 
produced and radiolabeled with Gallium-68 (68Ga). Since F(ab’)2 fragments are smaller 
and lack the Fc domain (CH2 – CH3 domain), they are eliminated more rapidly from the 
circulation. This results in higher tumor-to-normal tissue contrast and imaging is possible 
at several hours after injection, compared to several days for intact antibodies (Table 3). 
In mice bearing breast cancer xenografts, 68Ga-trastuzumab F(ab’)2 PET has been shown 
to be a sensitive method to monitor changes in HER2 expression during treatment with 
Hsp90 inhibitors.(83) However, a clinical study failed to show the feasibility to image HER2 
expression with 68Ga-trastuzumab F(ab’)2 in patients with HER2-positive metastatic breast 
cancer. Only in 3 out of 7 patients, one or more tumors lesions were visualized using 68Ga-
trastuzumab F(ab’)2 PET. Moreover, all patients had multiple other lesions identified by 
conventional imaging methods that were not visualized with 68Ga-trastuzumab F(ab’)2 
PET. The reason for this insensitivity is unknown.(84)
A new class of targeting agents are Affibody molecules. These 
are based on a 58-amino-acid (7 kDa) scaffold and can be 
selected to bind with high affinity to various tumor-associated 
antigens. Their small size allows rapid extravasation in tumors 
and rapid clearance from the blood, resulting in high-contrast 
imaging within several hours after injection.(10, 85-88) The 
HER2-targeting Affibody molecule ZHER2:342 and its derivates 
have been radiolabeled with several radionuclides and have 
shown specific targeting of HER2-expressing tumors (Figure 
3). Previous studies in xenograft models have shown that the 
Affibody molecule 111In-ZHER2:2395 can discriminate between 
tumors with high and low HER2 expression.(88) Moreover, 
Affibody molecules bind to a different domain of HER2 than 
trastuzumab and can therefore be used to measure HER2 
expression during trastuzumab therapy. Kramer-Marek et al. 
have shown that tumor targeting of 18F-labeled ZHER2:342 was 
reduced during trastuzumab treatment and this correlated 
with tumor response and downregulation of HER2 expression 
measured by immunohistochemistry.(10) These results 
suggest that 18F-labeled ZHER2:342 can be used to monitor 
response to trastuzumab therapy. 
The potential of radiolabeled Affibody molecules to image 
HER2 expressing tumors has also been demonstrated in a 
clinical pilot study in 3 patients who received 111In- and 68Ga-
ABY-002.(40) The rapid kinetics of ABY-002 enabled high-
contrast SPECT or PET to be performed as early as 2 to 3 hours 
Figure 3. PET/CT of a mice 
with a subcutaneous HER2-
expressing xenograft 4 hours 
after injection of18F-labeled 
ZHER2:2395 (reprinted with 
permission) (87).
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after injection. Adequate imaging results were obtained even in a patient that was on 
trastuzumab treatment and in the presence of circulating shed HER2. Future clinical 
studies are needed in larger patient populations to determine the sensitivity, specificity 
and optimal imaging conditions (e.g. timing, peptide dose and radioactivity dose) of 
radiolabeled ABY-002.
In conclusion, a series of radiotracers have been developed for in vivo imaging of HER2 
expression and several clinical studies have shown their feasibility in patients. However, 
the reasons for nonvisualization of tumor lesions has to be resolved. Whether this is 
caused by heterogeneous HER2 expression or by suboptimal imaging conditions (such 
as dosing, timing and uptake in normal organs) needs to be investigated. Moreover, no 
clinical studies have been performed yet to study whether tumor uptake of radiotracers 
is predictive for response to HER2 targeted therapy or has a prognostic value. If these 
radiotracers are further characterized, they may be used to improve diagnosis and 
staging, especially in patients with lesions difficult to biopsy. Moreover, HER2 imaging can 
potentially be used for early response monitoring, for example in drug development of 
new anti-HER2 agents. 
Table 3. Type of radiotracers.
Radiotracer Advantages Disadvantages
Antibodies •	 High absolute tumor uptake
•	 Well established safety in 
patients
•	 Slow clearance from circulation
•	 Non-specific uptake due to 
enhanced permeability and 
retention effect
•	 low contrast with normal tissue 
early after injection
•	 Delayed imaging (3-4 days p.i.)
Antibody 
fragments 
(F(ab’)2 and Fab)
•	 More rapid tumor targeting 
and clearance from 
circulation
•	 Early imaging (2-6 h p.i.)
•	 High tumor to normal tissue 
contrast
•	 Lower absolute tumor uptake
•	 High kidney uptake
Small peptides and 
Affibody molecules
•	 Very rapid tumor targeting 
and clearance from 
circulation
•	 Early imaging (1-4 h p.i.)
•	 Very high tumor to normal 
tissue contrast
•	 High kidney uptake
p.i.= post injection
EGFR 
EGFR, also known as HER1, plays an important role in tumor cell proliferation, migration and 
protection against apoptosis.(89) EGFR is often overexpressed in breast cancer, especially 
in triple negative tumors, and its expression has been associated with poor prognosis.
(90-92) Several agents have been developed to inhibit EGFR, such as the monoclonal 
antibodies cetuximab and panitimumab. However, clinical trials with cetuximab showed 
limited efficacy and studies with panitimumab are still ongoing.(93, 94) Another class of 
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EGFR inhibitors consists of the tyrosine kinase inhibitors gefitinib, erlotinib and the dual 
HER2/EGFR inhibitor lapatanib. Lapatinib is currently the only agent with EGFR inhibitory 
activity which is approved for treatment of breast cancer.(75)
One of the first reports on imaging of EGFR expression in xenografts was published in 
1989 by Goldenberg et al.(95) In 1994, first results were published on a clinical study 
in patients with gliomas, showing the feasibility of visualizing EGFR expressing tumors 
with 111In-labeled anti-EGFR antibodies.(41) Since then, several approaches have been 
developed to improve EGFR imaging. For example, 89Zr-labeled cetuximab PET successfully 
visualized EGFR expressing xenografts in mice. However, unlike ER and HER2 expression, 
EGFR expression as measured with immunohistochemistry is not predictive for response 
to cetuximab, at least in colorectal cancer.(96, 97) In mice bearing EGFR expressing 
xenografts, 89Zr-cetuximab PET tumor uptake did not correlate with EGFR expression.
(98) A potential explanation may be that the antibody dose was used in this study was 
suboptimal. In addition, uptake of radiolabeled cetuximab may depend on KRAS mutation 
level. Patients with KRAS wild-type tumors are more likely to respond to cetuximab 
treatment than patients with KRAS mutant tumors.(99) Achmad et al. have shown that 
the uptake of Copper-64 (64Cu)-labeled cetuximab was significantly higher in KRAS wild-
type xenografts compared with mutant xenografts, and based on KRAS mutation status, 
a correlation was found between uptake of radiolabeled cetuximab and EGFR level.(100) 
Besides KRAS mutation status, other factors may play a role in targeting of cetuximab 
to tumors, such as vascularity, interstitial pressure and vascular permeability. Because in 
vivo imaging also takes into account target accessibility, this might be used to improve 
patient selection. However, to date the predictive value of tumor uptake of radiolabeled 
cetuximab on response to EGFR targeted treatment has not been investigated.
Another approach to image EGFR expression is targeting the tyrosine kinase domain. To 
this end, different drugs and their derivates such as PD153035, gefitinib, erlotinib, ZD6474 
and ML01 have been labeled with various radionuclides. Most of these tracers were not 
suitable to image EGFR expression due to low tumor uptake and high uptake in non-
targeted organs.(101) Furthermore, none of these tracers were selective for mutant EGFR 
kinases that confer sensitivity to EGFR targeted therapy (102). Yeh et al. have developed 
a promising approach to image the expression of active mutant EGFR, using [18F]F-PEG6-
IPQA for PET imaging.(103) This tracer was able to distinguish between active mutant 
xenografts sensitive to gefitinib treatment and wild-type EGFR expressing xenografts 
resistant to gefitinib. Moreover, gefitinib treatment resulted in a significant decrease 
in [18F]F-PEG6-IPQA uptake in mutant EGFR expressing xenografts. In contrast, in non-
responding xenografts that expressed wild type EGFR, [18F]F-PEG6-IPQA uptake was not 
significantly reduced. These results suggest that high uptake of [18F]F-PEG6-IPQA may 
predict favorable responses to EGFR TKIs, whereas lack of uptake may predict resistance.
(103)
Three clinical studies in patients with non-small cell lung cancer (NSCLC) have shown the 
feasibility of using radiolabeled TKIs to image EGFR expressing tumors.(42-44) Memon et 
al. showed that 11carbon (11C) labeled erlotinib accumulated in tumor lesions of 4 out of 
13 patients. However, no information was available on EGFR expression. After this scan, 
patients were treated with erlotinib and 3 out of 5 patients with stable disease had tumor 
uptake before start of therapy.(42) In a second study, patients (n=21) with advanced 
chemotherapy refractory NSCLC were prospectively enrolled in a trial of erlotinib and 
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imaged by 11C-PD153035 (a positron-emitting analog of the EGFR TKI PD153035) PET/CT 
at baseline and during treatment with erlotinib. Baseline uptake correlated strongly with 
overall survival and progression free survival; patients with a high SUVmax (≥ median SUVmax) 
survived more than twice as long as patients with a low SUVmax (median overall survival 
11.4 months versus 4.6 months). 11C-PD153035 uptake on follow-up scans was less well 
correlated with survival.(44) The results of these two studies suggest that baseline uptake 
of 11C-labeled TKIs can potentially be used to identify NSCLC patients that are likely to 
respond to EGFR tyrosine kinase inhibitors. However, their role in breast cancer still needs 
to be assessed.
Angiogenesis
Angiogenesis, the growth of new blood vessels from pre-existing vessels, is an essential 
process if solid tumors are to grow beyond a few millimeters. Angiogenesis can be 
induced by hypoxia, due to the induction of  gene expression and transcription leading 
to increased levels of vascular endothelial growth factor (VEGF), platelet-derived growth 
factor (PDGF), carbonic anhydrase IX (CAIX) and transforming growth factor-α (TGF-α). As 
a result, endothelial cells are activated and express αvβ3, which regulates the migration of 
endothelial cells, leading to the formation of immature vasculature. 
Anti-angiogenic treatment has been approved for different types of cancer, including 
glioblastomas, metastatic renal cell carcinoma and metastatic colorectal cancer. The 
role of angiogenesis inhibitors in breast cancer is still under debate. Bevacizumab, a 
monoclonal antibody directed against VEGF-A, was granted accelerated FDA approval in 
2008 for first line treatment of HER2-negative metastatic breast cancer. This approval was 
based on evidence showing improved progression-free survival in patients treated with 
bevacizumab in combination with paclitaxel, as compared with paclitaxel alone.(104, 105)
However, two additional trials showed no clinically significant improved progression-free 
survival, no improved overall survival and there was a higher incidence of  serious adverse 
events in the bevacizumab treated group compared to the control group.(106) Therefore, 
FDA revoked the approval of bevacizumab in combination with paclitaxel in November 
2011. Despite this decision, clinical trials with bevacizumab are still ongoing, for example 
in the neoadjuvant setting.(107) However, selecting the right patient population that 
may benefit from anti-angiogenic treatment remains difficult. Molecular imaging of the 
angiogenic pathway may aid in optimizing anti-angiogenic treatment in breast cancer 
patients. Several approaches have been developed to image angiogenesis. 
Extra Domain B (ED-B) of Fibronectin
Fibronectin is expressed in the extracellular matrix. ED-B is a sequence of 91 amino 
acids that is inserted into fibronectin molecule at sites of tissue remodeling. Fibronectin 
containing ED-B is specifically expressed around neovascular structures in tumor or other 
tissue undergoing angiogenesis or extensive remodeling, and is undetectable in normal 
adult tissue.(108) The human single-domain antibody (scFv), L19, has subnanomal affinity 
for ED-B and the noncovalent homodimeric form of L19, L19(scFv)2), has been radiolabeled 
with 123I for scintigraphic imaing of tumor neovasculature.(60, 109) In 20 patients with 
lung, colorectal or brain cancer, 123I-L19(scFv)2 selectively localized in tumors lesions of 
aggressive lung cancer as well as in liver metastases of colorectal cancer. Since ED-B 
fibronectin is expressed only during angiogenesis or extensive remodeling, 123I-L19(scFv)2 
might be able to distinguish between quiescent and active growing lesions.
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Integrin αvβ3
Integrin αvβ3 binds the tripeptide arginine-glycine-aspartic acid (RGD). The potential of 
radiolabeled RGD-containing peptides for imaging of angiogenesis has been studied 
extensively. Examples of RGD-based radiotracers to image αvβ3 that have been applied 
in patients are 18F-galacto-RGD, 99mTc-NC100692, 18F-AH111585, 99mTc-3P4-RGD2 and 
68Ga-
NOTA-RGD.(46, 52, 54, 55, 110) The first radiotracer tested in patients was 18F-galacto-
RGD.(46) 18F-galacto-RGD can visualize various of malignancies, including melanomas, 
sarcomas, squamous cell carcinomas, renal cell carcinoma, glioblastomas and breast 
carcinomas. Several studies have shown that uptake of 18F-galacto-RGD correlates with 
immunohistochemically determined αvβ3 expression.(45-51) In a study in 16 breast cancer 
patients, Beer et al. showed that all primary tumors were identified using 18F-galacto-RGD 
without false-positive results in the contralateral breast. However, 18F-galacto-RGD was 
less sensitive to detect lymph node and distant metastases. The uptake in primary tumor 
and metastases was very heterogeneous, suggesting that the levels of αvβ3 expression 
vary widely in human breast cancer. Immunohistochemistry of tumor lesions revealed 
αvβ3 expression on endothelial cells as well as on tumor cells.(50) Integrin αvβ3 expression 
on tumor cells plays a role in metastatic capacity of cells and has been reported to be a 
prognostic factor in breast cancer.(111-113) Consequently, 18F-galacto-RGD PET is not a 
pure marker of angiogenesis and results should therefore be interpreted with caution. 
Another RGD-based radiotracer that has been applied in breast cancer patients is 
99mTc-NC100692, which targets both αvβ3 and αvβ5. Bach-Gansmo et al. showed that 19 
of 22 primary breast cancer lesions were clearly detected by scintigraphic imaging.(52) 
Furthermore, 99mTc-NC100692 could visualize brain and lung metastases, while liver and 
bone lesions were poorly visualized.(53) In contrast to the 18F-galacto-RGD studies, the αvβ3 
expression of tumor lesions was not determined. Therefore, it is unknown whether tumor 
uptake of 99mTc-NC100692 correlates with αvβ3 expression. Furthermore, 
99mTc-NC100692 
SPECT has a lower sensitivity and spatial resolution compared to 18F-galacto-RGD PET. 
VEGF and VEGFR
VEGF is a key regulator of angiogenesis. VEGF121 has been radiolabeled with 
64Cu for PET 
imaging of VEGFR expression. In mice, 64Cu-VEGF121 revealed rapid and specific targeting of 
tumors with high VEGFR expression, while targeting was significantly lower in tumors with 
low VEGFR expression.(114) In patients with gastrointestinal tumors (n=18), scintigraphic 
imaging using 123I-labeled VEGF165 identified 58% of the tumor lesions. It is unknown 
whether tumor uptake of 123I-VEGF165 correlates with VEGFR expression.(56) 
Other studies have used the anti-VEGF antibody bevacizumab to image angiogenesis. 
Preclinical studies showed specific accumulation of radiolabeled bevacizumab in VEGF 
expressing tumors.(115, 116) Clinical studies with 111In-labeled bevacizumab have shown 
the feasibility to visualize VEGF expression of various malignancies. Scheer et al. have 
studied targeting of 111In-bevacizumab in patients with liver metastases of colorectal 
cancer. Metastases were visualized in 9 out of 12 patients. However, there was no clear 
correlation with VEGF-A expression of the tumor lesions, as determined by in situ 
hybridization and ELISA, suggesting that other factors such as vascularity play a role in 
targeting of bevacizumab to tumors.(57) This was illustrated by a study by Desar et al. who 
performed 111In-bevacizumab scintigraphy in 9 renal cell cancer patients that were treated 
neoadjuvantly with sorafenib (a VEGFR inhibitor).(58) Sorafenib treatment significantly 
reduced tumor uptake of 111In-bevacizumab (- 61%, range: +2 to -290%) as compared to 
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the pretreatment scan (Figure 4).  Immunohistochemistry revealed that the decrease in 
tumor uptake was most likely due to destruction of the tumor neovasculature, whereas 
VEGF-A expression did not change.  A similar effect has been observed by Nagengast 
et al. who studied 111In-bevacizumab uptake in patients with melanoma (n=9).(59) All 
tumors lesions were visualized by 111In-bevacizumab SPECT. After the first scan, patients 
were treated with a single therapeutic dose of bevacizumab and two weeks later the 
111In-bevacizumab SPECT was repeated. Bevacizumab treatment resulted in a significant 
decrease in tumor targeting (-21% ± 4%) of 111In-bevacizumab. This decrease is most 
likely explained by a combination of decreased targeting due to blockade of VEGF by 
the therapeutic bevacizumab dose, which hampers 111In-bevacizumab to bind VEGF, and 
by the vascular changes induced by bevacizumab. However, vascular density was not 
examined in this study. 
Figure 4. Anterior and posterior 111In-bevacizumab scans at baseline (A) and after 4 wk of treatment with 
sorafenib (B). Decrease of 111In-bevacizumab uptake (arrows), more enhanced in central parts of tumor, is shown 
(reprinted with permission) (58).
In summary, clinical studies have shown the feasibility to image expression of targets such 
as ED-B, αvβ3 and VEGF, which are closely related to angiogenesis. However, in many studies 
uptake of the radiotracers could not be correlated with the expression of the targets 
since no biopsies were available. Moreover, tumor uptake of tracers do not solely reflect 
angiogenesis. For example, αvβ3 is not only expressed on vessels, but also on tumor cells 
themselves.(50) Furthermore, bevacizumab has been shown to accumulate in tumors in 
the absence of VEGF-A expression. This might be due to enhanced vascular permeability 
of tumor vessels, which results in nonspecific enhanced extravasation of radiolabeled 
antibodies.(57) An interesting finding was that targeting of 111In-bevacizumab was 
significantly reduced during anti-angiogenic treatment with tyrosine kinase inhibitors. 
This suggest that this tracer can be used for early response monitoring. The role of anti-
angiogenic therapy in breast cancer is still under debate. Therefore, new biomarkers or 
early response monitoring can be used to select subgroups of patients that may benefit 
from this type of treatment. Non-invasive imaging of the angiogenic pathway may aid 
in optimizing the use of angiogenesis inhibitors in breast cancer. However, to date, no 
studies have been performed to determine whether imaging is be predictive for response 
to anti-angiogenic treatment. Future studies are warranted to determine the role of these 
tracers in assessing response to antiangiogenic treatment.
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Receptor imaging for new targeted therapies
IGF-1R
IGF-1R plays a role in proliferation, apoptosis, angiogenesis and tumor invasion of several 
cancer types.(117) Approximately 40 to 60% of ER positive tumors express IGF-1R, while 
expression in ER negative tumors is only 10 to 20%.(118) In general, IGF-1R expression 
correlates with good prognostic markers, such as ER positivity. However, in ER-negative 
tumors its expression is associated with a worse prognosis.(118, 119) Furthermore, data 
suggest that IGF-1R expression may be related to resistance to cytotoxic, anti-estrogen, 
HER2 and EGFR-targeted therapy.(120-123) Therefore, targeting IGF-1R may be useful in 
patients developing resistance against conventional breast cancer treatment. Phase I/II 
studies with anti-IGF-1R antibodies have shown the safety and tolerability of targeting IGF-
1R. Furthermore, these studies demonstrated a wide range of responses, from progressive 
disease to near complete response.(124) Therefore, it is important to develop methods 
for the selection of those patients that could potentially benefit from this new treatment. 
Patient selection for IGF-1R targeted therapy may be based on receptor expression since 
in vitro studies have shown that expression is necessary for antitumor activity of anti-IGF-
1R antibodies.(125, 126) 
Currently, three different approaches have been studied for in vivo imaging of IGF-
1R imaging with SPECT or PET. First, radiolabeled IGF-1 has been used to image IGF-1R 
expression in preclinical models.(127-129) However, the interaction of IGF-1 with IGF-1R 
was modulated by binding of IGF-1 to IGF binding proteins (IGFBPs). Cornelissen et al. 
have used an IGF-1 analogue (IGF-1(E3R)), that does not bind IGFBPs to visualize IGF-1R 
expressing xenografts. However, in their mouse model, absolute tumor uptake was low.
(127)
A second tracer used for visualization of IGF-1R expression is the Affibody molecule ZIGF-
1R:4551. ZIGF-1R:4551 has affinity for both murine as well as human IGF-1R. As a result, targeting 
of human tumors and IGF-1R expressing normal tissue can be studied in mice. This makes 
it an adequate model to evaluate IGF-1R targeting in vivo because a high expression in 
normal organs can affect tumor-normal tissue contrast.(3) SPECT imaging with this tracer 
was able to visualize IGF-1R expressing prostate cancer xenografts, while the uptake in 
normal IGF-1R expressing organs was considerable. 
IGF-1R imaging was also studied in a mouse model for triple negative breast cancer, 
using R1507, a high affinity monoclonal antibody direct against the extracellular domain 
of IGF-1R. R1507 was radiolabeled with 111In and 89Zr for respectively immunoSPECT 
and immunoPET. Both tracers could clearly visualize IGF-1R expressing triple negative 
breast cancer xenografts (Figure 5).(130) In addition, 111In-R1507 SPECT could distinguish 
between bone sarcoma xenografts that were responsive and non-responsive to IGF-1R 
targeted therapy, whereas immunohistochemistry could not.(131) These results suggest 
that 111In-R1507 has potential for patient selection for IGF-1R targeted therapy. 
c-MET 
c-MET is the tyrosine kinase receptor for hepatocyte growth factor (HGF) and plays a role 
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in tumor cell invasion and metastases.(132) c-MET expression is associated with poor 
prognosis of breast cancer patients (133-135) and may be involved in the development of 
resistance against HER2- and EGFR-targeted treatment.(136, 137) Several c-MET inhibitors 
are currently under investigation and the tyrosine kinase inhibitors in particular have 
shown promising results in phase I and II trials.(132)
Two approaches to image c-MET expression have been developed. First, monoclonal 
antibodies have been radiolabeled with 89Zr or 125I, and clearly visualized c-MET expressing 
xenografts with PET and SPECT, respectively.(138, 139) Second, the tyrosine kinase 
inhibitor of c-MET SU11274 has been radiolabeled with carbon-11 (11C) for PET imaging, 
which has been shown to specifically accumulate in c-MET expressing xenografts.(140) 
None of these tracers have been studied in patients yet.
HER3 and HER4
The most widely studied members of the HER family are EGFR and HER2. However, there is 
increasing evidence that HER3 and HER4 also play an important role in the development 
and progression of breast cancer. HER3 is expressed on approximately 20-30% of all 
breast carcinomas and is frequently co-expressed with HER2.(141) It can be activated by 
heterodimerization with HER2, resulting in activation of the 
PI3K/Akt pathway, which plays an important role in tumor 
cell proliferation and inhibition of apoptosis. Therefore, HER3 
is a potential target for the treatment of breast cancer.(69) 
Furthermore, HER3 expression may be upregulated during 
treatment with other targeted agents. A recent study has 
shown that trastuzumab resistant breast cancer cells show 
increased HER3 expression.(11, 69) Several agents targeting 
HER3 have been developed. For example, the monoclonal 
antibodies MM-121 and AMG-888 inhibit tumor growth of 
several human tumor xenografts in nude mice.(142, 143) 
Also, inhibitors that target all three receptors, EGFR, HER2 
and HER3, are currently being developed.(144, 145)
The role of HER4 in oncogenesis is less clear. A study by Feng 
et al. suggested that this receptor is involved in inhibition of 
cell growth rather than proliferation.(146) HER4 is expressed 
on 10-40% of all breast carcinomas and its expression is 
associated with favorable prognostic factors.(141, 147-
149) There is evidence that upregulation of HER4 during 
chemotherapy predicts good response, and HER4 positive 
breast tumors may respond better to  trastuzumab treatment.
(150, 151) 
To date, no radiotracers have been published that can be 
used to non-invasively determine HER3 and HER4 expression. 
However, recently, a HER3-specific Affibody molecule has 
been described that can be used to image HER3 expression.
(152)
Figure 5. SPECT/CT of a mice 
with a subcutaneous IGF-
1R expressing breast cancer 
xenograft, 3 days after injection 
of 111In-labeled R1507. 
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FGFR and PDGFR
Fibroblast growth factor receptors (FGFRs) are likely to be involved in breast tumorigenesis 
and therapeutic targeting of FGF and FGFRs is an important area of drug development. 
Amplifications of FGFR1 occur in approximately 10% of all breast tumors and approximately 
4% of all triple negative breast tumors have FGFR2 amplifications.(153, 154) A recent study 
showed that especially triple negative and basal like breast cancer cell lines are sensitive 
to a FGFR inhibitor.(155) So far, no radiotracers have been developed for in vivo imaging 
of FGFR expression. 
CXCR4
Chemokine receptor 4 (CXCR4), a member of the G protein-coupled seven-span 
transmembrane receptor class, binds CXCL12 and plays an important role in the 
metastatic spread of cancer cells to organs that express CXCL12. Furthermore, CXCR4 itself 
can stimulate growth and survival of cancer cells and promote tumor angiogenesis.(156) 
CXCR4 is frequently expressed on primary breast tumors and its expression is associated 
with an aggressive phenotype and increased risk of recurrence.(157-159) Metastases 
frequently exhibit increased CXCR4 expression compared with the primary lesion.(158, 
160) Moreover, CXCR4 can transactivate HER2 and EGFR and mediates resistance to 
endocrine therapy.(161-163) Inhibition of the CXCR4-CXCL12 axis has been shown to 
reduce metastatic burden in mice models for breast cancer.(164) Agents targeting the 
CXCR4 axis are currently in clinical trials to investigate their potential as anti-cancer agents 
(AMD31000 and CTCE-9908). 
Different strategies to image CXCR4 expression have been developed, using small 
molecules, peptides or antibodies (165). A promising tracer is 64Cu-AMD3100, which in 
a preclinical study was able to distinguish between breast cancer xenografts with low 
CXCR4 expression (MDA-MB-231) and high CXCR4 expression (DU4475).(166) Although 
MDA-MB-231 cells have a low CXCR4 expression, a subset of cells with a propensity to 
metastasize to the lungs expresses increased levels of CXCR4. In an experimental model, 
these lung metastases were also visualized with 64Cu-AMD3100 PET imaging.(166)
Considering the important role of CXCR4 in metastasis and tumor progression, CXCR4 
imaging agents might be useful to identify primary tumors with an aggressive phenotype 
or to detect early metastasis. Moreover, CXCR4 might be used for patient stratification 
for CXCR4-targeted therapy and to monitor changes in expression that may occur during 
resistance against conventional anti-cancer treatment. This may be important in the 
design of CXCR4 combination therapy. 
Discussion
Molecular imaging in breast cancer is expanding rapidly and emerging studies have 
suggested its potential for patient selection and response monitoring. Although there 
are many advantages to molecular imaging, some limitations still exist. First of all, PET/
CT scans can cause non-negligible exposure to ionizing radiation, especially in case 
of repetitive imaging. This is not a relevant risk for patients with advanced cancer, but 
diagnostic radiation exposure should be limited in case of non-radiotherapy based, 
Chapter 2
2
38
curative treatment. Second, in contrast to preclinical scanners, clinical cameras have a 
limited resolution that does not allow for the detection of early and small tumor lesions. 
However, recently developed systems have a significantly better resolution and by using 
combined SPECT/CT and PET/CT systems, the anatomical interpretation of the data has 
also improved. Third, development of new radiotracers requires rigorous validation in 
clinical studies. 
Despite these limitations, molecular imaging using radiotracers allows (functional) 
characterization of tumors, while the sensitivity to detect all tumor lesions is generally 
lower compared to conventional imaging techniques such as 18F-FDG-PET. However, 
detecting all lesions is not the primary aim of molecular imaging. New radiotracers 
should be used for other purposes, such as tumor characterization, patient selection and 
stratification, or early response monitoring. Up to now, most studies have been performed 
in preclinical models but an increasing number of clinical studies shows the potential of 
molecular imaging. Most clearly, progress has been made in radionuclide imaging of ER 
and HER2 expression. For example, it has been shown that 18F-FES PET can be a valuable 
additional diagnostic tool if standard work-up in breast cancer patients is inconclusive (28). 
However, for most radiotracers this has not been shown yet and further characterization 
of the radiotracers is required to determine the sensitivity, specificity and correlation with 
treatment response and survival. 
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Abstract
Introduction: The insulin-like growth factor 1 receptor (IGF-1R) is a new target for the 
treatment of breast cancer. Patients with breast cancer lesions that express IGF-1R may 
benefit from treatment with anti-IGF-1R antibodies. Therefore, the aim of the present 
study was to develop a noninvasive,  imaging method, using radiolabeled antibodies, to 
visualize IGF-1R expression. 
Material and methods: R1507 is a monoclonal antibody directed against the IGF-1R. In 
vitro, the affinity and internalization kinetics of 111In-R1507 were determined using the IGF-
1R expressing triple negative breast cancer cell line SUM149. , the pharmacodynamics of 
111In-R1507 and 125I-R1507 were determined in mice with subcutaneous SUM149 tumors. 
SPECT and PET images were acquired of mice with subcutaneous SUM149 tumors one, 
three and seven days post injection of 111In-R1507 and 89Zr-R1507, respectively. 
Results: 111In-R1507 (IC50= 0.1 nM) was slowly internalized by SUM149 cells. 
111In-R1507 
specifically and efficiently accumulated in the SUM149 xenografts: the tumor uptake was 
20% ID/g, 33% ID/g and 31% ID/g at one, three and seven days post injection, respectively. 
125I-R1507 accumulated in the tumor less efficiently. MicroSPECT and microPET imaging of 
mice clearly visualized the subcutaneous SUM149 xenograft with increasing contrast at 
later time points. 
Conclusion: 111In-R1507 and 89Zr-R1507 are new tracers to noninvasively determine IGF-
1R expression  in breast cancer xenografts using SPECT and PET imaging. In the future, 
these techniques may enable patient selection for IGF-1R targeted therapy.
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Introduction
Triple negative breast tumors are estrogen receptor (ER), progesterone receptor (PR) and 
HER2/neu negative. Although they account for only 10 – 17% of all breast carcinomas,(1-8) 
tumors are often high grade, patients are relatively young and have a reduced breast 
cancer specific survival compared to patients with ER or HER2/neu expressing tumors.(3, 
9) Since targeted treatments are currently not approved for patients with triple negative 
breast cancer, the standard systemic treatment is chemotherapy. However, several new 
targeted agents are currently tested in clinical trials for their efficacy in patients with triple 
negative breast cancer.(10) 
A potential new target for the treatment of triple negative breast cancer is the insulin-like 
growth factor 1 receptor (IGF-1R). The IGF-1R is a transmembrane receptor expressed in 
many human cancers, including 36% of all triple negative breast carcinomas.(11) It plays a 
role in proliferation, apoptosis, angiogenesis and tumor invasion (12-14) and its expression 
may be related to resistance to cytotoxic, anti-estrogen and HER2/neu targeted therapy.
(15-18) Upon binding of insulin-like growth factors (IGFs) to the receptor, adaptor proteins, 
such as insulin-receptor substrate-1 (IRS-1) and IRS-2, are recruited to the phosphorylation 
site of the cytoplasmic domain.(19-21) Subsequently, the phosphatidylinositol-3-kinase 
(PI3K) and mitogen-activated protein kinase (MAPK) pathways can be activated, resulting 
in proliferation and inhibition of apoptosis.(13, 14)
Currently, several small molecule inhibitors and antibodies directed against the IGF-1R 
are being developed and tested in phase I and II clinical trials. Preliminary results of these 
studies have shown the safety and tolerability of targeting the IGF-1R. Stable disease and 
objective responses have been reported in patients treated with these new agents, but 
no relation with the IGF-1R receptor expression has been tested in a structured way.(22) 
In vitro studies have shown that IGF-1R expression is necessary for antitumor activity of 
anti-IGF-1R antibodies.(23, 24) Therefore, patient selection for IGF-1R targeted therapy 
may be based on receptor expression. Thus far, studies on IGF-1R expression have mainly 
been performed on tumor tissue sections using immunohistochemistry. However, this 
technique cannot be used to measure the expression in different tumor lesions and 
different regions within a tumor, because this would require multiple invasive procedures. 
Furthermore, the expression of IGF-1R may change in the course of time for example due 
to tumor growth and therapy. Therefore, the aim of the present study was to develop 
a noninvasive imaging method, which allows monitoring of the membranous IGF-1R 
expression in all breast cancer lesions during the course of the disease. For this purpose 
the fully human anti-IGF-1R monoclonal antibody (MAb) R1507, directed against the 
human IGF-1R, was radiolabeled with 111In or with 89Zr for  imaging of IGF-1R expression 
with immunoSPECT and immunoPET, respectively.
Material and methods
Cell culture
The triple negative breast cancer cell line SUM149 (Asterand, Detroit, MI) was cultured and 
maintained as monolayer in culture flasks in Ham’s F12 medium (GIBCO, BRL Life Sciences 
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Technologies, The Netherlands) supplemented with 5% fetal calf serum (FCS), 10 mM 
HEPES, hydrocortisone (1 µg/ml), and insulin (5 µg/ml) at 37 °C in a humidified atmosphere 
with 5% CO2. MCF-7 cells were cultured in RPMI-1640 medium (GIBCO, BRL Life Sciences 
Technologies, The Netherlands), supplemented with 10% FCS, 2 mM glutamine, penicillin 
(100 units/ml) and streptomycin (100 µg/ml). 
Radiolabeling
Radiolabeling of R1507 with 111In
The fully human MAb R1507 was obtained from Roche Diagnostics (Penzberg, Germany) 
and is directed against an epitope on the extracellular domain of the human IGF-1R. 
R1507 was conjugated with isothiocyanatobenzyl-diethylenetriaminepentaacetic 
acid (ITC-DTPA, Macrocyclis, Dallas, TX) in 0.1 M NaHCO3, pH 9.5, using a ten-fold molar 
excess of ITC-DTPA for one hour at room temperature (RT). The unbound ITC-DTPA was 
removed from the reaction mixture by dialysis against 0.25 M ammonium acetate buffer, 
pH 5.4. DTPA-R1507 (10 µg) was incubated with 3.7 MBq 111In (Covidien BV, Petten, The 
Netherlands) in 0.1 M MES buffer, pH 5.4, at RT, under strict metal-free conditions for 30 
min. For SPECT imaging 22 µg DTPA-R1507 was incubated with 244 MBq 111In. Labeling 
efficiency was determined using instant thin-layer chromatography (ITLC) on TEC Control 
chromatography strips (Biodex, Shirley, NY), using 0.1 M citrate buffer, pH 6.0, as the mobile 
phase. In case labeling efficiency was below 95%, the reaction mixture was purified on 
a PD-10 column (Amersham Biosciences, Uppsala, Sweden), eluted with PBS, containing 
0.5% bovine serum albumin (BSA). Radiochemical purity of 111In-DTPA-R1507 (111In-R1507) 
exceeded 98% in all experiments.
Radioiodination of R1507
R1507 (40 µg) was iodinated with 18.5 MBq 125Iodine (125I, Amersham, Den Bosch, The 
Netherlands) in an iodogen-coated vial, in 0.5 M phosphate buffer, pH 7.2, at RT during 
15 min. Labeling efficiency as determined by ITLC was 92.0 %. The reaction mixture was 
purified on a PD-10 column eluted with PBS containing 0.5% BSA. Radiochemical purity 
of 125I-R1507 exceeded 99%.
Radiolabeling of R1507 with 89Zr
R1507 was modified with succinyl-desferal-Fe-tetrafluorophenol (TFP-N-suc-Df-Fe, VU 
University Medical Center, Amsterdam, The Netherlands) ester as described previously.
(25) In short, a two-fold molar excess of TFP-N-suc-Df-Fe was incubated with R1507 for 
30 min at RT in 0.1 M Na2CO3, pH 9.5. Subsequently, the sample was incubated with EDTA 
(final concentration 1.5 mg/ml) at pH 4.3 for 30 min at 35 °C to remove the iron from 
the chelate. The reaction mixture was purified on a PD-10 column, eluted with 5 mg/
ml gentisic acid. Radiolabeling of the R1507 conjugate (0.5 mg) with 500 MBq 89Zr (IBA 
Pharma, Leuven, Belgium) was performed in 0.5 M HEPES pH 7.2 for 90 minutes at 35 
°C. Labeling efficiency was determined by ITLC and was 54%. The reaction mixture was 
purified on a PD10 column eluted with 5 mg/ml gentisic acid. Radiochemical purity of 
89Zr-N-suc-Df-R1507 (89Zr-R1507) was 98%.
In vitro characteristics of 111In-DTPA-R1507
Immunoreactive fraction
The immunoreactive fractions of 111In-R1507, 125I-R1507 and 89Zr-R1507 were determined 
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as described by Lindmo et al.(26) A serial dilution of MCF-7 cells (4.8x106 – 30x106 cells/ml) 
in RPMI 0.5% BSA was incubated with 200 Bq 111In- R1507, 125I-R1507 or 89Zr-R1507. Non 
specific binding was determined by adding an excess of unlabeled R1507 (67 nM) to a 
duplicate of the lowest cell concentration. After one hour of incubation at 37 °C, cells were 
centrifuged and the activity in the cell pellet was measured in a shielded 3-inch-well-type 
gamma counter (Perkin-Elmer, Boston, MA, USA). The inverse of the specific cell bound 
activity was plotted against the inverse of the cell concentration and the immunoreactive 
fraction was calculated from the y-axis intercept.
Internalization
SUM149 cells were cultured in six-well plates and were incubated with 1.9 kBq of 111In-
R1507 (specific activity 0.3 MBq/µg) for 1, 2, 4, 8, 24 and 48 hours, in 2 ml binding buffer 
(Ham’s F12, 10 mM HEPES, 0.5% BSA) at 37 °C in a humidified atmosphere with 5% CO2. 
Nonspecific binding and internalization was determined by coincubation with 67 nM 
unlabeled R1507. After incubation, acid wash buffer (0.1 M HAc, 0.15 M NaCl, pH 2.6) was 
added for 10 min to remove the membrane-bound fraction of the cell-associated 111In-
R1507. Subsequently, cells were harvested from the six-well plates using cotton plugs 
and the amount of membrane bound and internalized activity was measured in a gamma 
counter. 
Affinity
SUM149 cells were cultured to confluency in six-well plates. To determine the concentration 
required to inhibit binding by 50% (IC50), cells were incubated for 4 hours at 4 °C in 2 
ml binding buffer with 1.9 kBq 111In-R1507 (specific activity 0.3 MBq/µg) and increasing 
concentrations of unlabeled R1507 (10-2 pM – 103 pM). After incubation and washing, cell 
associated activity was measured in a gamma counter. 
Immunohistochemistry of SUM149 tumors
IGF-1R expression on SUM149 xenografts was analyzed by immunohistochemistry. 
SUM149 tumors were fixed in 4% formalin and embedded in paraffin. Tumor sections 
(4 µm) were deparaffinized in xylol for 15 minutes and rehydrated in graded dilutions 
of ethanol in water. Antigen retrieval was performed in 10 mM sodiumcitrate, pH 6.0 
for 10 minutes at 100°C. Endogenous peroxidase activity was blocked with 3% H2O2 in 
PBS (10 minutes at RT) and non specific binding was blocked by incubation with normal 
goat serum (30 minutes at RT). Subsequently, tumor sections were incubated with 0.6 
µg/ml polyclonal rabbit anti-IGF-1Rβ antibody (Cell signaling Technology, Danvers, MA) 
overnight at 4 °C, followed by incubation with a goat-anti-rabbit biotinylated secondary 
antibody (Vector Laboratories, Burlingame, CA) for 30 minutes at 37 °C. Finally, avidin-
biotin-enzyme complex (Vector Laboratories, Burlingame, CA) was applied for 30 minutes 
at 37 °C and DAB was used to develop the tumor sections. 
Animal studies
Animal experiments were performed in female BALB/c nude mice and were conducted in 
accordance with the principles laid out by the revised Dutch Act on Animal Experimentation 
(1997) and approved by the institutional Animal Welfare Committee of the Radboud 
University Nijmegen. At 6-8 weeks of age, mice were inoculated subcutaneously with 5 
x 106 SUM149 cells (mixed 2:1 with matrigel, BD Biosciences, Pharmingen). Experiments 
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started when the tumors reached a size of approximately 0.1 cm3. 
Protein dose-escalation study of 111In-R1507
Seven groups (n=6) of mice with subcutaneous SUM149 xenografts received an 
intravenous injection in the tail vein of 0.2 MBq 111In-R1507 (specific activity 0.4 MBq/
µg). To study the effect of the antibody protein dose on the biodistribution of 111In-R1507 
the groups received increasing protein doses of R1507 (1 - 1,000 µg). Three days post 
injection, mice were euthanized using O2/CO2-asphyxiation. The uptake of
 111In-R1507 was 
measured in tumor, blood, muscle, lung, liver, kidney, spleen, small intestine, pancreas 
and salivary gland as described previously.(27) 
Pharmacodynamics of radiolabeled R1507
Three groups of mice (n=12) with subcutaneous SUM149 xenografts received an 
intravenous injection of 0.4 MBq 111In-R1507 (specific activity 0.8 MBq/µg) and 0.2 MBq 
125I-R1507 (specific activity 0.4 MBq/µg). To determine the IGF-1R-mediated uptake of the 
radiolabeled R1507, six mice per group received an excess of unlabeled R1507 (500 µg) to 
block the IGF-1R . One, three and seven days post injection of radiolabeled R1507, mice 
were euthanized and uptake of radiolabeled R1507 was determined as described above.
 
ImmunoSPECT imaging with 111In-R1507
Five BALB/c mice bearing SUM149 xenografts received an intravenous injection of 
17.2 MBq 111In-R1507 (specific activity 10.9 MBq/µg). One mouse received an excess of 
unlabeled R1507 (1000 µg) to determine the non-specific uptake of R1507. Immediately 
after injection and one, three and seven days post injection, images were acquired with 
the U-SPECT-II (MILabs, Utrecht, The Netherlands).(28) Mice were scanned under general 
anesthesia (isoflurane/O2) for 30 – 120 minutes using the 1.0 mm diameter pinhole rat 
collimator tube. At day seven, the mice were euthanized and the uptake of 111In-R1507 
in dissected tissue was determined as described above. Scans were reconstructed with 
MILabs reconstruction software, which uses an ordered-subset expectation maximization 
algorithm, with a voxel size of 0.375 mm. Representative cross sections located 
approximately in the center of the tumor were displayed. Tumor-to-liver ratios were 
calculated with the Inveon Research Workplace software (IRW, version 2.2).
ImmunoPET imaging with 89Zr-R1507
Six BALB/c mice bearing SUM149 xenografts received an intravenous injection of 5.3 MBq 
89Zr-R1507 (specific activity 0.53 MBq/µg). Immediately after injection and one, three and 
seven days post injection, PET images were acquired of three mice with the Inveon animal 
PET scanner (29) (Siemens Preclinical Solutions, Knoxville, TN) under general anesthesia 
(isoflurane/O2) for 10-30 minutes. At day seven, all mice were euthanized and the uptake 
of 89Zr-R1507 was determined ex vivo as described above. Scans were reconstructed using 
Inveon Acquisition Workplace software (IAW, version 1.2) using an ordered-set expectation 
maximization 3-dimensional/maximum a posteriori (OSEM3D/MAP) algorithm with the 
following parameters: matrix 256 x 256 x 159, pixel size 0.43 x 0.43 x 0.8 mm3 and an uniform 
variance MAP prior of 0.05 mm. Representative cross sections located approximately in 
the center of the tumor were displayed. Tumor-to-liver ratios were calculated with the 
Inveon Research Workplace software (IRW, version 2.2).
Statistical analysis
Statistical analyses were performed using SPSS software version 16.0 (Chicago, IL) and 
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GraphPad Prism version 4.00 (San Diego, CA) for Windows. Differences in uptake of 
radiolabeled R1507 were tested for significance using the nonparametric Mann Whitney 
test. A p-value below 0.05 was considered significant. 
Results
In vitro characteristics of R1507
The Lindmo assay showed that the immunoreactive fractions of 111In-R1507, 125I-R1507 
and 89Zr-R1507 were respectively 99%, 88% and 87%. 111In-R1507 was slowly internalized 
by SUM149 cells (Figure 1A). During the first hours of incubation, 111In-R1507 was mainly 
membrane bound. The internalized fraction gradually increased until 62% of the cell 
associated activity was internalized after 48 hours incubation. A typical binding plot 
of the IC50 analysis is shown in Figure 1B. R1507 exhibited an IC50 value of  0.1 nM (95% 
confidence interval 0.08 – 0.12 nM) for the IGF-1R on SUM149 cells.
Figure 1. A: Internalization kinetics of 111In-R1507 in SUM149 cells. Binding and internalization is presented as 
the percentage of the total cell associated activity after 48 hours of incubation (mean ± standard deviation). B: 
Typical binding plot of 111In-R1507 and SUM149 cells. Binding is presented as mean ± standard deviation. R1507 
exhibited an IC50 value of 0.1 nM.  
Immunohistochemistry of SUM149 tumors
Immunohistochemistry on tumor sections of SUM149 xenografts revealed both 
cytoplasmic and membranous IGF-1R expression (Figure 2).
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Figure 2. Typical example of immunohistochemical analysis of IGF-1R expression of a 
SUM149 tumor (tumor size 0.5 cm3). A: Negative control. B: Membranous and cytoplasmic 
IGF-1R staining. The arrow indicates membrane staining.
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Dose escalation study
A dose escalation study was performed with 111In-R1507 to determine the optimal protein 
dose of R1507 for in vivo imaging. Mean tumor weight at dissection was 112 ± 45 mg. 
111In-R1507 showed high specific uptake in SUM149 xenografts on day three at doses 
<10 µg of antibody per mouse (Figure 3). The highest uptake in the tumor was found at 
antibody protein doses of 3 µg or less (1 µg: 38% ID/g ± 11% ID/g and 3 µg: 35% ID/g ± 
6% ID/g). Tumor uptake was significantly lower at an antibody protein dose of 10 µg (15% 
ID/g ± 4% ID/g, p = 0.002). At a dose of 300 µg, the tumor uptake further decreased to 9% 
ID/g ± 1% ID/g (p=0.004). The highest tumor-to-blood ratio were obtained at a protein 
dose of 1 µg (2.7 ± 1.1) and 3 µg (2.4 ± 0.5) R1507. The SUM149 tumor was the only tissue 
showing specific uptake of R1507, as evidenced by the reduced uptake at antibody doses 
above 100 µg.
Figure 3. Dose escalation study of 111In-R1507 in mice with subcutaneous SUM149 xenografts, three days post 
injection. Values are presented as mean % ID/g of tissue ± standard deviation for 5 mice per group. (* P < 0.05)
Pharmacodynamics of radiolabeled R1507
Results of the pharmacodynamics study are summarized in Figure 4. Mean tumor weight 
at dissection was 142 ± 66 mg. At all time points, 111In-R1507 showed significantly higher 
tumor uptake than 125I-R1507 (p < 0.05). One, three and seven days post injection, the 
tumor uptake of 111In-R1507 was respectively 20 ± 6% ID/g, 33 ± 6% ID/g and 31 ± 4% 
ID/g, compared to 8 ± 1% ID/g, 7 ± 1% ID/g and 5 ± 1% ID/g for 125I-R1507. The tumor-
to-blood ratio of 111In-R1507 was the highest seven days post injection (3.8 ± 0.3) and 
for 125I-R1507 three days post injection (0.7 ± 0.1). Highest tumor-to-liver ratios of 111In-
R1507 and 125I-R1507 were also obtained at day seven (11.8 ± 1.7) and day three (3.3 ± 
0.6), respectively. The tumor was the only tissue showing IGF-1R-mediated uptake of 111In-
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R1507, as evidenced by the markedly reduced tumor uptake in the mice that received an 
excess of unlabeled R1507 (5.6% ID/g at day seven). Uptake in the other organs was not 
affected by an excess of unlabeled R1507.
Figure 4. Biodistribution of 111In-R1507 (A) and 125I-R1507 (B), one, three and seven days post injection, in mice 
with subcutaneous SUM149 tumors. Values are presented as mean % ID/g of tissue ± standard deviation for 5 
mice per group. (* P < 0.05)
ImmunoSPECT imaging with 111In-R1507
One day post injection, the subcutaneous SUM149 tumor was clearly visualized on the 
SPECT images (Figure 5). At later time points the tumor-to-background contrast improved 
further due to the clearance of 111In-R1507 from the blood. SPECT images also showed 
uptake of 111In-R1507 in the liver, spleen and salivary glands. Tumor-to-liver ratios were 
calculated from the SPECT images at one, three and seven days post injection and were 
1.9 ± 0.6, 3.5 ± 1.2, 5.8 ± 1.8, respectively. The ex vivo biodistribution, seven days post 
injection, revealed that the mean tumor uptake of 111In-R1507 was 20.9 ± 2.4 % ID/g (Table 
1). Mean tumor weight at dissection was 150 ± 60 mg. The tumor-to-blood ratio was 3.8 
± 0.7 and the tumor-to-liver ratio was 7.5 ± 1.2. The SUM149 tumor of the mouse which 
received an excess of unlabeled R1507 could hardly be visualized by SPECT imaging 
(Figure 5D). The tumor uptake of 111In-R1507 was only 4% and the tumor-to-blood and 
tumor-to-liver ratios were 0.8 and 1.5, respectively.
ImmunoPET imaging with 89Zr-R1507
One day post injection of 89Zr-R1507, SUM149 xenografts were clearly visualized with 
small animal PET imaging (Figure 6). From day one to seven, tumor to background 
contrast increased due to the clearance of 89Zr-R1507 from the blood and background 
tissues. Tumor-to-liver ratios were calculated from the PET images and increased over 
time. At day one, three and seven, tumor-to-liver ratios were 1.9 ± 0.1, 2.9 ± 0.3 and 4.7 
± 0.3, respectively. The ex vivo biodistribution study, seven days post injection, showed 
that the mean tumor uptake was 22 ± 3 %ID/g (Table 1). Mean tumor weight at dissection 
was 347 ± 70 mg. The tumor-to-blood ratio and tumor-to-liver ratio were 3.9 ± 0.5 and 
4.8 ±0.2, respectively. Besides tumor uptake, PET images also revealed nonspecific liver, 
spleen, salivary gland and bone uptake. 
 #! # 	

 	
 	
 	
 	
 	
 	
    "   "  "	
 	
	
	
	
	
	
!	  "  "	
 	
	
	
	
	
	
!	 A B
Chapter 3
3
58
Figure 5. SPECT images of a mouse with a subcutaneous SUM149 tumor immediately after injection (A) and 
one (B), three (C) and seven (D) days post injection of 17.2 MBq 111In-R1507 (1.6 µg). Tumor-to-liver ratios in this 
mouse, calculated from the SPECT images, were 1.5, 3.3 and 5.6 at one, three and seven days post injection, 
respectively. Ex vivo biodistribution study on day seven revealed that the tumor uptake of 111In-R1507 for this 
mouse was 23% ID/g. E: SPECT image of a mouse with a subcutaneous SUM149 tumor seven days post injection 
of  17.2 MBq 111In-R1507 and an excess of unlabeled R1507 (1000 µg). Tumor-to-liver ratios in this mouse, 
calculated from the SPECT images, were 1.1, 1.3 and 1.5 at one, three and seven days post injection, respectively. 
Ex vivo biodistribution on day seven revealed that the tumor uptake of 111In-R1507 was 4.0% ID/g. SUM149 
tumors are indicated by the arrows. 
Figure 6. PET images of a mouse with a subcutaneous SUM149 tumor immediately after injection (A) and one 
(B), three (C) and seven (D) days post injection of 5 MBq 89Zr-R1507 (10 µg). Tumor-to-liver ratios in this mouse, 
calculated from the PET images, were 1.8, 2.7 and 4.3 at one, three and seven days post injection, respectively. 
Ex vivo biodistribution study on day seven revealed that the tumor uptake of 89Zr-R1507 for this mouse was 22% 
ID/g. SUM149 tumors are indicated by the arrows.
Discussion
The present study showed that both 111In-R1507 and 89Zr-R1507 efficiently accumulated in 
IGF-1R expressing SUM149 tumors and were excellent tracers for noninvasive imaging of 
IGF-1R expression with immunoSPECT and immunoPET. experiments showed that R1507
has favorable characteristics for  imaging. The immunoreactivity of the R1507 antibody 
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was retained after the labeling procedure. Furthermore, R1507 is an internalizing 
antibody with high affinity for the IGF-1R (IC50 = 0.1 nM). The results of the comparative 
biodistribution study with 111In-R1507 and 125I-R1507 revealed higher tumor uptake of 
111In-R1507 compared to 125I-R1507, at all time points. Since R1507 is an internalizing 
antibody, residualizing radionuclides such as 111In result in higher tumor retention 
than the nonresidualizing radionuclide 125I.(30, 31) Therefore, we selected 111In-R1507 
and 89Zr-R1507 for immunoSPECT and immunoPET imaging of IGF-1R expression. The 
dose escalation study showed that 111In-R1507 efficiently targeted SUM149 xenografts 
at antibody protein doses up to 3 µg. At higher doses the tumor uptake decreased, 
presumably due to saturation of the IGF-1R.
Table 1. Biodistribution of 111In-R1507 and 89Zr-R1507 in mice with 
subcutaneous SUM149 xenografts, seven days post injection.
Tissue 111In-R1507 
(%ID/g)
89Zr-R1507 
(%ID/g)
Blood 5.6 ± 0.5 5.7 ± 0.7
Muscle 0.7 ± 0.1 0.7 ± 0.1
Tumor 20.9 ± 2.4 22.3 ± 2.5
Lung 4.5 ± 0.7 4.6 ± 0.5
Spleen 5.4 ± 0.9 5.7 ± 0.7
Kidney 4.4 ± 0.4 4.9 ± 0.7
Liver 2.9 ± 0.4 4.6 ± 0.4
Small intestine 2.5 ± 0.4 2.5 ± 0.4
Pancreas 1.0 ± 0.1 1.1 ± 0.1
Bone 1.3 ± 0.4 8.2 ± 4.2
Tumor-to-liver ratio 7.5 ± 1.2 4.8  ± 0.2
Tumor-to-blood ratio 3.8 ± 0.7 3.9 ± 0.5
Values are presented as mean ± standard deviation.
Both 111In-R1507 SPECT and 89Zr-R1507 PET clearly visualized the IGF-1R expressing breast 
cancer xenografts with increasing contrast at later time points. Although R1507 does not 
cross react with the murine IGF-1R, SPECT and PET images also revealed uptake in the 
liver, spleen and salivary glands. The dose escalation study showed that this uptake was 
not IGF-1R mediated. The biodistributions of 89Zr-R1507 and 111In-R1507 were comparable, 
except for uptake in the bone. PET images clearly revealed bone uptake of 89Zr-R1507 
whereas bone uptake was not observed in the 111In-R1507 SPECT images. Differences in 
bone uptake between 89Zr labeled antibodies and other residualizing radionuclides have 
been described previously for internalizing antibodies. Dijkers et al. showed that bone 
uptake of 89Zr-labeled trastuzumab was significantly higher compared to the uptake of 
111In-trastuzumab.(32) Furthermore, Perk et al. reported an increased bone uptake of 
89Zr-cetuximab compared to 88Yttrium (88Y) and 177Lutetium (177Lu) labeled cetuximab.
(33) These data indicate that 89Zr might be incorporated in the bone more efficiently than 
other radiometals. 
Previous studies have shown that IGF-1R expression strongly correlates with response 
to anti-IGF-1R antibodies.(23, 24) Therefore, IGF-1R expression on tumor lesions may be 
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a suitable criterion to select patients for IGF-1R targeted therapy. However, high IGF-1R 
expression alone was not sufficient to respond to anti-IGF-1R treatment.(23, 24) Other 
components in the IGF-1R pathway may also have a predictive value for response. Zha et 
al. showed that the adaptor proteins IRS-1 and IRS-2 and the ligand IGF-2, have predictive 
value for response to anti-IGF-1R antibodies.(24) Other studies have also shown that 
IGF-1R, IRS-1, IGF-1, and IGF-2 expression correlates with sensitivity to IGF-1R tyrosine 
kinase inhibitors.(34, 35) The subcellular location of IGF-1R expression may also influence 
whether patients will respond to anti-IGF-1R antibodies. Previous studies have focused on 
total IGF-1R expression (membranous and cytoplasmic) or mRNA expression,(23, 24, 34, 
35) while antibodies will only target IGF-1R expressed on the cell membrane. Therefore, 
membranous IGF-1R expression may be a better predictor of response than total IGF-1R 
expression, if and when the downstream pathway lacks escape mechanisms. 
Membranous IGF-1R expression can be determined on tumor sections using 
immunohistochemistry. Evaluation of IGF-1R expression is usually performed on archival 
tumor material because a new biopsy would require an invasive procedure. IGF-1R 
expression may change over time because of cytotoxic, anti-estrogen or anti-HER2 
treatment or tumor progression.(15-18) Noninvasive imaging of membranous IGF-1R 
expression would allow monitoring of the expression of all tumor lesions at several time 
points. Our studies showed that both 111In-R1507 SPECT and 89Zr-R1507 PET are excellent 
methods to visualize membranous IGF-1R expression in breast cancer xenografts. 
However, these experiments were performed under optimal conditions, since R1507 does 
not cross react with the murine IGF-1R. In patients, radiolabeled R1507 will also recognize 
the IGF-1R which is widely expressed in normal tissues. This could result in enhanced 
uptake in IGF-1R expressing normal tissues, including muscle, cartilage and bone.(36-38) 
Future studies will have to show whether imaging of IGF-1R expression with SPECT or PET 
is also feasible in patients. 
Other approaches, besides radiolabeled antibodies, for  imaging of the IGF-1R expression 
have already been studied. Cornelissen et al. have used 111In-IGF-1(E3R), an analogue of 
IGF-1 which does not bind IGFBPs, to visualize IGF-1R expression of subcutaneous MCF-7/
HER2-18 tumors with microSPECT. However, 111In-IGF-1(E3R) showed lower tumor uptake 
(2.5% ID/g versus 20.9% ID/g) and lower tumor-to-liver ratios (0.09 versus 7.5) compared 
to 111In-R1507.(39) Therefore, IGF-1R expressing tumors are much better visualized with 
111In-R1507 than with 111In-IGF-1(E3R). Also small-molecule fluorophores have been used 
to image IGF-1R expression in MCF-7 tumors.(40) In patients however, fluorescent imaging 
cannot detect tumor lesions in deeper organs due to limited tissue penetrations of visible 
light.
Conclusion
In conclusion, our experiments show that radiolabeled R1507 specifically accumulated in 
triple negative SUM149 xenografts and that 111In-R1507 SPECT and 89Zr-R1507 PET can be 
used to visualize IGF-1R expression . In the future, these techniques may enable patient 
selection for IGF-1R targeted therapy.
ImmunoSPECT and immunoPET of IGF-1R expressing xenografts
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Abstract
Introduction: The insulin-like growth factor 1 receptor (IGF-1R) is a potential new target 
for the treatment of breast cancer. Patients with breast cancer lesions that express IGF-
1R may benefit from treatment with anti-IGF-1R antibodies. IGF-1R expression can 
be visualized using radiolabeled R1507, a monoclonal antibody directed against IGF-
1R. However, antibodies clear slowly from the circulation, resulting in low tumor-to-
background ratios early after injection. Therefore, we aimed to accelerate targeting of 
IGF-1R using radiolabeled R1507 F(ab’)2 and Fab fragments. 
Material and methods: In vitro, immunoreactivity, binding affinity and internalization of 
R1507 IgG, F(ab’)2 and Fab were determined using the triple negative IGF-1R-expressing 
breast cancer cell line SUM149. In vivo, pharmacokinetics of 111In-labeled R1507 IgG, 
F(ab’)2 and Fab were studied in mice bearing subcutaneous SUM149 xenografts. SPECT/
CT images were acquired and the biodistribution was measured ex vivo.
Results: The in vitro binding characteristics of radiolabeled R1507 IgG and F(ab’)2 were 
comparable, whereas the affinity of Fab fragments was significantly lower (Kd: 0.6 nM, 0.7 
nM and 3.0 nM for R1507 IgG, F(ab’)2 and Fab, respectively). Biodistribution studies showed 
that the maximum tumor uptake of 111In-R1507 IgG, F(ab’)2 and Fab was 31.8 %ID/g (72 h 
p.i.), 10.0 %ID/g (6 h p.i.), and 1.8 %ID/g (1 h p.i.), respectively. However, maximal tumor-
to-blood ratios for F(ab’)2 (24 h p.i.: 7.5) were more than twice as high than those obtained 
with R1507 (72 h p.i.: 2.8) and Fab (6 h p.i.: 2.8). Injection of an excess of unlabeled 
R1507 significantly reduced tumor uptake, suggesting that the uptake of R1507 IgG and 
F(ab’)2 was specific for IGF-1R, while the major fraction of the tumor uptake of Fab was 
nonspecific. IGF-1R-expressing xenografts were visualized with 111In-F(ab’)2 SPECT/CT as 
early as 6 h p.i., while with R1507 IgG, the tumor could be visualized after 24 h. No specific 
targeting was observed with 111In-Fab. 
Conclusion: 111In-F(ab’)2 fragments showed improved targeting of IGF-1R expressing 
tumors. Tumor-to-blood ratios were twice as high than those obtained with 111In-R1507 
and adequate tumor targeting on SPECT/CT images was observed as early as 6 h p.i. For 
individualization and optimization of IGF-1R targeted therapy, 111In-F(ab’)2 may be the 
tracer of choice.
IGF-1R SPECT/CT with 111In-labeled R1507 F(ab’)2 fragments
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Introduction
The insulin-like growth factor 1 receptor (IGF-1R) is a potential new target for the treatment 
of breast cancer. It is a transmembrane receptor involved in proliferation, apoptosis, 
angiogenesis and tumor invasion of several cancer types.(1-3) Upon binding of the growth 
factors IGF-1 and IGF-2, two major anti-apoptotic pathways can become activated: Ras-
Raf-ERK/MAPK and PI3K/AKT.(4) Furthermore, IGF-1R induces hypoxia-inducible factor 1α 
(HIF-1α) protein synthesis, which induces expression of vascular endothelial growth factor 
(VEGF), a central mediator of angiogenesis.(5) Data suggest that IGF-1R expression may 
be related to resistance to cytotoxic, anti-estrogen and several other types of targeted 
therapy.(6-9) 
Phase I and II studies with anti-IGF-1R antibodies have shown the safety and tolerability 
of targeting IGF-1R. Furthermore, these studies demonstrated a wide range of clinical 
effects, from progressive disease to near complete response.(10) Therefore, it is of utmost 
importance to develop methods for the selection of those patients who potentially 
benefit from this new treatment. A first clue is found in the modest but increasing amount 
of evidence suggesting that IGF-1R expression by the tumor is required in order to 
benefit from these therapies.(11-14) Thus far, studies on IGF-1R expression have mainly 
been performed on tumor tissue sections using immunohistochemistry. However, IGF-1R 
expression may be heterogeneous within or between tumors lesions. Therefore, a single 
biopsy may not provide accurate information on IGF-1R expression of all tumors lesions. 
In vivo imaging would allow measurement of IGF-1R expression of all tumor lesions, 
avoiding misinterpretation due to intratumoral and interlesional heterogeneity. Moreover, 
IGF-1R expression can change during the course of disease, due to disease progression or 
treatment.(6-9) To  optimize timing of initiation of IGF-1R targeted and to find rational 
combinations of IGF-1R targeted therapy with other treatments, the dynamics of IGF-1R 
expression should be known. In vivo IGF-1R imaging could be a valuable tool to determine 
IGF-1R expression noninvasively.
In a previous study, we have shown that radiolabeled R1507, a fully human monoclonal 
antibody directed against an epitope on the extracellular domain of the human IGF-1R, 
can be used to image IGF-1R expression noninvasively.(15) IGF-1R expressing breast 
cancer xenografts could be clearly visualized by immunoSPECT and immunoPET using 
111In-labeled and 89Zr-labeled R1507, respectively. Moreover, we demonstrated that 
immunoSPECT could distinguish between bone sarcoma xenografts that were high, 
modest and nonresponsive to R1507 treatment, while conventional techniques, such as 
immunohistochemistry and western blotting, could not.(16) Therefore, this technique has 
potential for patient selection for IGF-1R targeted therapy. 
A disadvantage of using the intact antibody R1507 for in vivo imaging is its large size 
and long circulatory half-life, resulting in slow tumor accumulation and slow clearance 
from the circulation. It will take several days before satisfactory contrast between tumor 
and normal tissue is obtained. This is especially a disadvantage when repeated imaging 
is required within short time intervals, for example when studying the dynamics of IGF-
1R expression during treatment. Therefore, we aimed to accelerate targeting of IGF-1R 
by using F(ab’)2 and Fab fragments of R1507. These fragments lack the Fc domain (CH2 
– CH3 domain) of the antibody and are cleared from the circulation more rapidly.(17) In 
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this study, we compared the in vitro binding characteristics and in vivo targeting of 111In-
labeled R1507 IgG, F(ab’)2 and Fab, using SPECT/CT. 
Material and methods
Cell culture
The triple negative, IGF-1R expressing breast cancer cell line SUM149 (Asterand, Detroit, 
MI) was cultured and maintained as monolayer in culture flasks in Ham’s F12 medium 
(GIBCO, BRL Life Sciences Technologies, The Netherlands) supplemented with 5% fetal calf 
serum (FCS), 10 mM HEPES, hydrocortisone (1 µg/ml), and insulin (5 µg/ml) at 37 °C in a 
humidified atmosphere with 5% CO2. Hormone receptor positive and IGF-1R expressing 
MCF-7 cells were cultured in RPMI-1640 medium (GIBCO, BRL Life Sciences Technologies, 
The Netherlands), supplemented with 10% FCS and 2 mM glutamine.
Production and purification of antibody fragments
R1507 was a kind gift from Roche Diagnostics (Penzberg, Germany). R1507 F(ab’)2 
fragments were produced by incubating R1507 (10 mg) for 2-3 h at 37 °C with pepsin (final 
concentration 2.7 μM) in 0.15 M sodium citrate (pH 3.8, total volume reaction mixture: 
2.65 ml). The digestion was stopped by adding 1 M Tris, pH 10.5 (final concentration 0.17 
M Tris). F(ab’)2 fragments were purified on a cation exchange column (MONO-S 5/50 GL, 
Amersham Pharmacia Biotech Uppsala, Sweden) which was eluted with 40 mM sodium 
acetate buffer with a 0 to 400 mM lithium chloride gradient (1 ml/min, 100 min). Fractions 
containing F(ab’)2 were collected and analyzed on sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE, 8% bis-acrylamide).
Fab fragments were produced using the Pierce Fab preparation kit (Thermo Fisher 
Scientific, Rockford, Illinois) according to the protocol of the manufacturer. In short, F(ab’)2 
fragments were cleaved into Fab fragments by papain immobilized on agarose resin 
during 6 h at 37 °C, in Fab digestion buffer, pH 10.0. Subsequently, Fab fragments were 
analyzed on SDS-PAGE as described above.
Radiolabeling 
R1507 IgG, F(ab’)2, and Fab fragments were conjugated with isothiocyanatobenzyl-
diethylenetriaminepentaacetic acid (ITC-DTPA, Macrocyclics, Dallas, TX) in 0.1 M NaHCO3, 
pH 9.5, using five (Fab) or ten-fold (IgG and F(ab’)2) molar excess of ITC-DTPA for 1 h at 
room temperature (RT). Unbound ITC-DTPA was removed from the reaction mixture by 
dialysis against 0.25 M ammonium acetate buffer, pH 5.4.
For in vitro experiments and biodistribution studies, DTPA-conjugated R1507 IgG, 
F(ab’)2 and Fab (33 pmol) were incubated with 3.7 MBq 
111In (Covidien BV, Petten, The 
Netherlands) in 0.1 M MES buffer (twice volume of 111In), pH 5.4, at RT, under strict metal-
free conditions for 20 min. For SPECT/CT studies, DTPA-conjugated R1507 IgG (120 pmol), 
F(ab’)2 (160 pmol) and Fab (120 pmol) were incubated with 165 MBq, 195 MBq and 89 MBq 
111In, respectively. After incubation, 50 mM EDTA was added to a final concentration of 5 
mM. Labeling efficiency was determined using instant thin-layer chromatography (ITLC) 
IGF-1R SPECT/CT with 111In-labeled R1507 F(ab’)2 fragments
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on TEC Control chromatography strips (Biodex, Shirley, NY), using 0.1 M citrate buffer, pH 
6.0, as the mobile phase. Radiochemical purity of 111In-DTPA-R1507 IgG (111In-R1507 IgG), 
111In-DTPA-R1507-F(ab’)2 (
111In-F(ab’)2) and 
111In-DTPA-R1507-Fab (111In-Fab) exceeded 94% 
in all experiments.
In vitro characteristics of 111In-R1507 IgG, 111In-F(ab’)2 and 
111In-Fab
Binding to IGF-1R expressing tumor cells
SUM149 cells were cultured in six-well plates and were incubated with 25 pM 111In-R1507 
IgG , 111In-F(ab’)2 or 
111In-Fab, in 1 ml binding buffer (Ham’s F12, 10 mM HEPES, 0.5% BSA) 
for 4 h on ice. Nonspecific binding was determined by coincubation with 33 nM unlabeled 
R1507. After incubation, cells were washed once with PBS and harvested from plates 
using 0.1 M NaOH. The cell-associated activity was measured in a shielded 3-inch-well-
type gamma counter (Perkin-Elmer, Boston, MA, USA). 
Immunoreactive fraction
The immunoreactive fractions of 111In-R1507 IgG, 111In-F(ab’)2 and 
111In-Fab were 
determined essentially as described by Lindmo et al.(18) A serial dilution of MCF-7 (50x106 
– 1.6x106 cells) in RPMI containing 0.5% bovine serum albumin (BSA) was incubated for 
1 h at 37 °C with a tracer amount of 111In-R1507 IgG (1 pM), 111In-F(ab’)2 (1 pM) or 
111In-
Fab (0.5 pM). Nonspecific binding was determined by adding an excess of unlabeled 
R1507 IgG (0.67 µM) to a duplicate of the lowest cell concentration. After incubation, cells 
were centrifuged and the activity in the cell pellet was measured in a gamma counter. 
The inverse of the specific cell bound activity was plotted against the inverse of the cell 
concentration and the immunoreactive fraction was calculated from the y-axis intercept 
using GraphPad Prism software (version 5.03 for Windows; GraphPad Software).
Internalization
SUM149 cells were cultured in six-well plates and were incubated with 1.4 kBq 111In-
R1507 IgG, 111In-F(ab’)2 or 
111In-Fab for 1, 3 and 24, in 1 ml binding buffer at 37 °C in a 
humidified atmosphere with 5% CO2. Nonspecific binding and nonspecific internalization 
were determined by coincubation with 33 nM unlabeled R1507 IgG. After incubation, cells 
were washed once with PBS to remove the unbound radiotracer. Subsequently, acid wash 
buffer (0.1 M HAc, 0.15 M NaCl, pH 2.8) was added for 10 min to remove the membrane-
bound fraction of the cell-associated 111In-R1507 IgG, 111In-F(ab’)2 or 
111In-Fab. Next, cells 
were harvested from the six-well plates. The amount of membrane bound (acid wash) and 
internalized activity (harvested cells) was measured in a gamma counter.
50% Inhibitory Concentration (IC50) determination
The IC50 for binding IGF-1R on SUM149 was determined in a competitive binding assay 
using DTPA-conjugated R1507 IgG, F(ab’)2 or Fab  to compete for binding with 
111In-R1507. 
SUM149 cells were cultured to confluency in six-well plates and were incubated for 4 hours 
on ice in 1 ml binding buffer with 1.4 kBq 111In-R1507 IgG and increasing concentrations 
of unlabeled R1507 IgG (0.3 pM – 3,000 pM), F(ab’)2 (0.3 pM – 3,000 pM) or Fab (0.03 nM 
– 300 nM). After incubation, cells were washed with PBS and the cell-associated activity 
was measured in a gamma counter. The IC50 was defined as the concentration required to 
inhibit binding  by 50%. IC50
 values were calculated using GraphPad Prism software.
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Scatchard analysis
Scatchard analysis was performed to determine the dissociation constant (Kd) and the 
number of binding sites (Bmax) for 
111In-R1507 IgG, 111In-F(ab’)2 or 
111In-Fab on SUM149 
cells. Cells were cultured to confluency in six-well plates and were incubated for 4 h on 
ice with increasing concentrations 111In-R1507 IgG (0.03 – 3 nM), 111In-F(ab’)2 (0.03 – 3 nM) 
or 111In-Fab (0.3 – 30 nM) in 1 ml binding buffer. Nonspecific binding was determined by 
co-incubation with an excess of 300 nM unlabeled R1507 IgG. After incubation, cells were 
washed with PBS and the cell-associated activity was measured in a shielded well-type 
gamma counter. The ratio bound over free was plotted against the bound fraction. Kd 
and Bmax were calculated from the slope and intercept with the x-axis, respectively, using 
GraphPad Prism software.
Animal experiments
Animal experiments were performed in female BALB/c nude mice and were conducted in 
accordance with the principles laid out by the revised Dutch Act on Animal Experimentation 
(1997) and approved by the institutional Animal Welfare Committee of the Radboud 
University Nijmegen. At 6-8 weeks of age, mice were inoculated subcutaneously with 5 
x 106 SUM149 cells (mixed 2:1 with matrigel, BD Biosciences, Pharmingen). Experiments 
were started when the tumors reached a size of approximately 0.1 cm3. 
Biodistribution of 111In-R1507 IgG, 111In-F(ab’)2 and 
111In-Fab
Twelve groups of athymic BALB/c mice (N=5) with subcutaneous SUM149 xenografts 
received an intravenous injection of 0.4 MBq 111In-R1507 IgG, 111In-F(ab’)2 or 
111In-Fab 
(protein dose: 6.7 pmol). Mice receiving 111In-R1507 IgG were euthanized 6, 24 and 72 h 
post injection. Mice receiving 111In-F(ab’)2 or 
111In-Fab were euthanized 2, 6, 24 h and 1, 2 
and 6 h post injection, respectively. Two days before injecting 111In-R1507 IgG, 111In-F(ab’)2 
or 111In-Fab, separate groups were injected with an excess of unlabeled R1507 IgG (2 nmol) 
to determine nonspecific uptake. 
Mice were euthanized by CO2/O2 asphyxiation. Tumor, blood, muscle, lung, spleen, 
pancreas, kidney, liver and small intestine were dissected and weighed. Activity was 
measured in a gamma counter. To calculate the uptake of the radiotracer in each sample as 
a fraction of the injected dose, aliquots of the injected dose were counted simultaneously. 
The results were expressed as percentage of the injected dose per gram (%ID/g).  
SPECT/CT with 111In-R1507 IgG, 111In-F(ab’)2 and 
111In-Fab
Three groups of five BALB/c mice with subcutaneous SUM149 xenografts received an 
intravenous injection of 20 pmol 111In-R1507 IgG (24 MBq), 111In-F(ab’)2 (23 MBq) or 
111In-
Fab (14 MBq). Two days before injection of the radiotracers, one mouse per group received 
an excess of unlabeled R1507 IgG (2 nmol) to determine the nonspecific uptake. SPECT/
CT images were acquired using the U-SPECT-II/CT system(19) (MILabs, Utrecht, The 
Netherlands) at 6, 24 and 72 h post injection of 111In-R1507 IgG and 2, 6, 24 h and 1, 2 
and 6 h post injection of 111In-F(ab’)2 and 
111In-Fab, respectively. Mice were scanned under 
general anesthesia (isoflurane/O2) for 30-60 min using the 1.0 mm diameter pinhole rat 
collimator tube. Before the last scan, mice were euthanized. After scanning, the uptake 
of the radiotracers in dissected tissue was determined as described above. Scans were 
reconstructed with MILabs reconstruction software, which uses an ordered-subset 
expectation maximization algorithm, with a voxel size of 0.375 mm. Representative cross 
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sections located approximately in the center of the tumor were displayed. A 3D volume 
of interest was drawn around the tumor and uptake was quantified as the percentage 
injected dose per gram (%ID/g), assuming a tissue density of 1 g/cm3.
Statistical analysis
Statistical analyses were performed using PASW Statistics version 18.0 (Chicago, IL) and 
GraphPad Prism version 5.03 (San Diego, CA) for Windows. Results are presented as 
mean ± standard deviation (SD). Differences in tumor uptake of radiotracers were tested 
for significance using the nonparametric Kruskal-Wallis and  Mann-Whitney U test. The 
correlation between tumor uptake measured by SPECT and ex vivo biodistribution was 
calculated with the Spearman’s rank correlation coefficient.  A p-value below 0.05 was 
considered significant. 
Results
In vitro characteristics of 111In-R1507 IgG, 111In-F(ab’)2 and 
111In-Fab
Table 1 summarizes the in vitro characteristics of the three radiotracers. All tracers showed 
specific binding to IGF-1R expressing SUM149 cells, but the absolute binding of 111In-Fab 
was 7 times lower compared to 111In-R1507 IgG (Figure 1A). Lindmo assays revealed that 
the immunoreactive fractions of 111In-R1507 IgG, 111In-F(ab’)2 and 
111In-Fab were 88%, 83% 
and 67%, respectively. All three radiotracers were gradually internalized by SUM149 cells, 
although the absolute binding and internalization of 111In-Fab was much lower than that 
of the other radiotracers. The internalization rates of the tracers were similar. After 24 hours 
of incubation, approximately 70% of the total cell-associated activity was internalized. The 
IC50 of the intact IgG and F(ab’)2 for IGF-1R were similar (0.06 and 0.22 nM, respectively), 
while the IC50 of the Fab fragments was much lower (2.56 nM, Figure 1B). These results 
were confirmed in the Scatchard analysis. Kd values of 
111In-R1507 IgG, 111In-F(ab’)2 and 
111In-Fab were 0.61 nM, 0.72 nM and 3.04 nM, respectively. 
Figure 1. A: Binding of 111In-R1507 IgG, 111In-F(ab’)2 and 
111In-Fab to SUM149 cells. B: Competitive binding curves 
of IC50 determination of DTPA-conjugated R1507 IgG, F(ab’)2 and Fab on SUM149 cells. 
111In-R1507 was used as 
radiotracer. Binding is presented as mean ± SD.
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Table 1. Comparison of in vitro characteristics of 111In-R1507 IgG, 111In-F(ab’)2 and 
111In-Fab.
R1507 IgG F(ab’)2 Fab
Immunoreactive fraction 88% 83% 67%
Internalization (% of cell-associated 
activity at 24 h that is internalized, 
mean ± sd)
74% ± 4% 74% ± 2% 72% ± 20%
IC50 (nM, 95% CI) 0.06 
(0.02 – 0.18)
0.22
(0.06 – 0.86)
2.56
(1.68 – 3.89)
Kd (nM, 95% CI) 0.61 
(0.46 – 0.91)
0.72
(0.47 – 1.55)
3.04
(1.73 – 12.38)
Bmax (receptors/cell, 95% CI) 8,073
(6,513 – 10,957)
6,291
(4,678 – 11,077)
3,472
(2,516 – 9,072)
Animal experiments
Biodistribution of 111In-R1507 IgG, 111In-F(ab’)2 and 
111In-Fab
Figure 2 summarizes the results of biodistribution study. Highest absolute tumor uptake 
was found for 111In-R1507 IgG. Tumor uptake was 11.1 ± 0.9 %ID/g, 20.9 ± 3.3 %ID/g and 
31.8 ± 6.3 %ID/g at 6, 24 and 72 h after injection, respectively. Tumor-to-blood ratios 
gradually increased over time and were 0.5 ± 0.04, 1.2 ± 0.2 and 2.8 ± 0.7 at 6, 24 and 72 
h after injection, respectively. At 72 h after injection, tumor uptake and tumor-to-blood 
ratios were significantly lower in mice that received an excess of unlabeled R1507 IgG, 
suggesting that the tumor uptake was IGF-1R mediated. Uptake in the other organs was 
not affected by an excess of unlabeled R1507.
The absolute tumor uptake of 111In-F(ab’)2 was lower than that of 
111In-R1507 IgG. Two, 6 
and 24 h after injection, tumor uptake was 6.7 ± 1.2 %ID/g, 10.0 ± 1.2 %ID/g and 7.2 ± 1.6 
%ID/g, respectively. However, tumor-to-blood ratios of 111In-F(ab’)2 were higher due to the 
faster clearance of 111In-F(ab’)2 from the blood. At 24 h after injection, the concentration 
of 111In-F(ab’)2 in the blood was 1.0 ± 0.1 %ID/g, compared with 21.4 ± 2.5 %ID/g for 
111In-R1507 IgG. As a result of this faster clearance, tumor-to-blood ratios at 2, 6 and 24 
h after injection were 0.4 ± 0.1, 1.2 ± 0.3 and 7.5 ± 1.4, respectively. Tumor targeting and 
tumor-to-blood ratios were significantly lower in mice that were injected with an excess of 
unlabeled R1507 IgG, suggesting that the uptake was IGF-1R mediated.
Of all three radiotracers, 111In-Fab showed the lowest tumor uptake: 1.8 ± 0.4 %ID/g, 1.4 ± 
0.1 %ID/g and 0.8 ± 0.1 %ID/ g at 1, 2 and 6 h after injection, respectively. Although 111In-
Fab was cleared from the circulation very rapidly (1.2 ± 0.1 %ID/g at 1 h p.i.), tumor-to-
blood ratios remained low: 1.4 ± 0.2, 2.0 ± 0.1 and 2.8 ± 0.6, at 1, 2 and 6 h after injection, 
respectively. Injection of an excess of unlabeled R1507 IgG indicated that the major 
fraction of the tumor targeting was due to nonspecific uptake.
Besides differences in tumor targeting and tumor-to-blood ratios, there were also 
differences in targeting to normal organs. Most apparent were the differences in kidney 
uptake. For 111In-R1507 IgG, kidney uptake was  highest 6 h after injection (8.0 ± 0.7 %ID/g). 
Uptake of 111In-F(ab’)2 and 
111In-Fab at the same time point was much higher: 65.4 ± 5.6 
%ID/g and 156.0 ± 13.3 %ID/g, respectively.  
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Figure 2. Ex vivo biodistribution results of mice bearing subcutaneous IGF-1R expressing SUM149 xenografts at 
several time points after intravenous injection of A: 111In-R1507 IgG, B: 111In-F(ab’)2 or C: 
111In-Fab. D: Summary of 
tumor-to-blood ratios of all three radiotracers. Data are presented as mean ± SD (n = 5 per group).
SPECT/CT with 111In-R1507 IgG, 111In-F(ab’)2 and 
111In-Fab
Figure 3A shows typical SPECT/CT images of 111In-R1507 IgG. At 6 h after injection, tumors 
were visible but uptake in the tumor was the same in mice that were injected with an excess 
of unlabeled antibody and was therefore not specific for IGF-1R. At later time points (24 
and 72 h), tumors were more clearly visualized and tumor uptake was IGF-1R mediated. 
Due to the increase in tumor uptake and clearance from the circulation, tumor-to-normal 
tissue contrast increased over time. SPECT/CT images also showed nonspecific uptake of 
111In-R1507 IgG in the liver and spleen. Tumor uptake was derived from the SPECT images 
obtained at 6, 24 and 72 h post injection and was 12.4 ± 2.8 %ID/g, 15.9 ± 2.4 %ID/g, 26.9 
± 3.0 %ID/g, respectively. In the ex vivo biodistribution (72 h p.i.), mean tumor uptake of 
111In-R1507 IgG was 25.7 ± 3.4 % ID/g and tumor-to-blood ratio was 2.3 ± 0.3 (Table 3).
Representative SPECT/CT images of 111In-F(ab’)2 are presented in Figure 3B. As early as 2 
h after injection of 111In-F(ab’)2, SUM149 xenografts were clearly visualized. At later time 
points (6 and 24 h), tumor-normal tissue contrast improved due to the clearance of 111In-
F(ab’)2 from the circulation. At all time points, tumor uptake was likely to be specific for 
IGF-1R, as indicated by the higher tumor-normal tissue contrast than in mice injected 
with an excess of unlabeled R1507 IgG. High accumulation of radiolabeled F(ab’)2 in the 
kidneys was observed, with activity mainly localized in the renal cortex. In addition, 111In-
F(ab’)2 also accumulated in spleen and liver. However, uptake in these organs was not IGF-
1R mediated. Tumor uptake was calculated from the SPECT images obtained at 2, 6 and 
24 h post injection and was 6.0 ± 2.5 %ID/g, 6.3 ± 2.1 %ID/g, 6.2 ± 1.7 %ID/g, respectively. 
The ex vivo biodistribution (24 h p.i.), showed a mean tumor uptake of 111In-F(ab’)2 of 6.7 ± 
1.6 % ID/g and a tumor-to-blood ratio of 9.1 ± 2.4 (Table 3).
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Table 3. Ex vivo biodistribution of 111In-R1507 IgG, 111In-F(ab’)2 and 
111In-Fab in mice with 
subcutaneous SUM149 xenografts. Data are presented as mean ± SD (n = 4 per group).
111In-R1507 IgG 
(72 h p.i.)
111In-F(ab’)2 
(24 h p.i.)
111In-Fab  
(6 h p.i.)
Blood 11.3 ± 0.7 0.7 ± 0.04 0.2 ± 0.03
Muscle 1.0 ± 0.04 0.3 ± 0.04 0.2 ± 0.04
Tumor 25.7 ± 3.4 6.7 ± 1.6 0.8 ± 0.1 
Lung 7.3 ± 0.5 1.2 ± 0.1 0.4 ± 0.1
Spleen 8.0 ± 2.1 7.3 ± 1.4 0.9 ± 0.1
Pancreas 1.9 ± 0.3 0.5 ± 0.04 0.2 ± 0.01
Kidney 6.3 ± 1.5 80.2 ± 6.9 155.6 ± 9.2
Liver 4.7 ± 0.3 4.5 ± 0.9 1.0 ± 0.1
Small intestine 2.4 ± 0.5 1.1 ± 0.3 0.3 ± 0.1
Tumor-to-muscle ratio 26.7 ± 3.6 21.7 ± 6.1 4.8 ± 1.1
Tumor-to-blood ratio 2.3 ± 0.3 9.1 ± 2.4 4.3 ± 0.7
Figure 3C shows typical SPECT/CT images of 111In-Fab. Tumors were visualized, however, 
tumor-to-normal tissue contrast was low and similar to those in mice that received an 
excess of unlabeled R1507, indicating that tumor uptake was not IGF-1R mediated. Similar 
to 111In-F(ab’)2, high accumulation of radiolabeled Fab in the kidneys was observed, with 
activity  mainly localized in the renal cortex. In addition, 111In-Fab also accumulated in 
spleen and liver. Tumor uptake was calculated from the SPECT images obtained at 1, 2 and 
6 h post injection and was 1.7 ± 0.1 %ID/g, 1.3 ± 0.1 %ID/g, 0.9 ± 0.1 %ID/g, respectively.
The ex vivo biodistribution (6 h p.i.), showed that the mean tumor uptake of 111In-F(ab’) 
was 0.8 ± 0.1 % ID/g and tumor-to-blood ratio was 4.3 ± 0.7 (Table 3).
Tumor uptake obtained from SPECT images correlated significantly with the uptake 
measured in the ex vivo biodistribution study (Pearson R = 0.98).
Discussion
This study showed the potential of 111In-F(ab’)2 to image IGF-1R expressing tumors. The main 
advantages of 111In-F(ab’)2 compared to 
111In-R1507 IgG are the more rapid accumulation 
in the tumor and more rapid clearance from the circulation. Therefore, IGF-1R expressing 
xenografts can be visualized within several hours after injection. In addition, tumor-to-
blood ratios at 24 h after injection were significantly higher as compared to intact R1507. 
Further reducing the size of the antibody into Fab fragments decreased the affinity for 
IGF-1R and resulted in an almost complete loss of specific in vivo tumor targeting. 
In vitro experiments were performed to compare the IGF-1R binding characteristics 
of R1507 IgG, F(ab’)2 and Fab. Overall, binding characteristics (immunoreactivity, 
internalization, IC50 and Kd) of 
111In-R1507 and 111In-F(ab’)2 were similar. In contrast, 
111In-Fab had a markedly lower IC50 and Kd, most likely due to the monovalency of Fab 
fragments. A similar reduction of the affinity has been observed for other Fab fragments, 
like trastuzumab and cG250 Fab.(20, 21) 
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Figure 3. Representative SPECT and SPECT/CT images of mice bearing subcutaneous IGF-1R expressing SUM149 
xenografts (white arrows) at several time points after intravenous injection of A: 111In-R1507 IgG, B: 111In-F(ab’)2 
or C:111In-Fab.
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In vivo biodistribution studies showed that both 111In-R1507 IgG and 111In-F(ab’)2 
efficiently and specifically accumulated in the IGF-1R expressing tumors, while 111In-Fab 
fragments hardly showed any specific tumor uptake. Absolute tumor uptake was highest 
for 111In-R1507 IgG (maximum uptake at 72 h p.i.: 31.8 %ID/g), compared with 111In-F(ab’)2 
(maximum uptake at 6 h p.i.: 10.0 %ID/g) and 111In-Fab (maximum uptake at 1 h p.i.: 1.8 
%ID/g). However, tumor-to-blood ratios were more than 2-fold higher for 111In-F(ab’)2 
(optimal time point 24 h p.i.: 7.5) compared to 111In-R1507 IgG (optimal time point 72 h p.i.: 
2.8), which can be explained by differences in the circulatory half-lives of the radiotracers. 
The more rapid elimination of F(ab’)2 from the circulation is most likely explained by its 
reduced size and the lack of Fc domains. Fc domains can interact with the neonatal Fc 
receptor which mediates recycling of these molecules.(17)
111In-F(ab’)2 was cleared via the kidneys, resulting in high kidney accumulation, which 
was not found for 111In-R1507 IgG. This high accumulation indicates that R1507 F(ab’)2 
fragments were reabsorbed after glomerular filtration. Although the threshold for 
glomerular filtration is around 60 kDa, several F(ab’)2 fragments have been shown to 
accumulate in the kidneys.(22-25) The mechanism of kidney uptake is poorly understood. 
A potential explanation might be that F(ab’)2 fragments are dissociated or enzymetically 
cleaved into smaller molecules such as Fab’ which can pass the glomerular membrane. This 
hypothesis is supported by the fact that chemically stabilized F(ab’)2 fragments showed 
significantly lower renal accumulation than enzymatically prepared F(ab’)2 fragments.(26)
High kidney accumulation may be a disadvantage because it can interfere with the 
visualization of tumor lesions located in the vicinity of the kidney. However, in most breast 
cancer patients this is not a major problem, since kidneys metastases are uncommon.(27, 
28) Nevertheless, visualization of lower vertebral lesions could be improved by applying 
strategies to reduce the tubular reabsorption of antibody fragments in the kidneys. For 
example, by using positively charged amino acids, gelofusin or albumin fragments.(29-31)
The main advantage of 111In-F(ab’)2 over 
111In-R1507 IgG is the possibility to perform imaging 
as early as 6 hours after injection. At that time, tumor uptake and tumor/normal tissue 
contrast is sufficient to visualize tumor lesions with 111In-F(ab’)2, while at that time point 
no specific targeting of 111In-R1507 IgG can be detected yet. Also, 24 hours after injection, 
tumor-to-blood ratios of 111In-F(ab’)2 were significantly higher than those of 
111In-R1507 
IgG at 72 hours. Even at 144 h after injection, tumor-to-blood ratios of 111In-F(ab’)2 were 
twice as high than those of 111In-R1507 IgG (3.8 versus 7.5, previously published data).(15) 
Imaging at early time points after injection is especially important when repeated imaging 
is required within short time intervals. For example when studying the dynamics of IGF-1R 
expression during treatment or disease progression in preclinical studies. This is relevant 
since IGF-1R expression may change over time because of cytotoxic, anti-estrogen or anti-
HER2 treatment or tumor progression.(6-9) Moreover, imaging at several hours instead of 
several days after injection is more practical in the clinical situation. 
Besides radiolabeling of antibodies and antibody fragments, other approaches for in vivo 
imaging of  IGF-1R expression have been studied. Cornelissen et al. have used 111In-IGF-
1(E3R), an analogue of IGF-1 which does not bind IGF binding proteins, to visualize IGF-1R 
expression of subcutaneous MCF-7/HER2-18 tumors with microSPECT. However, 111In-IGF-
1(E3R) showed lower tumor uptake and lower tumor-to-normal tissue contrast compared 
with 111In-R1507 IgG and 111In-F(ab’)2.(32) 
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Another tracer used for visualization of IGF-1R expression is the Affibody molecule ZIGF-
1R:4551.(33) ZIGF-1R:4551 has affinity for both murine as well as for human IGF-1R. As a result, 
targeting of human tumors and IGF-1R expressing normal tissue can be studied in mice 
with human tumor xenografts. This makes it an adequate model to evaluate IGF-1R 
targeting in vivo because a high expression in normal organs can affect tumor-normal 
tissue contrast. SPECT imaging with this tracer allowed the visualization of IGF-1R 
expressing prostate cancer xenografts, even while the uptake in normal IGF-1R expressing 
organs was considerable.
Our studies have shown the feasibility of 111In-R1507 IgG and 111In-F(ab’)2 SPECT/CT for 
in vivo imaging of IGF-1R expression. However, these experiments were performed 
under optimal conditions, since R1507 does not cross react with the murine IGF-1R. In 
patients, radiolabeled R1507 IgG and F(ab’)2 will also recognize IGF-1R which is widely 
expressed in normal tissues, including muscle, cartilage and bone.(34-36) This could result 
in enhanced uptake in IGF-1R expressing normal tissues, as shown by Tolmachev et al.(33) 
Future studies will have to show whether imaging of IGF-1R expression with SPECT is also 
feasible in patients. 
Conclusion
111In-F(ab’)2 fragments improved the imaging of IGF-1R expressing tumors by faster and 
better targeting. Tumor-to-blood ratios were twice as high compared to 111In-R1507 IgG 
and SPECT/CT images could be acquired as early as 6 h p.i. For individualization and 
optimization of IGF-1R targeted therapy,  111In-F(ab’)2 may be the tracer of choice.
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Abstract
Introduction: The aim was to assess changes in IGF-1R expression with immunoSPECT/CT 
and to study the dynamics of IGF-1R expression of human breast tumors during endocrine 
treatment. 
Material and methods: Mice with MCF-7 xenografts were treated with estradiol 
or tamoxifen and IGF-1R expression was measured by immunohistochemistry and 
immunoSPECT/CT using 111In-R1507 (anti-IGF-1R antibody). Moreover, IGF-1R expression 
was analyzed immunohistochemically on 22 human breast tumors, treated preoperatively 
with endocrine therapy.
Results: Estradiol resulted in an increased expression of IGF-1R, as measured by 
immunohistochemistry and immunoSPECT/CT. In contrast, tamoxifen resulted in a down 
regulation of IGF-1R, whereas this could not be measured with immunoSPECT/CT. A down 
regulation was also detectable in 9 out of 22 (41%) human breast tumors after endocrine 
therapy.  
Conclusion: Anti-estrogen treatment can cause a reduction in membranous IGF-1R 
expression. Based on these results, a combination of anti-IGF-1R antibodies with anti-
estrogen therapy might not be a rational treatment strategy. 
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Introduction
The insulin-like growth factor 1 receptor (IGF-1R) is a target for the treatment of 
breast cancer. Upon binding of insulin-like growth factors (IGFs) to IGF-1R, the 
phosphatidylinositol-3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) 
pathways can be activated, resulting in proliferation and inhibition of apoptosis.(1, 2) In 
breast cancer, IGF-1R expression is positively correlated with the presence of the estrogen 
receptor (ER). Approximately 40 to 60% of ER-positive tumors express IGF-1R, while 
expression in ER-negative tumors is only 10 to 20%.(3) In general, IGF-1R correlates with 
good prognostic markers, however, in ER-negative tumors its expression is associated 
with a worse prognosis.(4, 5) 
Cross-talk between IGF-1R and ER has been described in multiple studies. For example, 
estradiol can increase the expression of IGF-1R.(6) IGF-1R is one of the target genes of ER 
and upon binding of estradiol to ER, transcription and translation of IGF-1R can be induced. 
(7) Also, estradiol can stimulate cytosolic ER, which can directly cause phosphorylation of 
IGF-1R, which results in activation of downstream pathways.(8) On the other hand, anti-
estrogens such as tamoxifen can downregulate the expression of IGF-1R (6) and anti-
estrogens can alter the expression of other molecules in the IGF pathway such as IGF-2, 
insulin receptor substrate 1 (IRS-1), IGF binding protein 3 (IGFBP3) or IGF-2R.(9) 
The effects of estrogens and anti-estrogens on IGF-1R expression can be of clinical 
importance, as in vitro studies have shown that IGF-1R expression is necessary for antitumor 
activity of anti-IGF-1R antibodies.(10, 11) Therefore, patient selection for IGF-1R targeted 
therapy may be based on receptor expression. Thus far, evaluation of IGF-1R expression 
is usually performed by immunohistochemistry on archival tumor material. However, 
immunohistochemistry is not a very suitable technique to measure receptor expression 
at several time points, or in several tumor lesions, as this would require multiple invasive 
procedures. In addition, target accessibility of the receptor for its therapeutic agent is not 
taken into account. Several factors may influence whether therapeutic agents will reach 
the tumor cells, such as blood vessel density, vascular permeability and intratumoral 
interstitial fluid pressure.(12, 13) If target accessibility is low, therapeutic agents cannot 
reach the tumor and may be ineffective despite adequate expression of receptors on the 
tumor cells as determined by immunohistochemistry.  Therefore, in vivo imaging of IGF-
1R expression using radiolabeled anti-IGF-1R antibodies may be useful to select patients 
who are most likely to benefit from IGF-1R targeted therapy. 
Previously, we have developed a noninvasive imaging technique using R1507, a fully 
human monoclonal antibody directed against human IGF-1R. After radiolabeling R1507 
with 111Indium (111In) or with 89Zirconium (89Zr), we were able to visualize IGF-1R expressing 
breast cancer xenografts with immunoSPECT and immunoPET, respectively.(14) This study 
was performed in a triple-negative breast cancer model with constant IGF-1R expression. 
The aim of the current study is to study the dynamics of IGF-1R expression in estrogen 
receptor (ER) positive breast cancer xenografts and human tumors upon endocrine 
treatment and to assess the dynamics of IGF-1R expression in vivo using 111In-R1507 
immunoSPECT/CT. 
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Material and methods
Cell culture
MCF-7 cells were cultured and maintained as monolayer in culture flasks in RPMI 1640 
(GIBCO, BRL Life Sciences Technologies, The Netherlands) supplemented with 10% fetal 
calf serum (FCS), 2 mM glutamine, penicillin (100 units/ml) and streptomycin (100 µg/ml) 
at 37 °C in a humidified atmosphere with 5% CO2. 
Radiolabeling
The human monoclonal antibody R1507 was obtained from Roche Diagnostics (Penzberg, 
Germany) and is directed against an epitope on the extracellular domain of the human 
IGF-1R. It does not cross react with the human insulin receptor (IR) and murine IGF-1R and 
IR. R1507 was conjugated with isothiocyanatobenzyl-diethylenetriaminepentaacetic acid 
(ITC-DTPA, Macrocyclis, Dallas, TX) and labeled with 111In as described previously.(14, 15) 
Radiochemical yield of 111In-DTPA-R1507 (111In-R1507) exceeded 95% in all experiments. 
The immunoreactive of 111In-R1507 exceeded 90%, as described previously.(14)
In vitro studies
Scatchard analysis
MCF-7 cells were cultured to confluency in six-well plates. To determine the dissociation 
constant (Kd) and receptor density of IGF-1R, cells were incubated in triplicate for 4 h at 
4 °C in 1.5 ml binding buffer (RPMI 1640, 0.5% BSA) with increasing concentrations 111In-
R1507 (0.3 – 3,000 pM, specific activity 0.4 MBq/µg). Nonspecific binding was determined 
by incubation in the presence of 300 nM unlabeled R1507. After incubation and, cells were 
washed twice with PBS and were lysed in 0.1 M NaOH and the cell-associated activity was 
measured in a gamma counter (Perkin-Elmer, Boston, MA, USA).
Regulation of IGF-1R expression by estradiol and tamoxifen
MCF-7 cells were cultured for 72 h in 6-wells plates with increasing concentrations of 
17β-estradiol (0 – 10 nM) or tamoxifen (0 - 10 µM). Subsequently, cells were washed once 
with PBS and incubated for 4 h at 4 °C in 1.5 ml binding buffer with 0.3 nM 111In-R1507 (0.4 
MBq/µg). Non specific binding was determined by co-incubation with an excess of 300 
nM unlabeled R1507. After incubation and washing, cell-associated activity was measured 
in a gamma counter (Perkin-Elmer, Boston, MA, USA). To study the effect of ER signaling on 
IGF-1R expression in time, MCF-7 cells were cultured in the presence of 17β-estradiol (10 
nM) or tamoxifen (1 μM) for 4 to 96 h. Cell-associated activity was measured as described 
above. 
Animal studies
Animal experiments were performed in female BALB/c nude mice (non-ovariectomized) 
and were conducted in accordance with the principles laid out by the revised Dutch Act 
on Animal Experimentation (1997) and approved by the institutional Animal Welfare 
Committee of the Radboud University Nijmegen. At 6-8 weeks of age experiments were 
started. Mice were inoculated subcutaneously with 5 x 106 MCF-7 cells (200 µl, mixed 
1:1 with matrigel, BD Biosciences, Pharmingen). Experiments were started when tumors 
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reach a size of approximately 0.1 cm3 (without estradiol: approximately 21 days after 
inoculation, with estradiol: approximately 14 days after inoculation)
Modulation of IGF-1R expression of MCF-7 xenografts by estradiol 
Ten out of twenty BALB/c nude mice with MCF-7 tumors were implanted subcutaneously 
with a slow release estradiol pellet (0.18 mg, 60 days, Innovative Research of America, 
Sarasota, FL) under general anesthesia (isoflurane/O2). The other ten mice (control group) 
underwent a sham operation. At the same day of pellet implantation, five control mice 
and five mice with estradiol pellets received an intravenous injection in the tail vein of 
30 MBq 111In-R1507 (specific activity 10 MBq/µg). Three days after implantation of the 
estradiol pellets, the remaining ten mice received 30 MBq 111In-R1507 intravenously. 
Animals were euthanized and SPECT/CT images were acquired with the U-SPECT-II 
(MILabs, Utrecht, The Netherlands), three days after injection of 111In-R1507.(16) Mice were 
scanned for 40 min using the 1.0 mm diameter pinhole rat collimator tube, followed  by 
a CT scan (spatial resolution 160 µm, 65 kV, 612 µA) for anatomical reference. Scans were 
reconstructed with MILabs reconstruction software, using an ordered-subset expectation 
maximization algorithm, with a voxel size of 0.375 mm. Representative cross sections 
located approximately in the center of the tumor were displayed. After scanning, the 
biodistribution of the radiolabel was determined ex vivo. Tumor, blood, muscle, lung, 
heart, spleen, pancreas, intestine, kidney and liver were dissected and weighed. Activity 
was measured in a gamma counter. To calculate the uptake of radiolabeled antibodies in 
each sample as a fraction of the injected dose, aliquots of the injected dose were counted 
simultaneously. The results were expressed as %ID/g.
Modulation of IGF-1R expression by tamoxifen 
Four groups of five mice bearing MCF-7 xenografts (with a subcutaneous estradiol pellet 
from the day of tumor cell inoculation), were treated for five days intraperitoneally with 
tamoxifen (6 mg/kg, 19 and 50 mg/kg body weight in corn oil) or vehicle only. After two 
days of tamoxifen treatment, mice were injected intravenously with 0.2 MBq 111In-R1507 
(specific activity: 0.4 MBq/μg). Three days later, mice were euthanized and uptake of the 
radiolabel in necropsied tissues was determined. In a separate study, four groups of five 
mice were treated for ten days with 19 mg/kg tamoxifen or vehicle only. At day seven of 
treatment, mice were injected with 0.2 MBq 111In-R1507 (specific activity: 0.4 MBq/µg). 
Two groups were coinjected with an excess of unlabeled R1507 (300 μg) to study the 
nonspecific tumor uptake.
For immunoSPECT/CT studies, two groups of five mice with MCF-7 xenografts were 
treated with tamoxifen (19 mg/kg body weight or vehicle only). At day 7 of treatment, 
mice were injected intravenously with 22 MBq 111In-R1507 (specific activity: 9.6 MBq/μg) 
and three days later SPECT/CT images were acquired as described previously. In addition, 
the biodistribution of the radiolabeled antibody was determined ex vivo. 
Immunohistochemistry of MCF-7 tumors
IGF-1R and CD34 expression in MCF-7 xenografts was analyzed by immunohistochemistry. 
Tumors were fixed in 4% formalin and embedded in paraffin. Antigen retrieval was 
performed in 10 mM sodiumcitrate, pH 6.0 for 10 minutes at 99°C. Endogenous peroxidase 
activity was blocked with 3% H2O2 in PBS (10 minutes at RT) and nonspecific binding was 
blocked by incubation with 20% normal goat serum (30 minutes at RT). Subsequently, 
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tumor sections were incubated with rabbit-anti-IGF-1R (3027, Cell Signaling, Danvers, MA, 
overnight at 4 °C) or rabbit-anti-CD34 primary antibody (ab8458, Abcam, Cambride, UK, 1 
h at RT), followed by incubation with a goat-anti-rabbit biotinylated secondary antibody 
(Vector Laboratories, Burlingame, CA) for 30 minutes at RT. Finally, avidin-biotin-enzyme 
complex (Vector Laboratories, Burlingame, CA) was applied for 30 minutes at RT and 3, 
3’-diaminobenzidine (DAB) was used to develop the tumor sections. 
IGF-1R expression was scored as negative (0), incomplete weak (1+), complete weak to 
moderate (2+) and strong (3+) membrane staining (Table 1). The mean vascular density 
(MVD) was scored as the number of vessels counted in 3 hot spot areas that contained the 
maximum number of vessels. 
Table 1. Scoring of membranous IGF-1R expression
Score Staining pattern
0 No staining is observed, or membrane staining is observed in <10% of the tumor cells
1+ A faint/barely perceptible membrane staining is detected in >10% of tumor cells. The 
cells exhibit incomplete membrane staining 
2+ A weak to moderate complete membrane staining is observed in >10% of tumor cells 
3+ A strong complete membrane staining is observed in >10% of tumor cells 
Analysis of IGF-1R expression of human breast tumors treated with endocrine 
therapy
Biopsies and surgical material was obtained from patients that were included in the 
AFTER study (ClinicalTrials.gov Identifier NCT00738777). In short, the AFTER study is 
an pre-operative window study to determine the molecular and biological changes in 
breast cancer after short term endocrine therapy exposure. Patients with proven estrogen 
receptor-positive invasive adenocarcinoma (size ≥ 1 cm) and a WHO-performance score of 
0 or 1 were eligible to enter the study. After informed consent, patients were randomized 
to receive pre-operative treatment for 2 – 6 weeks with tamoxifen (loading dose of 40 mg, 
three times a day, orally during 7 days, followed by 20 mg, daily, orally), Anastrozole (1 mg, 
daily, orally) or Fulvestrant (500 mg intramuscular at day 1, 15 and 29). The clinical study 
was approved by the regional ethical review board (CMO).
IGF-1R membrane expression before and after endocrine therapy was analyzed by 
immunohistochemical analysis of tumor sections obtained from the biopsy at diagnosis 
and surgical resection material, respectively. First, endogenous peroxidase activity was 
blocked and antigen retrieval was performed as described above. Subsequently, tumor 
sections were incubated with anti-IGF-1R (3027, Cell Signaling, overnight at 4 °C) followed 
by incubation with Poly-HRP-Anti-mouse/rabbit/rat IgG (DPVO110HRP, Immunologic, 
Duiven, The Netherlands) for 30 minutes at RT. DAB was used to develop the tumor 
sections. IGF-1R expression was scored as described previously (Table 1). Tumors with a 
membrane expression of 0 or 1+ were scored as IGF-1R negative, while 2+ or 3+  tumors 
were IGF-1R positive. Down-regulation of IGF-1R expression was defined as a change from 
positive to negative.
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Statistical analysis
Statistical analyses were performed using SPSS software version 16.0 (Chicago, IL) and 
GraphPad Prism version 4.00 (San Diego, CA) for Windows. Differences in uptake of 
radiolabeled antibodies were tested for significance using the nonparametric Kruskal-
Wallis and Mann-Whitney U test. Differences in IGF-1R expression before and after 
endocrine therapy of patients included in the AFTER study was tested using the related-
samples Wilcoxon-signed rank test. All tests were two-sided and a p-value below 0.05 was 
considered significant.
Results
In vitro
Scatchard analysis
111In-R1507 exhibited a Kd value of 0.69 nM (95% CI: 0.54 – 0.96 nM) and the IGF-1 receptor 
density of MCF-7 cells was 34,000 receptor/cell (95% CI: 29,000 – 46,000 receptor/cell). 
Modulation of IGF-1R expression by estradiol and tamoxifen in vitro
IGF-1R expression of MCF-7 cells increased in a dose-dependent manner after incubation 
with estradiol (Figure 1A and 1B). Cells treated for 72 h with 1 nM estradiol showed IGF-
1R expression which was twice as high as untreated cells. IGF-1R expression started 
to increase between 24 and 48 hours of incubation. In contrast, IGF-1R expression of 
tamoxifen treated cells was twice as low as the expression of untreated cells. A decrease in 
expression could be measured as early as 16 h after start of treatment (Figure 1C and1D).
Figure 1. MCF-7 cells cultured (A) for 72 h with increasing concentrations estradiol or (B) with 10 nM estradiol 
at various time points, showed enhanced binding of 111In-R1507, compared with untreated cells. MCF-7 cells 
cultured (C) for 72 h with increasing concentrations tamoxifen or (D) with 1 μM tamoxifen at various time point, 
showed decreased binding of 111In-R1507, compared with untreated cells. Binding is expressed relative to 
baseline, which is defined as binding of 111In-R1507 to untreated cells. 
A B
C D
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In vivo
Modulation of IGF-1R expression of MCF-7 xenografts by estradiol 
Treatment of mice with estradiol resulted in an increased expression of IGF-1R on the cell 
membrane of MCF-7 xenografts. In Figure 2A, typical examples of IGF-1R expression of 
estradiol-treated and untreated tumors are presented. IGF-1R expression of untreated 
tumors was generally scored as 0 or 1+, while estradiol-treated tumors exhibited an IGF-
1R expression of 2+. 
Accumulation of 111In-R1507 was significantly enhanced in estradiol-treated tumors. After 
three days of treatment, tumor uptake in untreated versus treated tumors was 10.9 ± 1.5 
%ID/g and 14.2 ± 1.8 %ID/g (p = 0.01), respectively. Tumor-blood ratio of the tracer also 
increased significantly by 50%: from 1.2 ± 0.2 to 1.8 ± 0.1 (p = 0.01, Figure 2). There was 
a trend towards faster clearance of 111In-R1507 from the blood in estradiol-treated mice 
compared to untreated mice. The concentration of 111In-R1507 in blood of untreated mice 
compared to treated mice was 9.3 ± 1.5 %ID/g and 7.9 ± 0.7 %ID/g (p = 0.08). A similar 
effect was observed after 6 days of estradiol treatment. Tumor-blood ratio increased 
significantly by 83% from 1.2 ± 0.2 to 2.2 ± 0.3 (p = 0.01) for untreated versus estradiol 
treated mice. Again, 111In-R1507 cleared more rapidly from blood in estradiol treated mice 
compared to untreated mice.
Figure 2. A: Immunohistochemical analysis of MCF-7 xenografts treated with or without an estradiol pellet 
showed increased membranous IGF-1R expression (magnification 40x). Targeting of 111In-R1507 was significantly 
increased after estradiol treatment. Tumor-blood ratios (* p<0.05) are depicted in B and ImmunoSPECT/CT 
images of mice bearing MCF-7 xenografts (with or without estradiol pellet for 6 days) are depicted in C. White 
arrows indicate the MCF-7 xenograft, red arrows indicate the estradiol pellet.
The results from the ex vivo biodistribution were confirmed by the imaging studies (Figure 
2). SPECT/CT images showed enhanced uptake of 111In-R1507 in tumors of the estradiol-
A
B C
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treated mice. Quantitative analysis of the images revealed that mean uptake of 111In-R1507 
in tumors treated for 3 days with estradiol was 11.0 ± 1.9 %ID/g, compared to 9.2 ± 1.7 
%ID/g for untreated tumors (p = 0.35). After six days of estradiol treatment, tumor uptake 
increased by 42% from 6.8 ± 1.3 %ID/g (untreated tumors) to 9.7 ± 0.8 %ID/g (estradiol 
treated tumors) (p= 0.009). 
To study whether targeting of 111In-R1507 was affected by changes in tumor vasculature 
caused by estradiol treatment, immunohistochemical analysis of CD34 was performed. 
No differences in CD34 expression were observed. The mean vascular density was similar 
in estradiol-treated and untreated xenografts.
Modulation of IGF-1R expression of MCF-7 xenografts by tamoxifen 
Tamoxifen treatment of mice with MCF-7 xenografts, that were grown in the presence 
of an estradiol pellet, resulted in a reduced membranous IGF-1R expression. Non-
treated xenografts exhibited an average IGF-1R expression of 2+, while the expression in 
tamoxifen-treated xenografts was scored as 1+. Typical examples are presented in Figure 
3A. 
Figure 3. A: Immunohistochemical analysis of MCF-7 xenografts treated with or without an tamoxifen  showed 
reduced membranous IGF-1R expression (magnification 40x). Targeting of 111In-R1507 was not significantly 
decreased after tamoxifen treatment. Tumor-blood ratios are depicted in B and ImmunoSPECT/CT images of 
mice bearing MCF-7 xenografts (with or without tamoxifen treatment for 10 days) are depicted in C. White 
arrows indicate the MCF-7 xenograft, red arrows indicate the estradiol pellet.
While immunohistochemistry showed reduced membranous IGF-1R expression after 
tamoxifen treatment, the ex vivo biodistribution studies in mice did not show reduced 
targeting of 111In-R1507 following tamoxifen treatment. Tumor uptake of 111In-R1507 in 
mice treated for five days with vehicle only, 6, 19 and 50 mg/kg body weight tamoxifen 
B C
A
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was 16.4 ± 3.2 %ID/g, 16.1 ± 4.1 %ID/g, 14.1 ± 1.9 %ID/g and 17.1 ± 5.8 %ID/g, respectively. 
Also, ten days after tamoxifen treatment, tumor uptake was similar in treated versus 
untreated animals. In addition, nonspecific tumor uptake was not affected by tamoxifen 
treatment.  Tumor uptake in mice co-injected with an excess of unlabeled R1507 was 10.5 
± 2.8 %ID/g and 10.8 ± 3.8 %ID/g, for treated and untreated mice, respectively. 
ImmunoSPECT/CT in mice that were treated for 10 days with tamoxifen confirmed 
that treatment did not result in decreased tumor targeting of 111In-R1507. SPECT/CT 
and biodistribution studies showed similar tumor uptake in tamoxifen-treated versus 
untreated animals (Figure 3). 
No differences were observed in the CD34 staining. The mean vascular density was similar 
in tamoxifen-treated and untreated xenografts.
Analysis of IGF-1R expression of human breast tumors treated with endocrine 
therapy
Membranous IGF-1R expression was analyzed in samples from 22 patients treated 
preoperatively for 2 to 6 weeks with tamoxifen, fulvestrant or anastrozole. Characteristics of 
the patient population are presented in Table 2. At diagnosis, 12 patients (55%) presented 
with IGF-1R positive tumors. After anti-estrogen treatment, immunohistochemistry was 
performed on the surgical resection material. Only one patient (5%) still had an IGF-1R 
positive tumor (Table 2). In total, IGF-1R expression was down regulated in 9 patients (41%) 
and did not change in another 9 patients (41%). No patient showed an upregulation of 
IGF-1R expression. For four patients (18%), changes in expression could not be analyzed, 
because insufficient tumors 
cells were present in the tissue 
sections to reliably estimate 
IGF-1R expression. The decrease 
in IGF-1R expression was 
significant (p=0.003). In Figure 
4 typical examples of paired 
samples of IGF-1R expression 
before and after endocrine 
therapy are presented. 
Figure 4. Typical examples of down 
regulation of membranous IGF-1R 
expression of paired biopsy (pre 
treatment) and surgical resection 
material (post treatment) of patients 
who received anti estrogen treatment. 
Scoring of IGF-1R membrane expression 
is depicted in the lower left corner.
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Table 2. Patient and tumor characteristics
Characteristic N (%) or 
mean  ± sd
Number of patients 22
Age at diagnosis 61 ± 9 years
Menopausal status
   Premenopausal
   Post menopausal
   Male
4 (18%)
17 (77%)
1 (5%)
Pathology (at diagnosis)
   ER positive
   PR positive
   HER2 positive
22 (100%)
18 (82%)
1 (5%)
Treatment
   Tamoxifen
   Fulvestrant or anastrozole
14 (64%)
8 (36%) 
IGF-1R membrane expression pre treatment
  Negative (0, 1+)
  Positive (2+, 3+)
  Unknown*
8 (36%)
12 (55%)
2 (9%)
IGF-1R membrane expression post treatment
  Negative (0, 1+)
  Positive (2+, 3+)
  Unknown*
19 (83%)
1 (5%)
2 (9%)
*Insufficient tumor cells in biopsy or surgical material to accurately 
determine IGF-1R expression.
Discussion
This study showed that estradiol induced an upregulation of membranous IGF-1R 
expression of MCF-7 cells and xenografts, while tamoxifen treatment resulted in a down 
regulation of IGF-1R expression. Furthermore, we showed that down regulation of IGF-1R 
expression also occurred in breast cancer patients after short-course preoperative anti-
estrogen treatment. 
Based on clear cross talk between IGF-1R and ER,(6-9) it has been hypothesized that 
patients with ER positive cancer may benefit from IGF-1R targeted therapy and that the 
combination of IGF-1R and ER inhibitors may result in improved therapeutic efficacy. 
However, a clinical trial with the anti-IGF-1R antibody AMG479 failed to show clinical 
benefit in patients with ER-positive tumors who had progressed on previous endocrine 
therapy. The combination of AMG479 with exemestane or fulvestrant did not improve the 
progression free survival compared to patients that received placebo and exemestane 
or fulvestrant.(17) Of note, preclinical studies have evaluated IGF-1R expression during 
tamoxifen resistance and reported reduced expression of IGF-1R mRNA. (18) Also, in a 
study in patients with recurrent breast tumors treated with tamoxifen for at least 6 months, 
IGF-1R expression was significantly lower in the recurrent lesions, compared to the 
primary tumors.(19) In fact, as shown in our study, already after a short course (2-6 weeks) 
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of endocrine therapy, levels of IGF-1R expression may be reduced and,  therefore, these 
patients may not benefit from IGF-1R targeted therapy. Together, these results suggest 
that it might not be effective to combine endocrine therapy with IGF-1R inhibitors or to 
treat hormone resistant breast tumors with anti-IGF-1R antibodies.
In addition to immunohistochemical studies, we used 111In-R1507 immunoSPECT/CT 
to noninvasively study IGF-1R expression of hormone receptor positive breast cancer 
xenografts in mice. After estradiol treatment, the uptake of 111In-R1507 in MCF-7 tumors 
was significantly enhanced which correlated with increased levels of membranous IGF-1R 
as observed immunohistochemically. However, in this model 111In-R1507 immunoSPECT/
CT could not detect the tamoxifen-mediated down regulation in membranous 
IGF-1R expression levels. A similar discrepancy between immunoSPECT/CT and 
immunohistochemical results has been obtained in a previous study in sarcoma xenografts. 
(19) This study showed that IGF-1R expression as measured by immunohistochemistry 
and western blot did not always correlate with the targeting of 111In-R1507 to sarcoma 
xenografts. However, accumulation of 111In-R1507 in the tumor measured by 111In-R1507 
immunoSPECT/CT, rather than immunohistochemistry and western blot, was predictive 
for response to anti-IGF-1R treatment.(20) These results indicate that although receptor 
expression is an important factor for antibody tumor targeting and therapeutic efficacy, 
other factors should be taken into account as well. 
For example, previous studies have reported that IRS-1, IRS-2, IGF-2 or nuclear IGF-
1R expression may be predictive for response to IGF-1R targeted therapy.(11, 21, 22) 
In addition, antibody targeting can be affected by tumor vascular density, vascular 
permeability, interstitial fluid pressure, necrosis and perfusion all contribute to the amount 
of antibody accumulating in a tumor.(12, 13, 23) Importantly, several types of therapy such 
as anti-angiogenic treatment directed at vascular endothelial growth factor (VEGF), can 
alter tumor vasculature in such a way that it could hamper effective drug delivery.(24, 25) 
Interestingly,  several studies have also reported that hormones and endocrine therapy 
can have an effect on the VEGF pathway.(26-28) This suggests that tamoxifen treatment in 
our xenograft models may have altered tumor vascularization which might have affected 
targeting of 111In-R1507 to MCF-7 xenografts. 
Phase I/II studies with anti-IGF-1R antibodies have shown the safety and tolerability of 
targeting IGF-1R. Furthermore, these studies demonstrated a wide range of responses, 
from progressive disease to near complete response (29-31). Although these results 
seemed promising, larger randomized phase III trials failed to show a clear benefit from 
targeting IGF-1R in combination with conventional treatment strategies.(17, 32, 33) 
However, these trials were conducted in unselected patient populations. Since early 
phase trials have shown meaningful single-agent responses, it is of importance to be able 
to identify those patient that potentially benefit from IGF-1R targeted therapy. Therefore, 
in vivo imaging may be useful to select patients who are most likely to benefit from IGF-1R 
targeted therapy. 
The advantage of a therapeutic antibody such as R1507 as an imaging agent is that the 
targeting of the therapeutic drug can be imaged directly. However, when quick changes 
in receptor expression are being studied, intact antibodies such as R1507 are not the 
preferred tracer since they accumulate slowly in the tumor (3 – 7 days). Therefore, we 
have previously shown the feasibility of using R1507 F(ab’)2 fragments to image IGF-1R 
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expression, which allows imaging as early as 6 hours post injection. (34) Also, 111In-IGF-
1(E3R), an analogue of IGF-1 which does not bind IGF binding proteins, has been used to 
visualize IGF-1R expression of subcutaneous breast cancer xenografts with microSPECT. 
However, the tumor uptake and tumor-to-normal tissue contrast of 111In-IGF-1(E3R) were 
lower than that of 111In-R1507 IgG and 111In-F(ab’)2.(35) Another radiotracer that has been 
developed to target IGF-1R is the Affibody molecule ZIGF-1R:4551.(36) ZIGF-1R:4551 has affinity for 
the murine and the human IGF-1R. Therefore, this tracer can be used to study targeting 
of human tumors and IGF-1R expressing normal tissue in mice bearing human tumor 
xenografts. SPECT imaging with ZIGF-1R:4551 showed that IGF-1R expressing prostate cancer 
xenografts can be visualized as early as 1 hour post injection, even while the targeting to 
normal IGF-1R expressing tissues was considerable.
Conclusion
Anti-estrogen therapy can down regulate membranous IGF-1R expression, both in 
the preclinical and clinical setting. In patients, this effect can occur within a few weeks 
after start of treatment. Targeting of 111In-R1507 to IGF-1R expressing xenografts can be 
measured by immunoSPECT/CT. However, next to expression of IGF-1R other factors may 
influence antibody accumulation in the tumor. Future research is warranted to determine 
which mechanisms are involved. 
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Abstract
Introduction: The insulin-like growth factor 1 receptor (IGF-1R) is a potential target for 
breast cancer treatment and may be involved in the development of resistance against 
conventional cancer treatment. The aim of this study was to assess whether IGF-1R 
expression of breast tumors changes during neoadjuvant therapy and to study whether 
these changes were associated with survival. 
Material and methods: Paraffin embedded tumor tissue was collected from pretreatment 
biopsies and surgical resections of 62 breast cancer patients who were treated with 
neoadjuvant chemotherapy or endocrine therapy. IGF-1R, ER, PR, HER2, Ki67 and cleaved 
caspase-3 expression were determined immunohistochemically and compared before 
and after treatment. 
Results: High membranous IGF-1R expression at diagnosis correlated significantly with 
ER positivity, low tumor stage (stage I/II) and longer overall survival (p < 0.05). After 
neoadjuvant treatment, membranous IGF-1R expression remained the same in 41 (65%) 
tumors, was upregulated in 11 (18%) tumors and downregulated in 11 (18%) tumors. 
Changes in membranous IGF-1R expression were significantly associated with overall 
survival (log-rank test: p = 0.013, multivariate cox-regression: p = 0.086). Mean overall 
survival time for upregulation, no change, and downregulation in IGF-1R expression 
was 3.0 ± 0.5 years, 7.3 ± 1.0 years and 15.0 ± 1.8 years, respectively. Changes in other 
parameters were not significantly associated with survival. 
Conclusion: Neoadjuvant therapy can induce changes in IGF-1R expression. Upregulation 
of IGF-1R expression after neoadjuvant treatment is a poor prognostic factor in breast 
cancer patients, providing a rationale for incorporating anti-IGF-1R drugs in the 
management of these patients. 
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Introduction
The insulin-like growth factor 1 receptor (IGF-1R) is a receptor tyrosine kinase that plays 
a role in cancer development and progression.(1-3) In breast cancer, its expression is 
positively correlated with the presence of the estrogen receptor (ER). Approximately 40 
to 60% of ER-positive tumors express IGF-1R, while expression in ER-negative tumors is 
only 10 to 20%.(4) In general, IGF-1R correlates with good prognostic markers, such as ER 
positivity, older age, lower grade and human epidermal growth factor receptor 2 (HER2)-
negativity. However, its expression has differential effects in the different breast cancer 
subtypes. For example, IGF-1R expression has been shown to be positively correlated with 
improved breast cancer specific survival among patients with ER positive tumors, while its 
expression was associated with an inferior prognosis in patients with HER2-overexpressing 
or triple negative tumors.(4-6) 
IGF-1R expression can change during breast cancer treatment. Preclinical studies have 
shown that IGF-1R expression is down-regulated during tamoxifen treatment.(7, 8) 
Moreover, a clinical study in patients who received adjuvant treatment with tamoxifen 
showed a decrease in IGF-1R expression in tamoxifen-resistant recurrences compared 
to the primary tumor.(9) IGF-1R may also play a role in resistance to several types of 
treatment. For example, hyperactivation of IGF-1R has been shown to be involved in 
cisplatin resistance of ovarian cancer cells, while in breast and colorectal cancer cells, 
IGF-1R has been associated with resistance to 5-fluorouracil (5-FU).(10-12) Moreover, 
cross-talk between HER2 and IGF-1R by the formation of heterodimers can contribute to 
trastuzumab resistance.(13-15)
In summary, IGF-1R has a prognostic value in breast cancer, its expression can change 
during treatment, and it may play a role in resistance to conventional breast cancer 
therapies. In the present study we investigated the dynamics of IGF-1R expression during 
neoadjuvant breast cancer treatment, in order to determine whether the expression of 
IGF-1R in human breast tumors can be affected by neoadjuvant breast cancer treatment 
and whether changes are associated with survival.
Material and Methods
Patients and tumor tissue
Breast cancer patients who received neoadjuvant treatment between 1989 and 2010 
in the Radboud University Nijmegen Medical Centre or Canisius-Wilhelmina Hospital in 
Nijmegen were selected from the population-based cancer registry. All patients from 
whom paraffin embedded material was available from time of diagnosis (biopsy of primary 
tumor) and at surgical resection of the primary tumor, were included in the study. Patients 
from whom only a fine needle aspiration or material from another site than the primary 
tumor available was, were excluded. In total, paraffin embedded material was available 
from 62 patients. These patients received neoadjuvant chemotherapy or endocrine 
therapy. Chemotherapy consisted of 1) cyclophosphamide, methotrexate, fluorouracil 
(CMF), 2) an anthracycline based schedule or 3) a taxane-based schedule. Endocrine 
therapy consisted of tamoxifen, anastrozole or letrozole. The expression of IGF-1R, ER, 
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PR, HER2, Ki67 and cleaved caspase-3 was analyzed immunohistochemically. Additional 
information on neoadjuvant therapy, pathological parameters, clinical parameters, and 
survival data were collected from patient files. 
Immunohistochemistry
Tumor sections (4 µm) were stained for IGF-1R (3027, Cell Signaling), ER (RM-9101-S1, 
Neomarkers), PR (C89F1, Cell Signaling) and HER2 (A0485, Dako). First, endogenous 
peroxidase activity was blocked with 3% H2O2 in PBS (10 minutes at room temperature 
(RT) and antigen retrieval was performed in 10 mM sodiumcitrate, pH 6.0 for 10 minutes at 
99°C. Subsequently, for ER, PR and HER2, nonspecific binding was blocked by incubation 
with 20% normal goat serum (30 minutes at RT). Tumor sections were incubated with the 
primary antibodies for 1-2 h at RT (HER2) or overnight at 4 °C (ER, PR and IGF-1R). ER, PR and 
HER2 staining was followed by incubation with a goat-anti-rabbit biotinylated secondary 
antibody (Vector Laboratories, Burlingame, CA) for 30 min at RT and avidin-biotin-enzyme 
complex (Vector Laboratories, Burlingame, CA) for 30 min at RT. IGF-1R immunostaining 
was followed by incubation with Poly-HRP-Anti-mouse/rabbit/rat IgG (DPVO110HRP, 
Immunologic, Duiven, The Netherlands) for 30 minutes at RT. Finally, 3, 3’-diaminobenzidine 
(DAB) was used to develop the tumor sections. Membranous IGF-1R and HER2 expression 
was scored as negative (0), incomplete weak (1+), complete weak to moderate (2+) and 
strong (3+) membrane staining (Table 1). Tumors with a HER2 score of 3+ were considered 
HER2 positive. HER2 expression was only analyzed by immunohistochemistry, since no 
frozen tissue was available for FISH. IGF-1R cytoplasmic staining was scored as negative 
(0), weakly positive (1+) or strongly positive (2+). The percentage ER and PR positive cells 
was scored using an eye-piece grid. A tumor was considered positive if more than 1% of 
the tumor cells stained positive. The staining was scored by two independent readers who 
were blinded to the type of treatment and clinical outcome. 
Table 1. Scoring of membranous IGF-1R expression
Score Staining pattern
0 No staining is observed, or membrane staining is observed in <10% of the tumor cells
1+ A faint/barely perceptible membrane staining is detected in >10% of tumor cells. The 
cells exhibit incomplete membrane staining 
2+ A weak to moderate complete membrane staining is observed in >10% of tumor cells 
3+ A strong complete membrane staining is observed in >10% of tumor cells 
Cleaved caspase-3 (9661, Cell Signaling) and Ki67 (RM-9106S1, Thermo Scientific) staining 
was performed for all patients from the Radboud University Nijmegen Medical Centre 
(n=42). In short, endogenous peroxidase activity was blocked and antigen retrieval was 
performed as described previously. Non-specific binding was blocked by incubation with 
20% NGS (caspase-3) or 20% normal swine serum (Ki67), followed by incubation with the 
primary antibodies. Slides were incubated with a secondary peroxidase labeled swine-
anti-rabbit antibody (Ki67) or a goat-anti-rabbit biotinylated secondary antibody followed 
by an avidin-biotin-enzyme complex (Caspase-3). DAB was used to develop the tumor 
sections. The percentage of positive tumors cells was estimated using an eye-piece grid. 
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Statistical analysis
Statistical analyses were performed using IBM Statistics SPSS v20. Categorical variables 
were presented as frequencies and continuous variables as mean ± standard deviation 
(sd). To test whether IGF-1R expression correlated with clinical, pathological or other 
immunohistochemical parameters, pearson chi-square tests were performed for 
categorical variables. Mann-Whitney tests (2-group comparisons) or Kruskall-Wallis tests 
(more than 2 group comparisons) were performed for continuous variables. 
Correlations between clinical, pathological, and immunohistochemical variables and 
overall survival (OS) were analyzed by Kaplan-Meier survival test, and differences were 
calculated with the log-rank test. OS was defined as the time from diagnosis (date of 
biopsy) until the date of death or last follow-up for patients alive. Survival plots were 
estimated by the Kaplan-Meier method. Survival analyses for continuous variables 
and multivariate survival analyses were performed by using Cox proportional hazard 
regression models.  All tests were two-sided and a p < 0.05 was considered significant. 
Results
Patient characteristics
IGF-1R expression of biopsy and surgical resection material was analyzed for all 62 patients. 
One patient was diagnosed with two primary tumors which were analyzed separately. 
Therefore, the total number of tumors analyzed was 63. Patient and tumor characteristics 
are summarized in Table 2. Most patients were diagnosed with locally advanced or 
metastatic breast cancer (75%). All patients were female and mean age at diagnosis was 
55 ± 13 years. Patients who received neoadjuvant chemotherapy (n=49) were treated with 
CMF (n=7), an anthracycline based schedule (n=13) or a taxane-based schedule (n=29). 
Patients who received anti-estrogen treatment were treated with anastrozole (n=5), 
letrozole (n=3) or tamoxifen (n=5). Immunohistochemical analysis showed that 79% of 
all patients were diagnosed with an ER positive tumor, 51% with a PR positive tumor, 
43% with a HER2 positive tumor, and 6% with a triple negative tumor (ER, PR and HER2 
negative).
IGF-1R expression 
Table 3 summarizes the results of the immunohistochemical analyses. At time of diagnosis, 
IGF-1R membrane expression was scored 0, 1+, 2+, and 3+ for 12 (19%), 18 (29%), 26 (41%), 
and 7 (11%) tumors, respectively. Examples of IGF-1R membrane staining are presented in 
Figure 1. Membranous IGF-1R expression correlated significantly with ER and PR expression 
at time of diagnosis (χ2-test, p = 0.005 and 0.001). Moreover, it was significantly associated 
with tumor stage (χ2-test, p=0.011). Patients with tumors with low or absent membranous 
IGF-1R expression (0 or 1+) presented more frequently with locally advanced or metastatic 
disease.  Membranous IGF-1R expression at time of diagnosis did not differ significantly 
between chemotherapy or endocrine treated patients and was not correlated with any 
of the other clinical, pathological and immunohistochemical parameters. Cytoplasmic 
IGF-1R expression at time of diagnosis was scored as 1+ and 2+ for 60 (95%) and 3 (5%) 
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tumors, respectively. Cytoplasmic 
staining did not correlate with other 
immunohistochemical, pathological or 
clinical parameters.
To determine whether IGF-
1R expression changed during 
neoadjuvant treatment, expression at 
diagnosis was compared to expression 
at time of surgery. Membranous IGF-
1R expression remained the same in 41 
(65%) tumors, was upregulated in 11 
(18%) tumors and downregulated in 11 
(18%) tumors. The number of tumors 
showing an increase or decrease in 
membranous IGF-1R expression did not 
differ significantly between endocrine 
treated or chemotherapy treated 
patients. However, IGF-1R showed a 
trend towards more downregulation 
in the endocrine-treated group; IGF-1R 
was downregulated in 4/13 tumors and 
upregulated in 1/13 tumors. For patients 
who received chemotherapy, IGF-1R 
was downregulated 
in 7/50 tumors and 
upregulated in 10/50 
tumors. Upregulation of 
membranous IGF-1R was 
significantly associated 
with high tumor stage 
at diagnosis (χ2-test, 
p = 0.04). Changes in 
membranous IGF-1R 
expression did not 
correlate with other 
clinical, pathological or 
immunohistochemical 
variables. Changes in 
cytoplasmic IGF-1R 
expression occurred 
less frequently. In 
5 tumors (8%), a 
downregulation was 
observed, while none of 
the tumors showed an 
upregulation. Changes in cytoplasmic IGF-1R expression were not associated with any of 
the other immunohistochemical, pathological or clinical parameters.
Table 2. Patient (N=62) and tumor (N=63) 
characteristics
N (%)
Age at diagnosis (mean ± sd) 55 ± 13
Tumor morphology
     Ductal carcinoma
     Lobular carcinoma
     Ductal + lobular carcinoma
     Other 
45 (71%)
10 (16%)
4 (6%)
4 (6%)
Stage
     Stage I
     Stage II
     Stage III
     Stage IV
     Unknown
1 (2%)
13 (21%)
37 (60%)
9 (15%)
2 (3%)
Neoadjuvant therapy
     Chemotherapy
         CMF
         Anthracycline-based
         Taxane-based
Anti-estrogen therapy
         Anastrozole
         Letrozole
         Tamoxifen  
49 (79%)
7 (11%)
13 (21%)
29 (48%)
13 (21%)
5 (8%)
3 (5%)
5 (8%)
Figure 1. Examples of IGF-1R immunostaining of breast tumors. Scoring of 
IGF-1R membrane expression is depicted in the lower left corner. Magnification 
400X, DAB staining.
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Survival analysis
Mean follow-up of patients 
included in the study was 4.6 
± 0.4 years (range 0.7 – 17.9 
years). Membranous IGF-1R 
expression at diagnosis was 
significantly associated with 
OS (log-rank test, p < 0.001, 
Figure 2A). Mean OS time for 
patients with 0, 1+, 2+ and 3+ 
tumors was 2.4 ± 0.4 years, 6.9 
± 1.4 years, 9.7 ± 1.1 years, and 
13.4 ± 2.6 years, respectively. 
Since membranous IGF-1R 
expression strongly correlated 
with ER expression and 
tumor stage, multivariate 
Cox regression analysis was 
performed to correct for these 
variables. In multivariate 
analysis, the correlation 
between membranous 
IGF-1R expression and OS 
remained significant (Table 4). 
Membranous and cytoplasmic IGF-1R expression after neoadjuvant treatment were not 
significantly associated with OS. 
Since membranous IGF-1R expression changed during neoadjuvant treatment, we 
analyzed whether these changes were associated with OS. Kaplan-Meier analysis showed 
a significant association (log-rank test, p = 0.013, Figure 2B). Patients whose tumors 
showed an increase in membranous IGF-1R expression after neoadjuvant therapy had a 
significantly shorter mean OS compared to patients with no change in expression or a 
downregulation. Mean OS time for an upregulation, no change, and a downregulation 
in membranous IGF-1R expression was 3.0 ± 0.5 years, 7.3 ± 1.0 years and 15.0 ± 1.8 
years, respectively. Since changes in membranous IGF-1R expression were significantly 
associated with tumor stage, multivariate Cox regression analysis was performed. 
After correction for tumor stage, patients whose tumors showed an increase in IGF-1R 
expression still had a poorer prognosis compared to patients with tumors showing a 
decrease in IGF-1R expression (Table 4). 
Changes in cytoplasmic IGF-1R expression and changes in other immunohistochemical 
markers (ER, PR, HER2) were not significantly associated with survival.  Ki67 was significantly 
reduced after neoadjuvant treatment (paired t-test, p = 0.008). However, Ki67 expression 
itself, or changes in expression, were not significantly associated with IGF-1R expression, 
changes in IGF-1R expression, and survival.  Cleaved caspase-3 expression did not differ 
significantly before and after neoadjuvant treatment and was not associated with IGF-1R 
expression, changes in IGF-1R expression, and survival. 
Table 3. Immunohistochemical markers of the 63 breast 
tumors
Pretreatment Posttreatment
ER
     Positive
     Negative
     Unknown
50 (79%)
12 (19%)
1 (2%)
54 (86%)
8 (13%)
1 (2%)
PR
     Positive
     Negative
     Unknown
32 (51%)
29 (46%)
2 (3%)
26 (41%)
37 (59%)
0 (0%)
HER2
     Positive
     Negative
     Unknown
27 (43%)
30 (48%)
6 (10%)
22 (35%)
41 (65%)
0 (0%)
IGF-1R membrane
     0
     1+
     2+
     3+
12 (19%)
18 (29%)
26 (41%)
7 (11%)
6 (10%)
30 (48%)
20 (32%)
7 (11%)
IGF-1R cytoplasm
     0
     1+
     2+
0 (0%)
60 (95%)
3 (5%)
2 (3%)
61 (97%)
0 (0%)
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Figure 2. A: Kaplan-Meier survival curve estimates of overall survival of patients with an IGF-1R 0, 1+, 2+ or 3+ 
tumors at time of diagnosis (p < 0.001). B: Kaplan-Meier survival curve estimates of overall survival of patients 
with a tumor showing a downregulation, no change or an upregulation in IGF-1R expression after neoadjuvant 
treatment (p = 0.013).
Table 4. Cox proportional hazard regression analysis 
Baseline IGF-1R expression
Univariate
HR (95 %CI) p
Multivariate
HR (95% CI) P
IGF-1R expression
     1+ vs 0
     2+ vs 0
     3+ vs 0
0.38 (0.16 – 0.89)
0.17 (0.07 – 0.42)
0.12 (0.03 – 0.55)
<0.001
0.026
<0.001
0.006
0.36 (0.15 – 0.88)
0.24 (0.09 – 0.62)
0.21 (0.04 – 1.04)
0.013
0.025
0.003
0.056
ER expression
     positive vs negative 0.42 (0.20 – 0.92) 0.029 0.53 (0.22 – 1.25) 0.15
Tumor stage
     III/IV vs  I/II 3.52 (1.07 – 11.6) 0.038 2.26 (0.62 – 8.13) 0.21
Change in IGF-1R expression
Univariate
HR (95 %CI) p
Multivariate
HR (95% CI) P
Change in IGF-1R
     Unchanged vs downregulation
     Upregulation vs downregulation
     Upregulation vs unchanged
3.91 (0.92 – 16.6)
7.62 (1.64 – 35.5)
1.95 (0.89 – 4.25)
0.026
0.064
0.010
0.094
3.60 (0.84 – 15.4)
5.71 (1.20 – 27.2)
1.59 (0.71 – 3.53)
0.086
0.084
0.028
0.26
Tumor stage
     III/IV vs  I/II 3.52 (1.07 – 11.6) 0.038 2.71 (0.80 – 9.13) 0.11
Discussion
To our knowledge, this is the first study which showed that changes in membranous IGF-
1R expression during neoadjuvant breast cancer treatment are significantly associated 
with OS. Patients with tumors that showed an upregulation in IGF-1R expression had a 
shorter OS compared to patients with a down-regulation in IGF-1R expression. In addition, 
we found that baseline membranous IGF-1R expression was significantly associated with 
hormone receptor positivity, lower tumor stage and longer OS, which is in line with 
previous research.(4, 5, 16, 17) 
A B
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In patients receiving endocrine treatment, a down-regulation of membranous IGF-1R was 
observed more frequently than an upregulation. Although this subgroup consisted of only 
13 patients, this is in line with previous reports.(9) Recently, we have shown that a pre-
operative short course exposure to tamoxifen or anastrazole can induce a downregulation 
in IGF-1R expression in patients with primary hormone receptor positive breast cancer 
(manuscript in preparation). Moreover, in a study in patients with recurrent breast tumors 
treated with tamoxifen for at least 6 months, IGF-1R expression was significantly lower 
in the recurrent lesions, compared to the primary tumors.(9) These results show that 
endocrine therapy can downregulate IGF-1R expression and, therefore, this result argues 
against combining endocrine therapy with IGF-1R inhibitors, or treating hormone therapy 
resistant breast tumors with anti-IGF-1R antibodies.
A few previous clinical studies have shown changes in IGF-1R expression in breast 
cancer after endocrine therapy.(9) However, chemotherapy induced changes in IGF-1R in 
breast cancer have not been reported before. This study showed that chemotherapy can 
induce both an upregulation and a downregulation of membranous IGF-1R expression. 
Most importantly, we showed that a change in membranous IGF-1R expression is an 
independent prognostic factor in neoadjuvantly treated breast cancer patients. Patients 
with tumors showing an increase in membranous IGF-1R expression had a shorter overall 
survival, compared with patients with tumors showing a down regulation in IGF-1R 
expression. The observation that treatment induced upregulation is associated with poor 
outcome may suggest that IGF-1R plays a role in treatment resistance. There are several 
ways by which IGF-1R can play a role in therapy resistance. For example, IGF-1R may protect 
cancer cells from apoptosis by activation of the PI-3K/AKT pathway or protect cells from 
drug-induced cytostatic effects by activation of the MAPK pathway.(18) Moreover, Gou ea. 
stated that IGF-1R can promote multidrug resistance (MDR) by increasing the expression 
of MDR-related genes such as mdr-1, c-H-ras and MnSOD.(19)
Although upregulation of membranous IGF-1R expression seems to be a poor prognostic 
factor, patients with these tumors may potentially benefit from IGF-1R targeted therapy. 
Phase I/II studies with these agents have shown the safety and tolerability of targeting 
IGF-1R and have demonstrated a wide range of responses, from progressive disease to 
near complete response.(20-23) However, larger randomized phase II//III trials failed to 
show a clear benefit from targeting IGF-1R in combination with conventional treatment 
strategies.(24-26) It should be noted that these trials were conducted in large unselected 
patient populations, while studies have shown that IGF-1R expression is a prerequisite 
for antitumor activity of anti-IGF-1R antibodies.(27-29) Thus, patient selection for IGF-1R 
targeted therapy could be based on receptor expression and patients showing increased 
IGF-1R expression during conventional anti-cancer treatment may potentially benefit 
from IGF-1R targeted treatment. Of note, the cellular location of IGF-1R (membranous 
versus cytoplasmic) seems to be of importance, since membranous expression was a 
strong prognostic factor, whereas cytoplasmic expression was not. Moreover, Asmane et 
al. reported that exclusive intranuclear IGF-1R staining was associated with progression 
free survival of sarcoma patients who were treated with an anti-IGF-1R antibody.(29) 
However, exclusive nuclear staining of IGF-1R was not observed in this study. 
We attributed the changes in IGF-1R expression to neoadjuvant treatment. However, 
other potential explanations need to be addressed. First, staining was performed on 
archival tumor tissue. Pretreatment expression was analyzed on a single biopsy and post 
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treatment expression was analyzed using one representative tumor section from the 
resection material. Due to possible heterogeneous IGF-1R expression within the tumor, 
sampling errors may have occurred. Second, tissue processing for biopsies and surgical 
resection material were different. Parameters such as time between excision and fixation, 
duration of fixation, and type of fixative can potentially affect the immunoreactivity of the 
antigen and thus the immunohistochemical staining. To our knowledge, no information 
is available on the effect of tissue fixation on IGF-1R staining. However, several studies 
have shown that the concordance rates for comparable markers like ER, PR, HER2 and 
Ki67 are high between biopsies and surgical resection material.(30-32) Third, differences 
in IGF-1R expression may occur naturally during the course of disease, for example due to 
disease progression. Fourth, our sample size was relatively small and thus findings may 
have occurred by coincidence. And finally, this study was performed only for neoadjuvant 
treated breast tumors and it contained a high number of HER2-overexpressing tumors. Of 
all biopsies, 43% overexpressed HER2 (immunohistochemistry score 3+) while literature 
reports that only 15 to 30% of the newly diagnosed breast tumors overexpress HER2.
(33) Also, it is unknown whether our results can be extrapolated to other settings, such 
as adjuvant breast cancer treatment. The precise role of these factors in our patient 
population cannot be assessed since this was a retrospective non-randomized study. 
Therefore, future prospective studies are warranted to confirm our findings. 
Conclusion
Neoadjuvant breast cancer therapy can induce changes in IGF-1R expression. An 
upregulation of membranous IGF-1R expression after neoadjuvant treatment is a poor 
prognostic factor in breast cancer patients, providing the rationale for incorporating anti-
IGF-1R drugs in the management of this patient group. Future studies in larger patient 
populations are warranted to confirm these findings.
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Abstract
Introduction: Affibody molecules are small (7 kDa) proteins with (sub)nanomolar 
targeting affinity. Previous SPECT studies in xenografts have shown that the Affibody 
molecule 111In-DOTA-ZHER2:2395 can discriminate between high and low HER2-expressing 
tumors, indicating that radiolabeled Affibody molecules have potential for patient 
selection for HER2-targeted therapy. PET with positron emitting radionuclides, such as 
18F, may improve imaging of HER2 expression due to higher sensitivity and improved 
quantification of PET compared to SPECT. The aim of the present study was to determine 
whether 18F-labeled NOTA-conjugated Affibody molecule ZHER2:2395  is a suitable agent 
for imaging of HER2 expression. The tumor targeting properties of 18F-labeled ZHER2:2395 
were compared to 111In and 68Ga-labeled ZHER2:2395 in mice with HER2-expressing SK-OV-3 
xenografts.
Material and methods: ZHER2:2395 was conjugated with NOTA and radiolabeled with 
18F, 
68Ga and 111In. Radiolabeling with 18F was based on the complexation of Al18F by NOTA. 
The IC50 values for NOTA-ZHER2:2395 labeled with 
19F, 69Ga and 115In were determined in a 
competitive cell binding assay using SK-OV-3 cells. Mice bearing subcutaneous SK-OV-3 
xenografts were injected intravenously with radiolabeled NOTA-ZHER2:2395. One and four 
hours after injection, PET/CT or SPECT/CT images were acquired and the biodistribution 
was determined by ex vivo measurement.
Results: The IC50 values for 
19F-, 69Ga- and 115In-NOTA-ZHER2:2395 were respectively 5.0 nM, 
6.3 nM and 5.3 nM. One hour after injection, tumor uptake was 4.4 ± 0.8 %ID/g, 5.6 ± 1.6 
%ID/g and 7.1 ± 1.4 %ID/g and tumor-to-blood ratios were 7.4 ± 1.8, 8.0 ± 1.3 and 4.8 ± 1.3 
for respectively 18F-, 68Ga- and 111In-NOTA-ZHER2:2395. Tumor uptake was specific since uptake 
could be blocked efficiently by co-injection of an excess unlabeled ZHER2:2395. PET/CT and 
SPECT/CT images clearly visualized HER2-expressing SK-OV-3 xenografts.
Conclusion: This study showed that 18F-NOTA-ZHER2:2395 is a promising new imaging agent 
for HER2 expression in tumor. Affibody molecules were successfully labeled with 18F 
within 30 min, based on the complexation of Al18F by NOTA. Further research is needed 
to determine whether this technique can be used for patient selection for HER2-targeted 
therapy. 
PET imaging of HER2 expression with 18F-NOTA-ZHER2:2395
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Introduction
Human epidermal growth factor receptor 2 (HER2) is a member of the epidermal growth 
factor receptor (EGFR) family. Dimerization of HER2 with other members of the EGFR 
family leads to activation of several downstream pathways, including PI3K-AKT and 
MAPK, resulting in increased tumor cell proliferation, cell motility and survival.(1) HER2 is 
overexpressed in 18-25% of all breast carcinomas and in subsets of ovarian, lung, prostate 
and gastric cancers.(1, 2) Breast cancers that overexpress HER2 have been associated 
with aggressive tumor growth, high relapse and poor prognosis.(2) Furthermore, HER2-
overexpressing tumors may be more resistant to endocrine- and chemotherapy.(3) 
Different therapeutic strategies have been developed to target HER2, including the 
monoclonal antibody trastuzumab and tyrosine kinase inhibitor lapatinib. Trastuzumab 
targets the extracellular domain of HER2, inhibits intracellular signaling pathways 
and causes antibody-dependent cell-mediated cytotoxicity (ADCC).(1)  Trastuzumab 
significantly improves survival of patients with HER2-positive advanced breast and gastric 
cancer, when combined with chemotherapy.(4-6) Lapatinib targets the intracellular 
domain of both HER2 and EGFR.(1)The addition of lapatinib to capecitabine prolongs 
progression free survival of patients with advanced HER2-positive breast cancer.(7)
Currently, trastuzumab treatment is only recommended for breast and gastric cancer 
patients with HER2 overexpressing tumors.(8) Therefore, accurate assessment of HER2 
expression is essential for patient selection for HER2-targeted therapy. Nowadays, HER2 
expression is determined on tumor biopsies by immunohistochemical staining of HER2 
protein expression or fluorescence in situ hybridization (FISH) of HER2 mRNA expression. 
Up to 20% of the current HER2 assessments may be inaccurate.(9, 10) Furthermore, HER2 
expression can differ between the primary tumor and metastases.(11, 12) Therefore, in vivo 
imaging of HER2 expression may result in more accurate detection of HER2 expression, 
avoiding misinterpretation due to intratumoral and interlesional heterogeneity. Moreover, 
such an imaging method would allow monitoring of HER2 expression during the course 
of disease, without the need of repetitive invasive biopsies.
Several approaches have been used for PET and SPECT imaging of HER2 expression, 
including radiolabeled antibodies trastuzumab and pertuzumab (HER2 dimerization 
inhibitor), as well as radiolabeled trastuzumab fragments.(13-16) These radiotracers were 
able to visualize HER2 expression, but their large size resulted in slow tumor accumulation 
and slow clearance from the circulation. A new class of targeting proteins are Affibody 
molecules. These are based on a 58-amino-acid (7 kDa) scaffold and can be selected 
to bind with high affinity to various tumor-associated antigens. Their small size allows 
rapid extravasation in tumors and rapid clearance from the blood, resulting in high-
contrast imaging within several hours after injection.(17, 18) The HER2-targeting Affibody 
molecule ZHER2:342 and its derivates have been radiolabeled with several radionuclides and 
have shown specific targeting of HER2.(17) Previous studies in xenografts have shown that 
the Affibody molecule 111In-DOTA-ZHER2:2395 can discriminate between tumors with high 
and low HER2 expression.(19) A clinical pilot study with 111In- and 68Ga-DOTA-ZHER2:342 has 
shown that it is feasible to visualize HER2-expressing tumors in patients with metastatic 
breast cancer.(20) Therefore, Affibody molecules have potential for patient selection for 
HER2 targeted therapy.
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Recently, ZHER2:2395, a variant of ZHER2:342 with a C-terminal cysteine, was coupled to 
maleimide monoamide NOTA (MMA-NOTA) and was radiolabeled with 111In. This site-
specifically labeled conjugate allowed high-contrast imaging of HER2-expressing 
xenografts.(21) Imaging of HER2 expression with Affibody molecules can be improved by 
the use positron emitting radionuclides such as 18F, because of the higher sensitivity and 
better quantification of PET compared to SPECT. Kramer et al. have conjugated ZHER2:342 
with N-2-(4-[18F]fluorobenzamido)ethyl]maleimide ([18F]FBEM).(22) [18F]FBEM-ZHER2:342 
could visualize HER2-expressing tumors. However, this labeling reaction required a long 
synthesis time. Lately, a new method was described for labeling of NOTA-conjugated 
peptides with 18F, which  is based on the formation of aluminum[18F]fluoride (Al18F) and its 
complexation by NOTA.(23, 24) This method allows rapid and efficient labeling of peptides 
and proteins with 18F. 
The aim of the present study was to determine whether 18F-labeled Affibody molecule 
ZHER2:2395 is a suitable imaging agent for HER2 expression in mice with SK-OV-3 xenografts. 
For this purpose, NOTA-conjugated ZHER2:2395 was radiolabeled with 
18F, based on the 
complexation of Al18F by NOTA. 18F-NOTA-ZHER2:2395 was compared to 
111In and 68Ga-labeled 
ZHER2:2395.
Material and methods
Cell line and Affibody molecule
The HER2-overexpressing ovarian cancer cell line SK-OV-3 was cultured and maintained 
as monolayer in RPMI1640 medium (GIBCO, BRL Life Sciences Technologies, The 
Netherlands), supplemented with 10% fetal calf serum (FCS), 2 mM glutamine, penicillin 
(100 units/ml) and streptomycin (100 µg/ml). The HER2-negative breast cancer cell line 
SUM149 (Asterand, Detroit, MI) was cultured and maintained as monolayer in Ham’s F12 
medium (GIBCO, BRL Life Sciences Technologies, The Netherlands) supplemented with 5% 
FCS, 10 mM HEPES, hydrocortisone (1 µg/ml), and insulin (5 µg/ml) at 37 °C in a humidified 
atmosphere with 5% CO2. ZHER2:2395 was produced as described previously.(25) 
Affibody conjugation with MMA-NOTA
The production MMA-NOTA and coupling of MMA-NOTA to ZHER2:2395 has been described 
elsewhere.(21, 25)  In short, reduced ZHER2:2395 was incubated for 1 h at 37 °C with a freshly 
prepared solution of MMA-NOTA in 0.2 M ammonium acetate, pH 5.5 (1 mg/ml) at a 
chelator-to-protein ratio of 3:1. The NOTA-conjugated Affibody molecules were purified 
by semi-preparative RP-HPLC, using a Zorbax 300SB C18 column 9.4 x 250 mm at a flow 
rate of 8 ml/min with the following buffer system: buffer A, 0.1% trifluoroacetic acid (TFA) 
in water; buffer B, 0.1% TFA in acetonitrile; and a gradient of 25%-40% buffer B over 11 
min.
Radiolabeling
18F labeling
Radiolabeling with 18F was based on the complexation of Al18F by NOTA as described 
elsewhere.(23,24) Briefly, a Chromafix PS-HCO3 cartridge (ABX, Radeberg, Germany) with 
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2–6 GBq of 18F (BV Cyclotron VU, Amsterdam, The Netherlands) was washed with 3 mL 
of metal-free water. 18F was eluted from the cartridge with 100 μl 0.9% NaCl. Al18F was 
prepared by adding 2 mM AlCl3 in 0.1 M sodium acetate pH 4 (8.5 μl AlCl3 per GBq 
18F). 
NOTA-ZHER2:2395 (250 μg) was dissolved in 25 μl 0.5 M sodium acetate, pH 4. To the dissolved 
Affibody molecule, 25 μl acetonitrile was added. After adding 50 μl Al18F (1.16-1.27 GBq) 
the reaction mixture was incubated for 15 min at 90 °C. Subsequently, the reaction 
mixture was applied on a 1-ml Oasis HLB cartridge (30 mg, Waters, Milford, MA) to remove 
unincorporated Al18F. The cartridge was washed with 3 ml H2O and 
18F-NOTA-ZHER2:2395 was 
eluted with 300 μl ethanol. Finally, 18F-NOTA-ZHER2:2395 was applied on a NAP-5 column 
(GE Healthcare Life Sciences, Uppsala, Sweden), pre-equilibrated with PBS, to change 
the buffer from ethanol to PBS. Before injection, 18F-NOTA-ZHER2:2395 was diluted in PBS 
containing 0.5% BSA. Labeling efficiency and radiochemical purity were determined with 
instant-thin layer chromatography (ITLC) and HPLC as described below.
68Ga labeling
NOTA-ZHER2:2395 was labeled with 
68Ga eluted from a TiO2-based 1,850-MBq
 68Ge/68Ga 
generator (IGG-100, Eckert&Ziegler, Berlin, Germany) using 0.1 M HCl (Ultrapure; J.T. 
Baker). NOTA-ZHER2:2395  was dissolved in 0.25 M ammonium acetate, pH 5.4. Radiolabeling 
with 68Ga was performed by adding 120 μl 2.5 M HEPES, pH 5.6 and 1 ml 68Ga eluate (165 
– 192 MBq) to NOTA-ZHER2:2395  (18 – 21 μg). The final pH of the labeling reaction was 3.5. 
The reaction mixture was incubated for 15 minutes at 90 °C. After the labeling reaction, 50 
mM ethylenediaminetetraacetic acid (EDTA) was added to a final concentration of 5 mM 
to complex non-incorporated 68Ga3+. Subsequently, the labeling mixture was purified on a 
PD10 column (GE Healthcare Life Sciences, Uppsala, Sweden), eluted with PBS containing 
0.5% BSA. Before injection, 68Ga-NOTA-ZHER2:2395 was diluted in PBS containing 0.5% BSA. 
Labeling efficiency, colloid and radiochemical purity were determined with ITLC and HPLC 
as described below.
111In labeling
NOTA-ZHER2:2395  was dissolved in 0.25 M ammonium acetate, pH 5.4. For radiolabeling, 70 μg 
NOTA-ZHER2:2395  was incubated with 260 MBq 
111In (Covidien BV, Petten, The Netherlands) 
in 0.1 M 2-(N-morpholino)ethanesulfonic acid (MES) buffer, pH 5.4 (twice volume of 111In) 
for 15 min at 90 °C. After incubation, 50 mM EDTA was added to a final concentration of 
5 mM. Subsequently, the reaction mixture was purified on a PD10 column, eluted with 
PBS containing 0.5% BSA. 111In-NOTA-ZHER2:2395 was diluted in PBS containing 0.5% BSA. 
Labeling efficiency and radiochemical purity were determined with ITLC and HPLC as 
described below.
Quality control
HPLC
Labeling efficiency was analyzed by RP HPLC on an Agilent 1200 system (Agilent 
Technologies). A monolithic C18 column (Onyx, 4.6 x 100 mm; Phenomenex, Torrance, CA) 
was used at a flow rate of 1 mL/min with the following buffer system: buffer A, 0.1% v/v 
TFA in water; buffer B, 0.1% v/v TFA in acetonitrile; and a gradient of 97% buffer A to 0% 
buffer A at 5 – 15 min. The radioactivity of the eluate was monitored using an in-line NaI 
radiodetector (Raytest GmbH, Straubenhardt, Germany). Elution profiles were analyzed 
using Gina-star software (version 2.18; Raytest GmbH). 
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ITLC
Radiochemical purity was determined using instant thin-layer chromatography (ITLC) 
on silica gel chromatography strips (Agilent Technologies, Palo Alto, CA), using 0.1 M 
ammonium acetate, containing 0.1 M EDTA, pH 5.5, as the mobile phase. The presence of 
colloid was analyzed using methanol:0.5 M HEPES, pH 3.5 (1:1) as mobile phase. 
In vitro studies
In vitro binding of radiolabeled NOTA-ZHER2:2395
Labeling with 18F requires incubation of the NOTA-conjugated Affibody molecule at 
90 °C in 25% acetonitrile. To determine whether HER2 binding was affected by these 
labeling conditions, an in vitro binding experiment was performed. NOTA-ZHER2:2395 was 
radiolabeled with 18F as described above. Unlabeled NOTA-ZHER2:2395 was incubated for 15 
min at RT without acetonitrile or at 90 °C in the presence of 25% acetonitrile. 
SK-OV-3 and SUM149 cells were cultured to confluency in six-well plates. Cells were 
washed with PBS and incubated for 2 h at 4 °C with 4 kBq 18F-NOTA-ZHER2:2395, without 
unlabeled Affibody molecules or in the presence of 50 nM unlabeled NOTA-ZHER2:2395 
(preincubated at RT or 90 °C) in a total volume of 1 ml binding buffer (SK-OV-3: RPMI1640 
containing 0.5% BSA, SUM149: Ham’s F12, 10 mM HEPES, containing 0.5% BSA). Separate 
wells were incubated with 4 kBq 18F-NOTA-ZHER2:2395 and 50 nM trastuzumab to study 
whether trastuzumab interferes with Affibody molecule binding. After incubation, cells 
were washed with PBS and the cell-associated activity was measured in a shielded well-
type gamma counter (Perkin-Elmer, Boston, MA, USA).
Scatchard analysis
Scatchard analysis was performed to determine the dissociation constant (Kd) and 
the number of binding sites for 18F-NOTA-ZHER2:2395 on SK-OV-3 cells. Cells were cultured 
to confluency in six-well plates and were incubated for 2 h at 4 °C with increasing 
concentrations 18F-NOTA-ZHER2:2395 (0.03 – 30 nM) in 1 ml binding buffer. Non-specific 
binding was determined by co-incubation with an excess of 1 μM unlabeled NOTA-
ZHER2:2395. After incubation, cells were washed with PBS and the cell-associated activity was 
measured in a shielded well-type gamma counter.
50% Inhibitory Concentration (IC50) determination
The IC50 for binding HER2 on SK-OV-3 was determined in a competitive binding assay 
using 19F-, 69Ga- or 115In-NOTA-ZHER2:2395 to compete for binding with 
111In-NOTA-ZHER2:2395. 
NOTA-ZHER2:2395 was dissolved in 0.25 M ammonium acetate, pH 5.4. 
19F-NOTA-ZHER2:2395 was 
prepared by adding  a 2.5 fold molar excess of AlCl3 and a five-fold molar excess of 
19F to 
15 μg NOTA-ZHER2:2395 in 0.5 M sodium acetate, pH 4. 
115In-NOTA-ZHER2:2395 was prepared by 
adding a three-fold molar excess of 115InCl3 to 15 μg NOTA-ZHER2:2395 in 0.1 M MES buffer, 
pH 5.4. 69Ga-NOTA-ZHER2:2395 was formed by adding a three-fold molar excess of 
69Ga 
nitrate to 15 μg NOTA-ZHER2:2395 in 2.5 M HEPES buffer, pH 7.0.  All labeling mixtures were 
incubated for 15 min at 90 °C. 50 mM EDTA was added to a final concentration of 5 mM. 
NOTA-ZHER2:2395 (10 μg) was radiolabeled with 1.9 MBq 
111In as described above. Labeling 
efficiency, determined using ITLC, was 95% and no further purification was required. 
SK-OV-3 cells were cultured to confluency in six-well plates. To determine the apparent 
IC50, cells were washed with PBS and incubated for 2 h at 4 °C in 2 ml binding buffer with 
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a trace amount of 1 kBq 111In-NOTA-ZHER2:2395 and increasing concentrations of 
19F-, 69Ga- 
or 115In-NOTA-ZHER2:2395 (0.001 nM – 30 nM). After incubation, cells were washed with PBS 
and the cell-associated activity was measured in a gamma counter. The IC50 was defined 
as the Affibody molecule concentration at which 50% of binding without competitor 
was reached. IC50
 values were calculated using GraphPad Prism software (version 5.03 for 
Windows; GraphPad Software). 
Serum stability
18F-NOTA-ZHER2:2395 (3.7 MBq) was incubated for 4 h at 37 °C in 500 μl human and mouse 
serum. After incubation, stability was analyzed using ITLC as described above.
Animal studies
Animal experiments were performed in female BALB/c nude mice (Janvier, le Genest-
Saint-Isle, France) and were conducted in accordance with the principles laid out by the 
revised Dutch Act on Animal Experimentation (1997) and approved by the institutional 
Animal Welfare Committee of the Radboud University Nijmegen. At 6-8 weeks of age, mice 
were inoculated subcutaneously with 5 x 106 SK-OV-3 cells (mixed 2:1 with matrigel, BD 
Biosciences). Experiments were initiated when the tumors reached a size of approximately 
0.1 cm3. 
Biodistribution studies
Five groups (n=6) of mice  were injected intravenously with 10 μg 18F-NOTA-ZHER2:2395 (1 
MBq), 68Ga-NOTA-ZHER2:2395 (5 MBq) or 
111In-NOTA-ZHER2:2395 (0.4 MBq). Separate groups (n=3) 
of mice were coinjected with an excess of unlabeled ZHER2:2395 (500 μg). One and 4 h (
18F and 
111In only) after injection, mice were euthanized by CO2/O2 asphyxiation. Tumor, blood, 
muscle, lung, heart, spleen, pancreas, intestine, kidney, liver, small intestine and bone 
were dissected and weighed. Activity was measured in a gamma counter. To calculate the 
uptake of radiolabeled Affibody molecules in each sample as a fraction of the injected 
dose, aliquots of the injected dose were counted simultaneously. The results were 
expressed as percentage of the injected dose per gram (%ID/g).  
PET/CT
Mice were injected intravenously with 10 μg 18F-NOTA-ZHER2:2395 (10 MBq) or 10 μg 
68Ga-
NOTA-ZHER2:2395 (11 MBq). One and 4 h (
18F only) after injection, mice were scanned on an 
animal PET/CT scanner (Inveon; Siemens Preclinical Solutions) with an intrinsic spatial 
resolution of 1.5 mm.(26) First, a CT scan (spatial resolution 113 µm, 80 kV, 500 µA) was 
acquired for anatomic reference, followed by a PET emission scan of 30 min (1 h p.i.) or 
60 min (4 h p.i.). Before the last scan, mice were euthanized and after acquisition, the 
biodistribution of radiolabeled Affibody molecules was measured ex vivo as described 
above. Scans were reconstructed using Inveon Acquisition Workplace software (version 
1.5; Siemens Preclinical Solutions), using an ordered-set expectation maximization 
3-dimensional maximum a posteriori algorithm with the following parameters: matrix, 
256 x 256 x 159; pixel size, 0.43 x 0.43 x 0.8 mm3; and β-value of 1.5 with uniform variance. 
Representative cross sections located approximately in the center of the tumor were 
displayed. Tumor-to-liver ratios were calculated with the Inveon Research Workplace 
software (IRW, version 3.0).
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SPECT/CT
Mice were injected with 10 μg 111In-NOTA-ZHER2:2395 (18 MBq). One and 4 h after injection, 
mice were scanned on an animal SPECT/CT (U-SPECT-II, MILabs, Utrecht, The Netherlands), 
using a 1.0 mm diameter pinhole rat collimator cylinder.(27) SPECT scans were acquired 
for 45 min (1 h after injection) or 60 min (4 h after injection), followed by CT scan (spatial 
resolution 160 µm, 40 kV, 612 µA) for anatomical reference. Before the last scan, mice 
were euthanized and after acquisition, the biodistribution of radiolabeled Affibody 
molecules was measured ex vivo as described above. Scans were reconstructed with 
MILabs reconstruction software, which uses an ordered-subset expectation maximization 
algorithm, with a voxel size of 0.375 mm. Tumor-to-liver ratios were calculated with the 
Inveon Research Workplace software (IRW, version 3.0).
Statistical analysis
Statistical analyses were performed using SPSS software version 16.0 (Chicago, IL) and 
GraphPad Prism version 5.03 (San Diego, CA) for Windows. Differences in uptake of 
radiolabeled Affibody molecules were tested for significance using the nonparametric 
Mann Whitney test. A p-value below 0.05 was considered significant. 
Results
Radiolabeling
Radiolabeling yield for 18F, 68Ga and 111In was respectively  21.0 ± 5.7%, 84.6 ± 0.9% and 
94.0%. After purification on HLB cartridge and NAP-5 column (18F) or PD10 column (68Ga 
and 111In), ITLC indicated that radiochemical purity exceeded 95%. No colloid (<1%) was 
formed during the labeling reactions. Specific activities of 7,700 ± 3,000 GBq/mmol, 
39,600 ± 500 GBq/mmol and 22,400 GBq/mmol were obtained for respectively 18F-, 68Ga- 
and 111In-NOTA-ZHER2:2395 (end of synthesis).
In vitro binding assays 
In vitro binding assays showed that incubation at 90 °C in 25% acetonitrile did not affect 
binding of NOTA-ZHER2:2395 to HER2 (Figure 1A). Both samples (pre incubated at RT and 90 
°C in acetonitrile) were equally effective in blocking the binding of 18F-NOTA-ZHER2:2395. 
Furthermore, 18F-NOTA-ZHER2:2395 did not show specific binding to the HER2 negative cell 
line SUM149 and in agreement with previous studies, trastuzumab did not interfere with 
Affibody molecule binding to SK-OV-3 cells. Scatchard analysis revealed that the Kd of 
18F-NOTA-ZHER2:2395 was 6.5 ± 1.2 nM and the number of binding sites on SK-OV-3 cells was 
1.3 x 106 ± 0.4 x 10
6 per cell.  The binding curves of the IC50 determination are shown in 
Figure 1B. The IC50
 of 19F-NOTA-ZHER2:2395 was 5.0 ± 0.1 nM, which was similar to 
69Ga- and 
115In-NOTA-ZHER2:2395 (6.3 ± 0.1 nM and 5.1 ± 0.04 nM, respectively). 
Serum stability
Stability studies showed that 18F-NOTA-ZHER2:2395 did not release Al
18F after incubation in 
human or mouse serum at 37°C for 4 h, indicating excellent stability. 
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Figure 1. A: In vitro binding of 18F-NOTA-ZHER2:2395 to SK-OV-3 and SUM149 cells. Cells were incubated with 
18F-NOTA-ZHER2:2395 in the presence of unlabeled NOTA-ZHER2:2395 which was preincubated for 15 min at RT without 
acetonitrile or at 90 °C in 25% acetonitrile (MeCN) or in the presence of trastuzumab. B: Competitive binding 
curves of IC50 determination of 
19F-, 69F- and 115In-NOTA-ZHER2:2395 on SK-OV-3 cells. 
111In-NOTA-ZHER2:2395 was used as 
radioactive tracer.
Animal studies
Biodistribution studies
The results of the biodistribution studies are summarized in Figure 2. Mean tumor 
weight was 112 ± 54 mg. Tumor uptake 1 h after injection of 18F-NOTA-ZHER2:2395 was 4.4 
± 0.8 %ID/g, compared to 5.6 ± 1.6 %ID/g and 7.1 ± 1.4 %ID/g for  68Ga- and 111In-NOTA-
ZHER2:2395. Coinjection of an excess of unlabeled ZHER2:2395 resulted in a significant (p < 0.05) 
reduction in tumor uptake to 2.9 ± 0.3 %ID/g, 1.7 ± 0.5 %ID/g and 3.0 ± 0.5 %ID/g for 18F-
, 68Ga- and 111In-NOTA-ZHER2:2395, respectively. Uptake in other organs was not affected by 
coinjecting an excess of unlabeled ZHER2:2395. All radiolabeled Affibody molecules showed 
rapid clearance from the blood and normal organs, resulting in tumor-to-blood ratios of 
7.4 ± 1.8 and 8.0 ± 1.3 for 18F- and 68Ga-NOTA-ZHER2:2395, respectively (Figure 2C). In contrast, 
111In-NOTA-ZHER2:2395 cleared from the blood slower, resulting in a significantly lower tumor-
to-blood ratio of 4.8 ± 1.3 (p < 0.05). 18F-NOTA-ZHER2:2395 showed good tumor retention: 4 h 
after injection, tumor uptake was 4.9 ± 0.7 %ID/g, which was comparable to the uptake 
1 h after injection. Tumor uptake of 111In-NOTA-ZHER2:2395 was 7.7 ± 2.6 %ID/g, 4 h after 
injection. Due to faster blood clearance, tumor-to-blood ratio of 18F-NOTA-ZHER2:2395 was 
significantly  higher than that of 111In-NOTA-ZHER2:2395 (145 ± 24 versus 42 ± 13). All three 
radiolabeled Affibody  molecules were excreted and reabsorbed by the kidneys, resulting 
in high kidney accumulation. The bone uptake was low, indicating stable complexation of 
18F by the NOTA chelator. 
PET/CT and SPECT/CT imaging
PET/CT and SPECT/CT images acquired 1 and 4 h after injection are shown in Figure 3. 
18F-NOTA-ZHER2:2395 clearly visualized HER2-expressing SK-OV-3 xenografts, with good 
contrast to normal tissue. 68Ga- and 111In-NOTA-ZHER2:2395 also visualized SK-OV-3 xenografts 
with PET/CT and SPECT/CT, respectively. High accumulation of radiolabeled Affibody 
molecules in the kidneys was observed, with activity mainly localized in the renal cortex. 
Tumor-to-liver ratios were derived from the PET and SPECT images and ranged between 
4.9 - 7.1, 1.6 – 5.3 and 2.6 - 5.8 for 18F-, 68Ga-, and 111In-NOTA-ZHER2:2395, respectively. These 
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ratios correlated significantly with the tumor-to-liver ratio measured in the biodistribution 
study (r = 0.87, p = 0.023).
Figure 2. Biodistribution of 18F-NOTA-ZHER2:2395, 
68Ga-NOTA-ZHER2:2395 and 
111In-NOTA-ZHER2:2395 in mice bearing 
subcutaneous SK-OV-3 xenografts at 1 h (A) and 4 h (B) after injection. C: Tumor-to-blood ratios of 18F-NOTA-
ZHER2:2395, 
68Ga-NOTA-ZHER2:2395 and 
111In-NOTA-ZHER2:2395 in mice bearing subcutaneous SK-OV-3 xenografts.
Discussion
The preclinical studies described in this paper show that 18F-NOTA-ZHER2:2395 is a promising 
radiotracer for HER2-expressing xenografts. This is the first time Affibody molecules were 
radiolabeled with 18F, based on the complexation of Al18F by NOTA, which is a fast (30 min) 
labeling reaction. 18F-NOTA-ZHER2:2395 has a high affinity for HER2 (Kd = 6.5 nM) and showed 
efficient and specific accumulation in HER2-expressing tumors. PET images revealed high 
tumor-to-normal tissue contrast. 
The in vitro affinity of cold labeled NOTA- ZHER2:2395 and the in vivo biodistribution of 
18F-NOTA-ZHER2:2395 were compared to 
68Ga- and 111In-labeled NOTA-ZHER2:2395. In vitro, all 
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three ‘cold’ labeled compounds showed similar IC50 in the nanomolar range. This indicates 
that the affinity was not affected by the radionuclide that was chelated by NOTA. The 
comparative biodistribution study showed HER2-specific accumulation in the tumor of all 
radiolabeled Affibody molecules, with the highest tumor uptake for 111In-NOTA-ZHER2:2395. 
However, 18F- and 68Ga-labeled Affibody molecules cleared more rapidly from the blood, 
resulting in higher tumor-to-blood ratios compared to 111In-labeled Affibody molecules. 
Radiolabeled Affibody molecules showed good tumor retention, tumor uptake remained 
high 4 h after injection and tumor-to-blood ratios increased rapidly due to the ongoing 
clearance from the blood. Both PET/CT and SPECT/CT images clearly visualized HER2-
expressing xenografts with high contrast to normal tissues. Radiolabeled Affibody 
molecules were reabsorbed by the kidneys, resulting in high kidney uptake, which was 
mainly localized in the cortex. PET/CT did not reveal any bone uptake, indicating that the 
18F was stably complexed by NOTA. 
Figure 3. PET/CT and SPECT/CT of mice bearing subcutaneous SK-OV-3 xenografts after injection of radiolabeled 
NOTA-ZHER2:2395.
Overall, all three radiolabeled Affibody molecules were able to target and visualize HER2-
expressing tumors. However, the use of positron emitting radionuclides such as 18F and 
68Ga is preferred over 111In because of the higher sensitivity and better quantification 
of PET compared to SPECT. Moreover, clinical PET/CT cameras have a better resolution 
than SPECT.  An advantage of 18F over 68Ga is the longer half-life (110 min versus 68 
min). Therefore, 18F-NOTA-ZHER2:2395 allows imaging at several hours after injection, which 
is preferred due to the higher tumor-normal tissue ratios. Moreover, imaging at several 
hours after injection is practical in the clinical situation.  Furthermore, the positron range 
of 18F (2.3 mm in water) is shorter than that of 68Ga (8.9 mm in water), which can improve 
image quality, especially in the preclinical setting.(28) 
Several other approaches for imaging of HER2 expression have been described. ZHER2:342 
or its derivates have been radiolabeled with different radionuclides and showed specific 
targeting of HER2-expressing xenografts.(17) Kramer et al. have conjugated ZHER2:342 with 
N-2-(4-[18F]fluorobenzamido)ethyl]maleimide ([18F]FBEM).(22) [18F]FBEM-ZHER2:342 was able 
to bind HER2 with good affinity and showed comparable uptake in SK-OV-3 xenografts 
compared to our 18F-labeled Affibody molecule. The specific activities of 18F-NOTA-
ZHER2:2395 and [
18F]FBEM-ZHER2:342 were comparable at the end of synthesis. However, the 
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preparation of [18F]FBEM-ZHER2:342 is based on the synthesis of a fluorinated synthon, which 
is subsequently reacted with the Affibody molecule. This requires a long synthesis time 
of approximately 2 h. We were able to radiolabel Affibody molecules with 18F within 30 
min using a 2-step, 1-pot reaction. In addition, in future studies the specific activity of 
18F-NOTA-ZHER2:2395 may be improved by using different chelators and solvents.(29, 30) 
Besides radiolabeled Affibody molecules, other radiotracers have been developed. For 
example, radiolabeled trastuzumab and pertuzumab have been used for SPECT and PET 
imaging of HER2 expression.(13-15, 31) However, these large proteins are characterized 
by slow tumor penetration and clearance from the circulation. A direct comparison of 
124I-labeled ZHER2:342 and trastuzumab showed that Affibody molecules have superior 
imaging properties.(32) Radiolabeled trastuzumab resulted in higher absolute tumor 
uptake, but tumor-normal tissue ratios were considerably higher for Affibody molecules. 
Moreover high contrast images with Affibody could be obtained within 6 hours after 
injection, in contrast to radiolabeled trastuzumab for which the highest tumor-normal 
tissue ratios were obtained several days after injection. A disadvantage of trastuzumab-
based tracers is that they cannot be used to monitor changes in HER2 expression during 
trastuzumab treatment, because of competition of the therapeutic antibody with the 
tracer molecule for the same epitope on HER2. In contrast, in agreement with previously 
published data(22), binding of NOTA-ZHER2:2395 to HER2 was not interfered by trastuzumab, 
due to binding to different domains. Therefore, Affibody  molecules can be used to study 
HER2 expression during trastuzumab treatment, which offers exciting opportunities to get 
more insight into the dynamics of the HER2 receptor during trastuzumab (combination) 
therapy.
Translation of HER2 imaging from the preclinical setting to patients may improve patient 
selection for HER2-targeted therapy, since in vivo imaging avoids misinterpretation due to 
intratumoral and interlesional tumor heterogeneity. Furthermore, HER2 imaging can be 
used to monitor expression during the course of disease or during trastuzumab treatment 
without the need of repetitive invasive biopsies. Recently, a clinical pilot study has shown 
that it is feasible to visualize HER2-expressing tumors in patients with metastatic breast 
cancer, using radiolabeled Affibody molecules.(20) 
Despite the advantages of imaging HER2 expression with Affibody molecules, a few 
potential limitations have to be considered. First, HER2-overexpressing tumors can release 
HER2 in the circulation. Circulating HER2 can bind radiolabeled Affibody molecules and 
may therefore interfere with tumor targeting. However, a first pilot study showed that 
HER2-overexpressing tumors could be visualized, even in the presence of shedded 
HER2.(20) A second potential limitation is the reabsorption of Affibody molecules by the 
kidneys resulting in high kidney accumulation. This may interfere with the visualization 
of tumor lesions located in the kidney, which is however not a major problem as far as 
breast and gastric cancers are concerned, since they are not very likely to metastasize 
to the kidneys. Still there are indications, such as the visualization of lower vertebral 
lesions, for which HER2 imaging with 18F-NOTA-ZHER2:2395 could be improved by developing 
strategies to minimize the reabsorption of Affibody molecules by the kidney. Potential 
ways of reducing kidney uptake are the use of positively charged amino acids, gelofusin 
or albumin fragments.(33-35)  
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Conclusion
This study showed that 18F-NOTA-ZHER2:2395 is a promising new imaging agent for HER2 
expression in tumor. Affibody molecules were successfully labeled with 18F within 30 min, 
based on the complexation of Al18F by NOTA. Further research is needed to determine 
whether this technique can be used for patient selection for HER2-targeted therapy.
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Abstract
Introduction: Bevacizumab (anti-VEGF) and cetuximab (anti-EGFR) are approved 
antibodies for treatment of cancer. However, in advanced colorectal cancer, the 
combination fails to improve survival. As the reason for the lack of activity is unknown, 
this study aims to determine the effect of bevacizumab on targeting of anti-EGFR and IGF-
1R antibodies in tumors with SPECT/CT imaging. 
Material and methods: Mice with subcutaneous EGFR and IGF-1R-expressing SUM149 
xenografts received a single dose of bevacizumab (10 mg/kg) or saline.  After four days, 
mice were injected with radiolabeled cetuximab or R1507, an anti-IGF-1R antibody. A 
control group received a radiolabeled irrelevant IgG (hLL2). Three days later, SPECT/
CT images were acquired and mice were dissected to determine the concentration of 
antibodies in the tissues. Tumors were analyzed immunohistochemically to determine 
vascular density (CD34), VEGF, EGFR and IGF-1R expression.
Results: SPECT/CT imaging revealed that bevacizumab treatment significantly reduced 
tumor targeting of radiolabeled cetuximab by 40% from 33.1 ± 1.1 %ID/g to 19.8 ± 
5.7 %ID/g (p = 0.009) for untreated and bevacizumab treated tumors, respectively. A 
similar effect was found for 111In-R1507: tumor targeting of R1507 decreased by 35%. No 
significant differences in tumor uptake were observed in mice that received an irrelevant 
IgG. Uptake in normal organs was not altered by bevacizumab. Immunohistochemical 
analysis showed that vascular density decreased with 43%, while EGFR and IGF-1R 
expression was unaltered.
Conclusion: Bevacizumab treatment significantly reduces tumor targeting of anti-EGFR 
and anti-IGF-1R antibodies. This emphasizes the importance of timing and sequencing of 
bevacizumab in combination with other antibodies. 
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Introduction
Angiogenesis, the growth of new blood vessels from pre-existing vessels, is an important 
target for cancer treatment. This was demonstrated in a randomized phase III trial which 
showed that bevacizumab combined with chemotherapy improved survival of patients 
with advanced colorectal cancer.(1) Bevacizumab is a monoclonal antibody that targets 
vascular endothelial growth factor (VEGF). Inhibition of VEGF affects tumor growth 
by several mechanisms, including inhibition of new vessel growth and induction of 
endothelial cell apoptosis. Moreover, it affects vessel function by vasoconstriction and 
vessel normalization. In addition, VEGF receptors (VEGFRs) and neuropilin-1 and 2 have 
been detected on tumor cells. Therefore, bevacizumab may have a direct effect on tumor 
cell function, including cell survival, migration and invasion. However, evidence from 
clinical studies to confirm this effect has been difficult to obtain.(2-5) Bevacizumab has 
been approved by the FDA for treatment of metastatic colorectal cancer, metastatic renal 
cell carcinoma, glioblastoma and non-small cell lung cancer.(1, 6-9) 
Several other antibodies have potential for treatment of cancer, including antibodies 
directed against the epidermal growth factor receptor (EGFR), human epidermal growth 
factor receptor 2 (HER2), HER3, and insulin-like growth factor 1 receptor (IGF-1R). A 
combination of these antibodies may further improve survival of cancer patients. However, 
finding a rational regimen for combining a particular pair of antibodies remains difficult. 
The VEGF and EGFR pathway are closely related and have potential for combination 
therapy. Activation of EGFR stimulates the production of VEGF by tumor cells, which results 
in increased proliferation and migration of endothelial cells,(10) while blocking EGFR 
by cetuximab can result in decreased VEGF expression.(11) In vitro studies have shown 
that increased VEGFR-1 expression is associated with resistance to gefitinib (a selective 
inhibitor of the EGFR tyrosine kinase domain) or the anti-EGFR antibody cetuximab.(12) 
Moreover, the key regulators of VEGF, hypoxia-inducible transcription factors, can induce 
upregulation of EGFR expression under hypoxic conditions.(13) 
Early preclinical and clinical studies have suggested that blocking both angiogenesis and 
EGFR may enhance therapeutic efficacy.(14-19) Moreover, cetuximab in combination with 
chemotherapy improves survival of patients with colorectal cancer.(20, 21) Therefore, the 
combination of chemotherapy with anti-EGFR antibodies has been studied in phase III 
clinical trials. The combination of chemotherapy and bevacizumab with cetuximab(22, 23) 
or panitumumab(24) did not result in improved progression free survival compared with 
patients who received chemotherapy and bevacizumab alone. The study of Hecht et al. 
even showed a significantly reduced survival for patients receiving the combination of 
antibodies.(24)
 Several explanations have been proposed for these observations. For example, toxicity 
may be enhanced by dual-pathway inhibition using bevacizumab and panitumumab, 
leading to dose delays or reduction and decreased survival.(24) However, this was 
not the case in all studies.(22) Also, pharmacokinetic interactions may have occurred 
between the two antibodies, as is suggested by the reduced incidence of bevacizumab-
induced hypertension in the patients that received the combination of antibodies.(24) 
Furthermore, interaction between downstream signaling pathways may have occurred. 
For example, EGFR-mediated alterations of downstream targets may be required for 
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the activity of bevacizumab or chemotherapy.(24) Alternatively, bevacizumab may 
alter tumor vascularity, thereby limiting the delivery of cetuximab or panitumumab to 
the tumor, leading to a reduced therapeutic effect. Up to now the reason for the lack of 
additive activity of the combination of bevacizumab and anti-EGFR antibodies remains 
speculative.
In this study we will test the hypothesis that bevacizumab treatment reduces targeting 
of other antibodies to the tumor. For that purpose we treated tumor bearing mice with 
bevacizumab and measured the effect on tumor targeting of radiolabeled anti-EGFR and 
anti-IGF-1R antibodies, using SPECT/CT imaging. 
Material and methods
Cell culture 
The breast cancer cell line SUM149 (Asterand, Detroit, MI) was cultured and maintained as 
monolayer in culture flasks in Ham’s F12 medium (GIBCO, BRL Life Sciences Technologies, 
The Netherlands) supplemented with 5% fetal calf serum (FCS), 10 mM HEPES, 
hydrocortisone (1 µg/ml), and insulin (5 µg/ml) at 37 °C in a humidified atmosphere with 
5% CO2. SK-BR-3 cells were cultured in RPMI-1640 medium (GIBCO, BRL Life Sciences 
Technologies, The Netherlands), supplemented with 10% FCS, 2 mM glutamine, penicillin 
(100 units/ml) and streptomycin (100 µg/ml).
Antibodies
Cetuximab, a chimeric monoclonal antibody directed against EGFR, was obtained 
from Merck (Darmstadt, Germany). The fully human monoclonal R1507 was a kind gift 
of Roche (Penzberg, Germany) and is directed against an epitope on the extracellular 
domain of the human IGF-1R. The humanized anti-CD22 antibody hLL2 kindly supplied 
by Immunomedics, Inc. (Morris Plains, NJ, USA) and was used as an irrelevant control 
antibody in these studies. 
Radiolabeling
Cetuximab, R1507 and hLL2 were radiolabeled as described previously.(25, 26) In brief, 
antibodies were conjugated with isothiocyanatobenzyl-diethylenetriaminepentaacetic 
acid (ITC-DTPA, Macrocyclis, Dallas, TX) in 0.1 M NaHCO3, pH 9.5, using a fifty-fold 
(cetuximab) or fifteen-fold (R1507 and hLL2) molar excess of ITC-DTPA for one hour at 
room temperature (RT). The unbound ITC-DTPA was removed from the reaction mixture 
by dialysis against 0.25 M ammonium acetate buffer, pH 5.4. DTPA-conjugated antibodies 
(37 µg) were incubated with 300 – 400 MBq 111In (Covidien BV, Petten, The Netherlands) 
in 0.1 M MES buffer, pH 5.4, at room temperature (RT), under strict metal-free conditions 
for 30 min. After incubation, 50 mM EDTA was added to a final concentration of 5 mM. 
Labeling efficiency was determined using instant thin-layer chromatography (ITLC) on 
silica gel chromatography strips (Agilent Technologies, Palo Alto, CA), using 0.1 M citrate 
buffer, pH 6.0, as the mobile phase. In case labeling efficiency was below 95%, the reaction 
mixture was purified on a PD-10 column (Amersham Biosciences, Uppsala, Sweden), eluted 
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with PBS, containing 0.5% BSA. Radiochemical purity of 111In-DTPA-Cetuximab (111In-
Cetuximab), 111In-DTPA-R1507 (111In-R1507), and 111In-DTPA-hLL2 (111In-hLL2) exceeded 
95% in all experiments.
In vitro studies
EGFR, IGF-1R and CD22 expression of SUM149 cells
Scatchard analysis was performed to quantitatively determine EGFR and IGF-1R 
expression of the SUM149 cells. Cells were cultured to confluency in six-well plates and 
were incubated for 4 h on ice with increasing concentrations 111In-Cetuximab (0.03 – 300 
nM) or 111In-R1507 (0.03 – 30 nM) in 1 ml binding buffer (Ham’s F12 containing 10 mM 
HEPES and 0.5% BSA). The cell-associated activity at each concentration was determined 
in triplicate. Non-specific binding was determined by co-incubation with an excess of 3 
μM cetuximab or 0.3 μM R1507. After incubation, cells were washed with PBS and the cell-
associated activity was measured in a shielded well-type gamma counter (Perkin-Elmer, 
Boston, MA, USA). The specific binding was plotted against the bound/free ratio and data 
were analyzed by linear regression to determine receptor density and the dissociation 
constant (Kd).
hLL2 was used as a control antibody without specific tumor targeting. To confirm that 
the SUM149 cell line did not express CD22, cells were incubated with 0.3 nM 111In-hLL2. 
Separate wells were coincubated with an excess of unlabeled hLL2 (30 nM). After 4 h on 
ice, cells were washed and cell-associated activity was measured as described above.
Effect of bevacizumab on EGFR and IGF-1R expression in vitro
SUM149 cells were cultured for 72 h in six-well plates in the presence of bevacizumab (0.1 
– 1,000 nM). Subsequently, EGFR and IGF-1R expression was measured by incubating cells 
for 4 h on ice with 3 nM 111In-cetuximab or 0.3 nM 111In-R1507 in 1 ml binding buffer. After 
incubation, cells were washed with PBS and the cell-associated activity was determined 
as described previously. A protein assay was performed to correct for the number of cells 
per well (BCA Protein Assay Reagent, Thermo Scientific). 
Animal experiments
Animal experiments were performed in female BALB/c nude mice (Janvier, le Genest-
Saint-Isle, France) and were conducted in accordance with the principles laid out by the 
revised Dutch Act on Animal Experimentation (1997) and approved by the institutional 
Animal Welfare Committee of the Radboud University Nijmegen. At 6-8 weeks of age, 
mice were inoculated subcutaneously with 5 x 106 SUM149 or SK-BR-3 cells (mixed 2:1 
with matrigel, BD Biosciences, Pharmingen). Experiments started 2 weeks after tumor cell 
inoculation when the tumors reached a size of approximately 0.1 cm3. 
Effect of bevacizumab on tumor growth
Mice with s.c. SUM149 tumors (N=5 per group) were injected intraperitoneally, twice a 
week, with 1, 10 or 20 mg/kg bevacizumab or saline.  Tumor size was measured three 
times a week by caliper measurements in three dimensions (radius x, y and z). Tumor size 
was calculated using the following formula: 4/3 · π · x · y · z. Body weight was measured 
three times a week.
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Effect of bevacizumab on targeting of anti-EGFR and IGF-1R antibodies in vivo
Mice with subcutaneous SUM149 tumors received a single intraperitoneal injection of 
bevacizumab (10 mg/kg) or PBS. Tumor size and body weight were measured before 
bevacizumab injection (day 1) and at day 7. Four days after the bevacizumab injection, 
mice (N=7 per group) received 16-21 MBq 111In-R1507 or 111In-Cetuximab (antibody dose 
2.2 μg per mouse) intravenously. To study the non-receptor mediated uptake, separate 
groups of mice (N=3 per group) were coinjected with an excess of unlabeled antibody (300 
μg) or received irrelevant IgG 111In-hLL2 (antibody dose 2.2 μg per mouse). Three days after 
injection of the radiolabeled antibody, mice were euthanized using O2/CO2-asphyxiation 
and SPECT/CT images were acquired using the U-SPECT-II/CT system (MILabs, Utrecht, The 
Netherlands).(27) Mice were scanned for 50 minutes using the 1.0 mm diameter pinhole 
rat collimator tube, followed by a CT scan (spatial resolution 160 µm, 65 kV, 612 µA) for 
anatomical reference. Scans were reconstructed with MILabs reconstruction software, 
which uses an ordered-subset expectation maximization algorithm, with a voxel size of 
0.375 mm. Representative cross sections located approximately in the center of the tumor 
were displayed. A 3D volume of interest was drawn around the tumor and uptake was 
quantified as the percentage injected dose per gram (%ID/g), assuming a tissue density 
of 1 g/cm3. 
After scanning, tumor, blood, muscle, lung, heart, spleen, pancreas, intestine, kidney and 
liver were dissected and weighed. Activity was measured in a gamma counter. To calculate 
the uptake of radiolabeled antibodies in each sample as a fraction of the injected dose, 
aliquots of the injected dose were counted simultaneously. The results were expressed as 
%ID/g.
To confirm that the findings in the SUM149 xenografts also applied to other xenograft 
models, we performed a similar experiment in mice bearing subcutaneous HER2-
overexpressing breast cancer xenografts SK-BR-3. After a single injection of bevacizumab 
(10 mg/kg) or PBS, mice were injected with 0.2 MBq 111In-R1507 (day 4) and euthanized at 
day 7. An ex vivo biodistribution was performed to determine the effect of bevacizumab 
on tumor targeting of 111In-R1507.  
Immunohistochemistry of SUM149 xenografts
Antibodies against EGFR (M7239, DAKO), IGF-1R (3027, Cell Signaling), CD34 (ab8458, 
Abcam), VEGF (555036, Pharmingen) and VEGFR-2 (2479, Cell Signaling) were used to 
determine expression of the respective antigens on paraffin-embedded tumor sections. 
In short, antigen retrieval was performed in 10 mM sodiumcitrate, pH 6.0 for 10 min at 99 
°C for IGF-1R and CD34 staining. For VEGF staining, sections were treated for 10 min at RT 
with proteinase K (20 μg/ml). Endogenous peroxidase activity was blocked with 3% H2O2 
and nonspecific binding was blocked by using a Mouse-on-Mouse blocking kit (EGFR 
[BMK-2202, Vector]) or by incubation with normal goat serum (IGF-1R, CD34, VEGF and 
VEGFR-2). After incubation with the primary antibody, tumor sections for EGFR, IGF-1R, 
CD34 and VEGFR-2 were incubated with a biotinylated secondary antibody, followed by 
incubation with an avidin-biotin-enzyme complex (Vector Laboratories, Burlingame, CA) 
and EGFR staining was further amplified using the CARD method. (28) Tumor sections for 
VEGF were incubated with a peroxidase-conjugated secondary antibody. Finally DAB was 
used to develop the tumor sections.
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EGFR, IGF-1R expression was scored as negative (0), incomplete weak (1+), complete weak 
to moderate (2+) and strong (3+) membrane staining (Table 1). The mean vascular density 
(MVD) was scored as the number of vessels counted in 3 hot spot areas that contained the 
maximum number of vessels.
Table 1. Scoring EGFR and IGF-1R staining 
Score Staining pattern
0 No staining is observed, or membrane staining is observed in <10% of the tumor cells
1+ A faint/barely perceptible membrane staining is detected in >10% of tumor cells. The 
cells exhibit incomplete membrane staining
2+ A weak to moderate complete membrane staining is observed in >10% of tumor cells
3+ A strong complete membrane staining is observed in >10% of tumor cells
Statistical analysis
Statistical analyses were performed using PASW Statistics version 18.0 (Chicago, IL) and 
GraphPad Prism version 5.03 (San Diego, CA) for Windows. Differences in tumor size and 
uptake of radiolabeled antibodies were tested for significance using the nonparametric 
Kruskal-Wallis and  Mann-Whitney U test. The correlation between tumor uptake measured 
by SPECT and ex vivo biodistribution was calculated with the Pearson correlation 
coefficient.  A p-value below 0.05 was considered significant. 
Results
In vitro experiments
EGFR, IGF-1R and CD22 expression of SUM149 cells 
Scatchard analysis showed that the receptor density of EGFR and IGF-1R was 86,700 
receptors/cell (95% CI: 76,700 – 100,900 receptors/cell) and 5,000 receptors/cell (95% 
CI:3,800 – 8,600 receptors/cell), respectively. The dissociation constant (Kd) of 
111In-
cetuximab and 111In-R1507 was 0.13 nM (95% CI: 0.11 – 0.17 nM) and 0.31 nM (95% CI: 
0.21 – 0.62 nM), respectively. The irrelevant IgG 111In-hLL2 did not show specific binding to 
SUM149 cells. Bevacizumab treatment did 
not affect membrane expression of EGFR 
and IGF-1R in vitro (Figure 1). 
Animal studies
Bevacizumab inhibits growth of SUM149 
xenografts
Bevacizumab treatment significantly 
inhibited tumor growth of SUM149 
tumors at all three dose levels (Figure 2). 
After two weeks of treatment, tumor size 
in the control group was 263 ± 86 mm3 
compared to 136 ± 9 mm3 for mice treated 
Figure 1. Binding of 111In-cetuximab and 111In-R1507 
to SUM149 cells treated with bevacizumab. Binding is 
expressed relatively to untreated cells (mean ± SD). 
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with 10 mg/kg bevacizumab (p = 0.007). At 
later time points this effect became more 
pronounced. At the end of the experiment 
(day 24 after start of treatment), tumor size in 
the control group and 10 mg/kg bevacizumab 
group was 889 ± 266 mm3 and 369 ± 41 mm3, 
respectively. No signs of toxicity or changes in 
body weight were observed. 
Bevacizumab decreases tumor uptake of 
cetuximab and R1507
A single injection of bevacizumab did not cause 
growth inhibition of SUM149 xenografts within 
7 days. Mean tumor size at day 7 was 143 ± 88 
mm3 compared to 147 ± 99 mm3 for untreated 
and bevacizumab treated mice, respectively.
SPECT/CT images showed  a clear reduction 
in tumor targeting of 111In-cetuximab and 
111In-R1507 after bevacizumab treatment, 
while targeting of 111In-hLL2 was not affected 
(Figure 3). Quantitative analysis of these images 
showed that the tumor targeting of 111In-
cetuximab significantly decreased by 40% from 33.1 ± 1.1 %ID/g to 19.8 ± 5.7 %ID/g (p 
= 0.009) for untreated and bevacizumab treated tumors, respectively. A similar effect was 
found for 111In-R1507: tumor targeting of R1507 decreased by 35%. Uptake in untreated 
tumors was 22.8 ± 4.4 %ID/g, compared to 14.9 ± 2.3 %ID/g in bevacizumab treated tumors 
(p = 0.009). Uptake of 111In-hLL2 decreased by 18%, however the difference between the 
bevacizumab treated (8.2 ± 1.4 %ID/g) and untreated tumors (9.7 ± 2.0 %ID/g) was not 
significant.  
Ex vivo biodistribution confirmed the data obtained by SPECT imaging. Bevacizumab 
treatment caused a 44% reduction in tumor targeting of radiolabeled cetuximab. The 
tumor uptake of radiolabeled cetuximab in untreated mice was 35.2 ± 1.6 %ID/g, compared 
to 19.7 ± 5.3 %ID/g for bevacizumab treated mice (p = 0.009, Figure 3). Tumor targeting of 
111In-R1507 decreased significantly by 29%. The uptake in treated and untreated mice was 
26.7 ± 2.8 %ID/g and 18.9 ± 2.8 %ID/g, respectively (p = 0.009). 
These results were confirmed in the SK-BR-3 model. Bevacizumab treatment caused 
a 33% reduction in tumor targeting of 111In-R1507 (bevacizumab treatment:18.6 ± 5.0 
%ID/g, untreated: 12.4 ± 2.8 %ID/g, p = 0.047). Mice that were coinjected with an excess of 
unlabeled antibody or that received the irrelevant IgG showed a trend towards reduced 
tumor targeting after bevacizumab treatment, however this was not significant. Uptake in 
normal organs was not affected by bevacizumab treatment.
Tumor uptake measured with SPECT showed an excellent correlation with the ex vivo 
biodistribution study (r =0.95, p < 0.001).
Figure 2. Tumor size of SUM149 xenografts 
treated twice a week with bevacizumab. After two 
weeks of treatment, tumor size was significantly 
smaller for bevacizumab treated mice compared 
to untreated mice (p = 0.007).
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Figure 3. SPECT/CT images of mice injected with (A) 111In-cetuximab, (B) 111In-R1507 and (C) 111In-hLL2. D: 
Tumor uptake measured by ex vivo biodistribution (mean ± SEM) of radiolabeled cetuximab, R1507 and 
hLL2 in untreated and bevacizumab treated mice. Tumor targeting of radiolabeled cetuximab and R1507 was 
significantly reduced by bevacizumab treatment (p = 0.009).
Bevacizumab decreases vascular density of SUM149 xenografts while IGF-1R and EGFR 
expression remains intact
HE staining showed that all xenografts consisted of viable tumor tissue only (no necrotic 
regions were found in the tumor sections). Immunohistochemical analysis revealed that 
the expression of EGFR and IGF-1R did not differ between tumors in the bevacizumab-
treated and untreated group (Figure 4b and 4c). Mean EGFR expression was scored as 
2+ for both groups, while IGF-1R expression was scored as 1+.  Also, VEGF and VEGFR-2 
expression was unaltered by bevacizumab treatment (Figure 4d and e). In contrast, the 
CD34 staining revealed a marked decrease in vascular density in bevacizumab-treated 
tumors compared to untreated tumors (Figure 4f ). Bevacizumab treatment caused a 43% 
reduction of the MVD in the SUM149 tumors (Figure 5). 
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Figure 4. Immunohistochemical analysis of SUM149 xenografts: (A) HE staining, (B) EGFR expression, (C) IGF-1R 
expression, (D) VEGF expression and (E) VEGFR-2 expression and (F) CD34 expression.
Discussion
This study showed that bevacizumab treatment 
can significantly reduce the targeting of anti-
EGFR and IGF-1R antibodies to a tumor. The 
most likely explanation for this finding is 
reduced accessibility of the targets (EGFR and 
IGF-1R, respectively), since vascular density 
significantly decreased while the expression 
of EGFR and IGF-1R remained unaltered. IGF-
1R and EGFR expression was measured semi-
quantitative by immunohistochemistry. Compared to other techniques such as western 
blot and qPCR, immunohistochemistry does not allow exact quantification. However, it 
can discriminate between membrane expression and cytoplasmic expression, which is 
very relevant since these receptors are also expressed intracellularly, and cetuximab and 
R1507 can only target the receptors expressed on the cell membrane. 
VEGF expression in the tumors was not affected by bevacizumab treatment. Bevacizumab 
neutralizes the function of VEGF by preventing its binding to VEGF receptor 1, VEGF 
receptor 2, neuropilin 1 and neuropilin 2. In this way, bevacizumab inhibits new vessel 
growth and induces endothelial cell apoptosis, resulting in decreased vascular density. 
Moreover, bevacizumab can cause changes in vessel function and integrity which could 
also prevent the antibodies from reaching EGFR and IGF-1R.(2) 
Since there is extensive crosstalk between the VEGF and EGFR pathways, there is a clear 
rational for combining EGFR and VEGF targeted therapy. However, phase III clinical trials 
A
B
C
D
E
F
Figure 5. Relative mean vascular density (MVD) 
presented as mean ± SEM of bevacizumab 
treated tumors and untreated tumors.
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have shown that the addition of cetuximab to bevacizumab and chemotherapy did not 
improve survival of patients with advanced colorectal cancer compared to bevacizumab 
and chemotherapy alone (22-24). These findings were unexpected since preclinical studies 
using combination therapy targeting both angiogenesis and EGFR showed encouraging 
results.(14-17). However, none of these early preclinical studies used the combination of 
bevacizumab and cetuximab. In more recent preclinical studies  the effect of combined 
bevacizumab and cetuximab treatment was evaluated. Wang et al. showed that tumor 
growth in mice bearing head and neck squamous cell carcinoma xenografts was less 
effectively inhibited by the triple agent combination of cetuximab, bevacizumab and 
cisplatin, compared with bevacizumab and cisplatin alone.(29) In addition, Poindessous et 
al. showed that simultaneous treatment with bevacizumab and cetuximab in mice bearing 
colorectal cancer xenografts was equally effective compared to either agent alone.(30)
Several mechanisms for the lack of additive efficacy of the combination of bevacizumab 
and cetuximab have been proposed: 1) increased toxicity, 2) pharmacokinetic interactions 
between the two antibodies, 3) interactions in signaling pathways of EGFR and VEGF and 
4) reduced target accessibility of EGFR due to bevacizumab treatment. In this study we 
showed that bevacizumab caused reduced targeting of antibodies against the growth 
factor receptors EGFR and IGF-1R. These results are in agreement with a recently published 
study showing that an anti-VEGF antibody caused reduced tumor accumulation of 
trastuzumab in mice bearing HER2 expressing KPL-4 breast cancer xenografts.(31) 
Reduced target accessibility limits the delivery of cetuximab and other antibodies to the 
tumor, which potentially results in a reduced therapeutic effect of these antibodies. Our 
results underline the importance of a careful evaluation of timing and sequencing of 
bevacizumab and other targeted agents. This is further illustrated by a retrospective study 
in patients with advanced colorectal cancer who were treated with cetuximab. Patients 
who received previous anti-VEGF therapy showed lack of response and poorer disease-
specific survival compared with patients who did not receive prior anti-VEGF therapy.(32)
A potential limitation of this study is the difference between preclinical models and 
human tumors. Typically, tumor growth and angiogenesis in preclinical models is more 
rapid compared to human tumors. Also, tumor vessels in murine models tend to be very 
responsive to anti-angiogenic therapy, while the effect on the vasculature of human 
tumors is usually less dramatic.(2) However, functional changes in the tumor vasculature 
in patients during anti-angiogenic treatment have been clearly observed.(33-35) For 
example, reduction in tumor vessel perfusion and permeability as assessed by DCE-MRI or 
15O-H2O PET was observed during bevacizumab containing treatment schedules in breast, 
colorectal cancer and non-small cell lung cancer.(35-37) 
We demonstrated that bevacizumab has a strong influence on target accessibility. This 
may have major consequences for combining antibodies with bevacizumab. In addition, 
similar effects may be observed for tyrosine kinase inhibitors such as sorafenib and 
sunitinib. Desar et al. have studied the targeting of radiolabeled bevacizumab during 
sorafenib treatment in patients with renal cell carcinomas and have found results 
comparable to our study. Sorafenib treatment resulted in a decreased targeting of 111In-
bevacizumab to the tumor and immunohistochemical analysis of tumor sections showed 
that vascular density was decreased, while VEGF expression did not change.(34)  
The current findings may also contribute to further speculations on the combination 
of bevacizumab and chemotherapy. It cannot be ruled out  that also minor changes in 
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sequence and timing of chemotherapy and bevacizumab can lead to different  results 
of these combined therapies. This is illustrated by a recent study which showed that 
bevacizumab reduces tumor targeting of radiolabeled docetaxel in patients with non-
small cell lung cancer.(35)
Conclusion
This study showed that bevacizumab treatment significantly reduces targeting of other 
antibodies to tumors. This underlines the importance of timing and sequencing of 
bevacizumab therapy in combination with other antibodies. Future studies are warranted 
to determine how different timing and sequencing schedules of bevacizumab therapy 
in combination with other antibodies is related to antibody targeting and therapeutic 
efficacy.
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Abstract
Introduction: Bevacizumab (anti-VEGF) and cetuximab (anti-EGFR) are approved 
agents for the treatment of cancer. However, in advanced colorectal cancer, addition of 
cetuximab to chemotherapy with bevacizumab did not improve survival. The reason for 
the lack of activity remains unclear. Previously, we have shown that bevacizumab reduced 
the vascular density of xenografts in mice and consequently limited the delivery of 
cetuximab to tumors. Thus, bevacizumab could limit the therapeutic efficacy of cetuximab. 
Conversely, the EGFR and VEGF pathway are closely related and cetuximab may change 
VEGF expression. Therefore, the aim of this study was to determine the effect of cetuximab 
on VEGF expression and targeting of bevacizumab to the tumor.  
Material and methods: Mice with subcutaneous SUM149 or WiDr xenografts, which 
express EGFR and VEGF, were treated with cetuximab, bevacizumab or the combination of 
the two antibodies, to study the therapeutic efficacy. In addition, before start of cetuximab 
treatment and after 7 and 21 days of treatment, the uptake of radiolabeled bevacizumab 
in the tumor was measured by immunoSPECT/CT. After scanning, tumors were dissected 
for ex vivo biodistribution and analyzed for VEGF expression and vascular density.
Results: Tumor growth of SUM149 xenografts was significantly inhibited by cetuximab, 
bevacizumab or the combination, while growth of WiDr xenografts was not affected. 
After cetuximab treatment, tumor targeting of bevacizumab to the SUM149 xenografts 
was significantly reduced: Tumor-to-blood ratios at day 0, day 7, and day 21 were 2.4 ± 
0.3, 1.6 ± 0.2, and 1.4 ± 0.2, respectively (p=0.004). Tumor-to-blood ratios in mice with 
WiDr xenografts did not change. Biodistribution studies with an irrelevant antibody in 
the SUM149 model also showed significantly reduced tumor-to-blood ratios (0.7 ± 0.1 
versus 0.5 ± 0.1, (p=0.016)). The expression of VEGF did not decrease during cetuximab 
treatment. 
Conclusion: Without decreasing VEGF levels, cetuximab reduces the targeting of 
bevacizumab to breast cancer xenografts. This could at least partly explain why the 
combination of bevacizumab and cetuximab does not result in improved therapeutic 
efficacy. 
 
Cetuximab reduces tumor targeting of bevacizumab
9
145
Introduction
Cetuximab is currently approved for treatment of patients with metastatic colorectal 
cancer and advanced squamous cell carcinoma of the head and neck. It is a chimeric 
monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), thereby 
competitively inhibiting the binding of EGF and other ligands to the receptor. This prevents 
the activation of intracellular kinases and subsequently downregulates PI3K, AKT, MAPK, 
SRC and STAT signaling.(1) 
Although cetuximab in combination with chemotherapy has been shown to improve 
survival of cancer patients, its therapeutic efficacy is still limited and ultimately most 
patients will develop progressive disease.(2, 3) Therefore, new therapeutic strategies are 
investigated. For example, cetuximab can be combined with other targeted agents such 
as antibodies directed against the vascular endothelial growth factor (VEGF), human 
epidermal growth factor receptor 3 (HER3), and insulin-like growth factor 1 receptor (IGF-
1R). A combination of these antibodies may further improve survival of cancer patients. 
However, the development of an effective, rational regimen combining a particular set of 
antibodies remains difficult in clinical practice. 
The VEGF and EGFR pathway are closely related and have potential for combination 
therapy. In vitro studies have shown that increased VEGFR-1 expression is associated 
with resistance to cetuximab and gefitinib (a selective inhibitor of the EGFR tyrosine 
kinase domain).(4) Moreover, the key regulators of VEGF, hypoxia-inducible transcription 
factors (HIFs), can induce upregulation of EGFR expression under hypoxic conditions.(5) 
Furthermore, activation of EGFR stimulates the production of VEGF by tumor cells, which 
results in increased proliferation and migration of endothelial cells,(6) while blocking 
EGFR can result in decreased VEGF expression.(7) 
Early preclinical and clinical studies have suggested that blocking both EGFR and 
angiogenesis may enhance therapeutic efficacy.(8-13) Moreover, bevacizumab in 
combination with chemotherapy improves survival of patients with colorectal cancer.(14) 
Therefore, the combination of chemotherapy with both cetuximab and bevacizumab has 
been studied in phase III clinical trials. However, the combination of chemotherapy and 
bevacizumab with cetuximab (15, 16) or panitumumab (17) did not result in improved 
progression free survival compared with patients who received chemotherapy and 
bevacizumab alone. The studies of Hecht et al. and Tol et al. even showed a significantly 
reduced survival for specific patient groups receiving the combination of antibodies.(15, 
17)
Several explanations have been proposed for these observations. For example, toxicity 
may be enhanced by dual-pathway inhibition using bevacizumab and panitumumab, 
leading to dose delays or dose reduction and decreased survival.(17) However, this was 
not the case in every study.(15) Also, pharmacokinetic interactions may have occurred 
between the two antibodies, as is suggested by the reduced incidence of bevacizumab-
induced hypertension in the patients who received the combination of antibodies.(17) 
Furthermore, we have shown that bevacizumab altered tumor vascularity of subcutaneous 
human xenografts in mice, thereby limiting the delivery of cetuximab to the tumor, which 
could lead to reduced therapeutic efficacy.(18) Finally, interaction between downstream 
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signaling pathways may have occurred. For example, EGFR-mediated alterations of 
downstream targets may be required for the activity of bevacizumab or chemotherapy.
(17) 
In this study we determined whether cetuximab treatment has an effect on VEGF 
expression and the accumulation of bevacizumab in the tumor. For that purpose, mice 
with subcutaneous VEGF and EGFR-expressing tumors were treated with cetuximab and 
we measured the effect on tumor targeting of radiolabeled bevacizumab with SPECT/CT 
and analyzed the tumors for VEGF expression.  
Material and methods
Cell culture and antibodies
The breast cancer cell line SUM149 (Asterand, Detroit, MI) was cultured in Ham’s F12 
medium (GIBCO, BRL Life Sciences Technologies, The Netherlands) supplemented with 5% 
fetal calf serum (FCS), 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 
hydrocortisone (1 µg/ml), and insulin (5 µg/ml) at 37 °C in a humidified atmosphere with 
5% CO2. The colorectal cancer cell line WiDr was cultured in DMEM with 1,000 mg/L 
D-glucose:Ham’s F12 medium (1:1 mixture), supplemented with 2 mM glutamine and 
10% FCS. 
Cetuximab, a chimeric monoclonal antibody directed against human EGFR, was obtained 
from Merck (Darmstadt, Germany). Bevacizumab, a humanized monoclonal antibody 
against VEGF, was obtained from Roche (Basel, Switzerland). The humanized anti-CD22 
antibody hLL2 was kindly supplied by Immunomedics, Inc. (Morris Plains, NJ, USA) and 
was used as an irrelevant control antibody in this study.
Radiolabeling
Bevacizumab and hLL2 (10 mg/ml) were conjugated with isothiocyanatobenzyl-
diethylenetriaminepentaacetic acid (ITC-DTPA, Macrocyclis, Dallas, TX) in 0.1 M NaHCO3, 
pH 9.5, at a fifteen-fold molar excess of ITC-DTPA for one hour at room temperature (RT). 
The unbound ITC-DTPA was removed from the reaction mixture by dialysis against 0.25 M 
ammonium acetate buffer, pH 5.4. DTPA-conjugated antibodies (10-20 µg) were incubated 
with (110 – 220 MBq) 111In (Covidien BV, Petten, The Netherlands) in 0.1 M 2-(N-morpholino)
ethanesulfonic acid (MES) buffer, pH 5.4, at room temperature (RT), under strict metal-
free conditions for 30 min.(19) After incubation, 50 mM ethylenediaminetetraacetic 
acid (EDTA) was added to a final concentration of 5 mM to chelate unincorporated 111In. 
Labeling efficiency was determined using instant thin-layer chromatography (ITLC) on 
silica gel chromatography strips (Agilent Technologies, Palo Alto, CA), using 0.1 M citrate 
buffer, pH 6.0, as the mobile phase. In case labeling efficiency was below 95%, the reaction 
mixture was purified on a PD-10 column (Amersham Biosciences, Uppsala, Sweden), 
eluted with PBS, containing 0.5% BSA. Radiochemical purity of 111In-DTPA-Bevacizumab 
(111In-Bevacizumab) and 111In-DTPA-hLL2 (111In-hLL2) exceeded 95% in all experiments.
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In vitro experiments
EGFR and CD22 expression of SUM149 and WiDr cells
Scatchard analysis was performed to quantitatively determine EGFR expression of SUM149 
and WiDr cells. Cells were cultured to confluency in six-well plates and were incubated for 
4 h on ice with increasing concentrations 111In-Cetuximab (0.03 – 300 nM) in 1 ml binding 
buffer (Ham’s F12 containing 10 mM HEPES and 0.5% bovine serum albumin (BSA)). The 
cell-associated activity at each concentration was determined in triplicate. Non-specific 
binding was determined by co-incubation with 3 μM cetuximab. After incubation, cells 
were washed with PBS and the cell-associated activity was measured in a shielded well-
type gamma counter (Perkin-Elmer, Boston, MA, USA). The specific binding was plotted 
against the bound/free ratio and data were analyzed by linear regression to determine 
EGFR receptor density per cell and to determine the dissociation constant (Kd) of 111In-
cetuximab.
The anti-CD22 antibody hLL2 (IgG1) was used as a control antibody without specific 
tumor targeting. To confirm that the SUM149 and WiDr cell lines do not express CD22, 
cells were incubated with 0.3 nM 111In-hLL2. Separate wells were coincubated with an 
excess of unlabeled hLL2 (30 nM). After 4 h on ice, cells were washed and cell-associated 
activity was measured as described above.
MTT assays
The effect of cetuximab on cell viability was assessed in a MTT assay. SUM149 or WiDr 
cells (5,000 cells/well) were allowed to adhere overnight in a 96-wells plate. Subsequently, 
cells were incubated with cetuximab (0.1 – 6,000 nM) for 72 h at 37 °C in a humidified 
atmosphere with 5% CO2. After incubation, MTT (final concentration 0.5 mg/ml) was 
added and incubated for 3.5 h at 37 °C, followed by 15 min incubation with MTT solvent 
(isopropanol containing 4 mM HCl, 0.1% NP-40) at RT. Absorbance was read at 560 nm and 
655 nm. IC50 values were calculated with GraphPad Prism version 6.00 software. 
In vitro effect of cetuximab on VEGF expression
SUM149 and WiDr cells were cultured in the presence of 1, 10, or 100 nM Cetuximab. Before 
treatment, and 1, 4, and 7 days after start of treatment, cells were trypsinized, washed, 
and lysed using T-per Tissue Protein extract (#78510, Thermo Scientific, Etten Leur, The 
Netherlands), followed by sonification. Cell extracts were diluted 5x and VEGF levels were 
determined with ELISA as described below. 
Animal experiments
Animal experiments were performed in female BALB/c nude mice (Janvier, le Genest-Saint-
Isle, France) and were conducted in accordance with the principles laid out by the revised 
Dutch Act on Animal Experimentation (1997) and approved by the institutional Animal 
Welfare Committee of the Radboud University Nijmegen. At 6-8 weeks of age, mice were 
inoculated subcutaneously with 5 x 106 SUM149 (in 0.2 ml 2:1, Ham’s F12 medium:matrigel, 
BD Biosciences, Pharmingen) or 5 x 106 WiDr cells (in 0.2 ml Ham’s F12:DMEM medium 1:1). 
Experiments started when the tumors reached a size of approximately 0.1 cm3. 
Effect of cetuximab, bevacizumab, and the combination on tumor growth
Mice with s.c. SUM149 or WiDr tumors (n = 6 per group) were injected intraperitoneally, 
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twice a week, with cetuximab (SUM149: 1 mg/kg, WiDr: 40 mg/kg), bevacizumab (10 mg/
kg) or a combination of these agents (using the same dosage as in the monotherapy 
groups). To be able to compare the results from the therapy studies with the imaging 
studies, in the combined treatment group, cetuximab treatment started at day 0, and 
bevacizumab treatment at day 4. Tumor size was measured three times a week by caliper 
measurements in three dimensions (radius x, y and z). Tumor size was calculated using the 
following	formula:	4/3	•	π	•	x	•	y	•	z.	Body	weight	was	measured	three	times	a	week.	EDTA	
blood samples were collected weekly of mice that were treated with cetuximal alone to 
determine the plasma levels of cetuximab by ELISA. Samples were centrifuged for 10 min 
at 1,600 g and plasma was stored at -80 °C until further analysis.
Effect of cetuximab on VEGF expression and targeting of radiolabeled bevacizumab
Mice with s.c. SUM149 or WiDr tumors (N=5 per group) were injected intraperitoneally, 
twice a week, with cetuximab (SUM149: 1 mg/kg, WiDr: 40 mg/kg) or vehicle. The effect 
of cetuximab treatment on targeting of 111In-bevacizumab and 111In-hLL2 to SUM149 
and WiDr xenografts was measured by ex vivo biodistribution and SPECT/CT. Before 
start of treatment (day -3), and at day 4 and 18 of treatment, mice were injected with 
111In-bevacizumab. Three days later (day 0, day 7, and day 21), mice were euthanized and 
tumor, blood, muscle, lung, spleen, pancreas, intestine, kidney and liver were dissected 
and weighed. Activity was measured in a gamma counter. To calculate the uptake of 
radiolabeled antibodies in each sample as a fraction of the injected dose, aliquots of 
the injected dose were counted simultaneously. The concentrations of the radiolabeled 
antibody were expressed as percentage injected dose per gram tissue (%ID/g). Tumor 
samples were fixated in 4% formalin or frozen at -80 °C to analyze VEGF expression by 
immunohistochemistry and ELISA. EDTA blood samples were collected, centrifuged for 10 
min at 1,600 g and plasma was stored at -80 °C until further analysis of VEGF levels.
Separate mice were used for SPECT/CT imaging. Three days prior to SPECT/CT acquisition, 
mice were injected intravenously with 2.4 µg (SUM149) or 2.0 µg (WiDr) 111In-bevacizumab 
(20 – 30 MBq). SPECT/CT images were acquired at day 0, 7, and 21, using the U-SPECT-
II/CT system (MILabs, Utrecht, The Netherlands).(20) Mice were scanned for 50 minutes 
using the 1.0 mm diameter pinhole mouse high sensitivity collimator tube, followed 
by a CT scan (spatial resolution 160 µm, 65 kV, 612 µA) for anatomical reference. Scans 
were reconstructed with MILabs reconstruction software, which uses an ordered-subset 
expectation maximization algorithm, with a voxel size of 0.2 mm. 
Immunohistochemistry
Antibodies against EGFR (D38B1, Cell Signaling), CD34 (MON1159, clone MEC14.7, 
Monosan) and VEGF (555036, Pharmingen) were used to determine expression of the 
respective antigens on paraffin-embedded tumor sections. In short, antigen retrieval 
was performed in 10 mM sodium citrate, pH 6.0 for 10 min at 99 °C for EGFR and CD34 
staining. Endogenous peroxidase activity was blocked with 3% H2O2 and nonspecific 
binding was blocked by incubation with normal goat serum. After incubation with the 
primary antibody, tumor sections were incubated with a biotinylated secondary antibody, 
followed by incubation with an avidin-biotin-enzyme complex (Vector Laboratories, 
Burlingame, CA). Finally 3,3’-Diaminobenzidine (DAB) was used to develop the staining 
of the tumor sections.
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EGFR expression was scored as negative (0), incomplete weak (1+), complete weak to 
moderate (2+) and strong (3+) membrane staining (Table 1). The mean vascular density 
(MVD) was scored as the number of vessels counted in 3 hot spot areas that contained the 
maximum number of vessels.
Table 1. Scoring EGFR staining
Score Staining pattern
0 No staining is observed, or membrane staining is observed in <10% of the tumor cells
1+ A faint/barely perceptible membrane staining is detected in >10% of tumor cells. The 
cells exhibit incomplete membrane staining
2+ A weak to moderate complete membrane staining is observed in >10% of tumor cells
3+ A strong complete membrane staining is observed in >10% of tumor cells
ELISA VEGF levels
VEGF levels in plasma and tumor tissue was determined with ELISA. Frozen tumors were 
pulverized with liquid nitrogen using a microdismembrator in EORTC buffer (20 mmol/L 
K2HPO4/KH2PO4, 1.5 mmol/L K2EDTA, 3 mmol/L sodium azide, 10 mmol/L monothioglycerol, 
10% [v/v] glycerol/water, pH 7.4) and centrifuged at 105,000 g.  The protein concentration 
of the cell lysates and tumor lysates were measured using a Pierce BCA assay kit (#23227, 
Pierce, Rockford, IL). Antigen levels of VEGF in cell extracts, plasma and tumor extracts 
were measured by a specific ELISA as described by Span et al.(21) The assay applies a 
combination of four polyclonal antibodies (raised in four different animal species) employed 
in a sandwich assay format to exclude heterophilic antibody interference.(22) To increase 
the sensitivity of the VEGF assay, the HRP-labeled goat anti-rabbit detection antibody was 
replaced by a goat anti-rabbit IgG biotin conjugate (#B-9642, Sigma Chemical Co, St. Louis, 
MO), streptavidin-labeled ß-galactosidase (#1112481, Boehringer Mannheim, Germany) 
was used as enzyme and 4-methylumbelliferyl-ß-D-galactopyranoside (MUG, Sigma 
Chemical, St. Louis, MO) as substrate. In this assay distinct molecular forms of VEGF-A such 
as VEGF-165 and VEGF-121 are measured. No cross-reactivity could be demonstrated 
with several other growth factors. The analytical sensitivity of the VEGF assay is 0.005 ng/
ml. The within-assay and between-assay coefficients of variation were 8.7% and 13.4%, 
respectively.
ELISA cetuximab levels
To determine plasma cetuximab levels, an ELISA was performed as described previously.
(23) Plates were coated with a recombinant form of EGFR (human Sf9, Genway, San 
Diego, CA 92121, USA, 0.1 µg/well) in 15 mmol/L Na2CO3 and 35 mmol/L NaHCO3, pH 9.6. 
After blocking (1% BSA in PBS), plasma samples (diluted 1600x in BSA/PBS/Tween-20) 
and reference samples (cetuximab, range 0 – 32 ng/ml) were incubated overnight 
at 4°C. Subsequently, plates were incubated with mouse anti-human IgG (Fc) HRP 
((SouthernBiotech, Birmingham, U.K., dilution 1:25000), followed by incubation with TMB 
solution (Kem-En-Tec, Taastrup, Denmark). The reaction was stopped by addition of 100 
µl 0.5 M H2SO4 and optical density was measured at 450 nm. Imprecision and accuracy of 
calibrators and samples were 10% or less. The lower limit of detection was 0.09 ng/L.
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Statistical analysis
Statistical analyses were performed using PASW Statistics version 18.0 (Chicago, IL) and 
GraphPad Prism version 5.03 (San Diego, CA) for Windows. Differences in tumor size and 
uptake of radiolabeled antibodies were tested for significance using the nonparametric 
Kruskal-Wallis and Mann-Whitney U test.  A p-value below 0.05 was considered significant. 
 
Results
In vitro experiments
Scatchard analysis showed that the receptor density of EGFR was 108,100 receptors/
cell (95% CI: 88,400 – 142,000 receptors/cell) and 21,100 receptors/cell (95% CI: 17,100 – 
28,100 receptors/cell) for SUM149 and WiDr cells, respectively. The dissociation constant 
(Kd) of 111In-cetuximab determined 
on SUM149 cells was 0.21 nM (95% 
CI: 0.16 – 0.28 nM). The irrelevant 
IgG 111In-hLL2 did not show specific 
binding on SUM149 or WiDr cells.
 
The growth of the SUM149 cells was 
inhibited by cetuximab: The IC50 
value for SUM149 was 6.0 nM (95% 
CI: 2.7 – 13.5 nM). WiDr cells were less 
sensitive to cetuximab treatment (IC50 
> 1 µM) (Figure 1). In vitro, cetuximab 
dose-dependently decreased the 
expression of VEGF in SUM149 cells, 
while the expression of WiDr cells was 
not altered (Figure 2).
Figure 2. VEGF expression of SUM149 (A) and WiDr (B) cells during cetuximab treatment in vitro.
Animal experiments
Effect of cetuximab, bevacizumab, and the combination on tumor growth
Plasma levels of cetuximab gradually increased over time and reached a plateau after 
21 days of treatment (Figure 3). Cetuximab, bevacizumab and the combination of these 
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Figure 1. Cell viability of SUM149 and WiDr cells after 72 h 
incubation with cetuximab. The IC50 value of cetuximab for 
SUM149 cells was 6.0 nM (95% CI: 2.7 – 13.5 nM). The IC50 for 
WiDr cells could not be reliably estimated. 
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two agents, significantly inhibited growth 
of the SUM149 tumors. Tumor size at day 
21 was significantly less for treated tumors 
compared to untreated tumors (p<0.001, 
Figure 4). Furthermore, tumor growth was 
more effectively inhibited by cetuximab alone, 
compared to bevacizumab alone (p = 0.017) and 
the combination of cetuximab and bevacizumab 
(p = 0.032). In the WiDr model, tumor growth 
was not significantly inhibited by cetuximab, 
bevacizumab or the combination therapy.
Figure 4. Tumor growth of SUM149 (A) and WiDr (B) xenografts during treatment.
Tumor targeting of 111In-bevacizumab and 111In-hLL2
The tumor targeting of 111In-bevacizumab was significantly reduced in cetuximab treated 
tumors compared to untreated tumors. Tumor uptake at day 0 (before treatment) and at 
day 7 and day 21 after treatment, as measured in the ex vivo biodistribution study, was 
28.9 ± 4.0 %ID/g, 21.9 ± 1.7 %ID/g, and 18.2 ± 2.8 %ID/g, respectively (p=0.003). Tumor-
to-blood ratios at these time points were 2.4 ± 0.3, 1.6 ± 0.2, and 1.4 ± 0.2, respectively 
(p=0.004, Figure 5). SPECT/CT imaging showed that tumor targeting of 111In-bevacizumab 
was clearly reduced after cetuximab treatment of mice with subcutaneous SUM149 
tumors (Figure 6).
SPECT/CT imaging of cetuximab treated mice with subcutaneous WiDr xenografts showed 
no effect on the biodistribution of 111In-bevacizumab at day 7 of treatment, while at day 
21, tumor uptake and blood levels of 111In-bevacizumab were significantly decreased. 
Tumor uptake at day 0, 7 and 21 was 17.3 ± 2.4 %ID/g, 14.2 ± 1.0 %ID/g, and 9.9 ± 1.7 
%ID/g, respectively (day 21 versus day 0,   p = 0.008). Tumor-to-blood ratios at these days 
were 1.3 ± 0.2, 1.2 ± 0.1, and 1.1 ± 0.1, respectively, and did not differ significantly. 
To study whether the effect of cetuximab on bevacizumab targeting was specific for 
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Figure 3. Plasma levels of cetuximab during 
treatment once per week ip. *Significant increase 
in cetuximab concentration compared to the 
previous time point.
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VEGF or whether other features of the tumor 
(e.g. vascularization, vascular permeability, 
interstitial fluid pressure, etc) were also 
involved, we determined the biodistribution 
of an irrelevant control antibody (hLL2) in 
SUM149 tumors. At day 21 of cetuximab 
treatment, tumor uptake and tumor-
to-blood ratios of 111In-hLL2 decreased 
significantly compared to day 0 (tumor 
uptake: 8.2 ± 2.2 %ID/g versus 4.6 ± 0.6 
%ID/g (p=0.016), tumor-blood ratio: 0.7 ± 
0.1 versus 0.5 ± 0.1 (p=0.016)), suggesting 
that cetuximab affects tumor physiological 
factor such as vascular permeability and/or 
interstitial fluid pressure.
To exclude that the changes in tumor 
targeting were caused by other tumor factors 
that changed during tumor progression, 
rather than cetuximab alone, we included a control group at day 7 and 21 that received 
saline only. In the ex vivo biodistribution, tumor uptake of before  treatment and after 
7 and 21 days of cetuximab treatment was 24.9 ± 3.1, 28.0 ± 3.4, and 24.9 ± 0.8 %ID/g, 
respectively. The tumor uptake of saline treated tumors at day 7 and 21 was 30.6 ± 2.9, and 
35.1 ±7.2 %ID/g, which is significantly higher compared to the cetuximab treated tumors. 
For WiDr tumors treated with cetuximab, tumor uptake at day 0, 7 and 21 was 16.1 ± 0.6, 
21.5 ± 2.5, and 13.1 ± 2.1 %ID/g, respectively. Tumors that were treated with saline showed 
a similar tumor uptake of 23.8 ± 2.0, and 12.1 ± 1.7 %ID/g, at day 7 and 21, respectively. 
Figure 6. SPECT/CT scans of mice with subcutaneous SUM149 and WiDr xenografts, before and during cetuximab 
treatment (3 days p.i. 2.4 – 3 µg 111In-bevacizumab)
Immunohistochemistry
Immunohistochemical analysis of the tumor xenografts of cetuximab untreated and 
treated mice showed that cetuximab treatment resulted in a decreased expression of 
EGFR. Untreated SUM149 xenografts were scored 3+, while 21 days of cetuximab treatment 
resulted in a score of 2+. For WiDr, EGFR expression before and after treatment was 2+ 
and 1+, respectively (Figure 7). Immunohistochemical analysis of VEGF expression did not 
Figure 5. Tumor blood ratios of mice with 
subcutaneous SUM149 and WiDr xenografts, before 
and during cetuximab treatment  (3 days p.i. 1 µg 
111In-bevacizumab or 111In-hLL2). * significant change 
compared to the tumor-blood ratio at day 0. 
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show a clear reduction, while some isolated fields of tumor cells showed increased VEGF 
expression. Further examination of these areas with high VEGF expression showed that 
these cells were negative for Ki67 expression, suggesting that these were differentiated 
tumor cells. The microvascular density (CD34) was not significantly reduced during 
cetuximab treatment.
Figure 7. Immunohistochemical analysis of SUM149 and WiDr xenografts. Magnification 200x (VEGF and CD34) 
and 400x (EGFR).
ELISA
Analysis of plasma and tumor VEGF levels with ELISA showed that the plasma VEGF did 
not change during cetuximab treatment. Tumor VEGF levels were significantly increased 
after 21 days of cetuximab treatment (Figure 8).
 
Figure 8. VEGF levels in plasma (A) and SUM149 tumors  (B) of cetuximab treated mice.
A B
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Discussion
This study showed that cetuximab treatment can significantly reduce the targeting of 
bevacizumab to a tumor. This is most likely caused by a change in tumor physiology, 
such as vascular permeability and intratumoral interstitial fluid pressure, since the tumor 
targeting of the irrelevant control antibody was also significantly reduced and no clear 
decrease in VEGF expression was observed.
Previous studies have shown that there is extensive crosstalk between the EGFR and 
VEGF pathway. Therefore, there is a clear rational to combine EGFR and VEGF targeted 
therapy. However, phase III clinical trials have shown that the addition of cetuximab to 
chemotherapy combined with bevacizumab treatment did not improve survival of 
patients with advanced colorectal cancer (15-17). These findings were unexpected, since 
preclinical studies using combination therapy targeting both angiogenesis and EGFR 
showed encouraging results.(8-11). However, none of these early preclinical studies 
used the combination of bevacizumab and cetuximab. In more recent preclinical studies 
the effect of combined bevacizumab and cetuximab treatment was evaluated. Wang 
et al. showed that tumor growth in mice with head and neck squamous cell carcinoma 
xenografts was less effectively inhibited by the triple agent combination of cetuximab, 
bevacizumab and cisplatin, compared with bevacizumab and cisplatin alone.(24) In 
addition, Poindessous et al. showed that simultaneous treatment with bevacizumab and 
cetuximab in mice with colorectal cancer xenografts was equally effective compared to 
either agent alone.(25) This is in line with the findings in our study that the combination 
of bevacizumab and cetuximab does not increase therapeutic efficacy compared to 
bevacizumab or cetuximab alone. 
Several explanations have been proposed for the lack of additive effect of the combination 
of bevacizumab and cetuximab. Previously, we and others have shown that bevacizumab 
can reduce the vascular density of the tumor and this could reduce effective targeting of 
other monoclonal antibodies, such as trastuzumab, R1507 (anti-IGF-1R), and cetuximab, 
to the tumor.(26-28) In this study we showed that cetuximab treatment can also reduce 
the targeting of bevacizumab to the tumor. One potential explanation for this reduced 
targeting is that cetuximab treatment decreases VEGF expression. Although previous 
studies showed that blocking of EGFR decreases VEGF protein and mRNA expression, (7, 29, 
30) we did not observe this in our study. Immunohistochemical analysis of tumor sections 
showed that overall the VEGF expression was not altered during cetuximab treatment. 
There were even some fields of cells showing increased VEGF expression. Also, ELISA did 
not show a decrease in VEGF levels in the cetuximab treated tumors. In fact, an increase 
in VEGF expression was measured with ELISA at day 21, which might be explained by the 
presence of small fields of differentiated tumor cells that express high levels of VEGF. 
Studies with the irrelevant control antibody hLL2 also showed significantly reduced tumor 
targeting, which suggest that tumor physiological factors may play a role in the reduced 
targeting of 111In-bevacizumab. In order to determine whether the vascular density was 
altered during cetuximab treatment we analyzed CD34 expression of the vessels in the 
tumors. Previous research has shown that treatment with anti-EGFR antibodies can 
reduce the microvascular density (29, 30), indicating that  EGFR blocking can alter tumor 
vascularity. In our study vascular density did not change upon cetuximab treatment. 
Cetuximab reduces tumor targeting of bevacizumab
9
155
However, other factors such as interstitial tumor pressure and vascular permeability also 
determine the accumulation of antibodies in tumors. These factors may have been altered 
during therapy and future research is warranted to investigate their precise role.
Reduced delivery of bevacizumab to the tumor can potentially result in a reduced 
therapeutic effect. Therefore, our results underline the importance of a careful evaluation 
of timing and sequencing of targeted agents. A potential limitation of this study is the 
difference between preclinical models and human tumors. Typically, tumor growth and 
angiogenesis in preclinical models is more rapid compared to human tumors. Also, tumor 
vessels in murine models tend to be very responsive to anti-angiogenic therapy, while the 
effect on the growth of human tumors is usually less dramatic.(31) To our knowledge, no 
clinical studies have shown that tumor VEGF expression and targeting of bevacizumab to 
the tumor is altered during cetuximab therapy. 
Conclusion
This study showed that cetuximab treatment significantly reduces the targeting of 
bevacizumab to tumors without reducing VEGF expression levels. This can potentially 
result in a reduced therapeutic effect of bevacizumab. Future studies are warranted 
to determine how different timing and sequencing schedules of cetuximab therapy 
in combination with other antibodies is related to antibody targeting and therapeutic 
efficacy.
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Abstract
Introduction: During the last decades, numerous antibodies and tyrosine kinase 
inhibitors have been developed for cancer treatment. However, only a limited number of 
these agents have been shown to significantly improve survival of patients. Therefore, it is 
of crucial importance to identify the subset of patients that benefit from targeted therapy. 
Biomarkers can play an important role in selecting the right drug for the right patient. 
Areas covered: In this review the potential role of molecular imaging of drug delivery for 
patient selection in targeted therapy will be discussed. The advantages and limitations of 
molecular imaging will be compared to those of conventional biomarkers. Moreover, we 
will address the factors that affect imaging of drug delivery, such as target expression, type 
of drug, in vivo accessibility of the receptor (e.g. vascular density, vascular permeability, 
interstitial pressure), enhanced permeability and retention effect (EPR), receptor 
internalization, tracer protein dose and timing of imaging. 
Expert opinion: Molecular imaging of drug delivery clearly has potential for patient 
selection for targeted therapy. The main advantage of this technique is that not only 
antigen expression can be measured noninvasively, but also target accessibility is taken 
into account. However, up to now, most of these studies have been performed in preclinical 
models. Therefore, future research should focus on bringing promising tracers to the 
clinic, preferable in an early stage of drug development in order to test their potential role 
as a biomarker. 
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Introduction
During the last decades, numerous new targeted agents have been developed and 
tested in cancer patients in phase I/II clinical trials. The development of these drugs is 
very expensive and only a limited number of agents have been shown to significantly 
improve survival and gained regulatory approval after phase III trials.(1, 2) For example, 
phase I/II studies with anti-insulin-like growth factor 1 receptor (IGF-1R) antibodies have 
shown the safety and tolerability of targeting IGF-1R and have demonstrated a wide range 
of responses, from progressive disease to near complete response.(3-7) Although these 
results seemed promising, larger randomized phase II/III trials failed to show a clear benefit 
from targeting IGF-1R in combination with conventional treatment strategies.(8-10) This 
has led to the discontinuation of several anti-IGF1R programs. It is important to note that 
these trials were conducted in large unselected patient populations, while early phase I/II 
trials did show meaningful single-agent responses in specific subgroups of patients, such 
as patients with Ewing sarcoma.(5-7) Therefore, it is of crucial importance to identify the 
subset of patients that benefits from targeted therapy. Conversely, the positive phase III 
trials and consequently the registration and implementation of trastuzumab, a human 
epidermal growth factor receptor 2 (HER2)-targeting drug, in standard clinical care for 
breast cancer and gastric cancer patients has only been possible due to the fact that these 
studies were carried out only in patients with HER2 overexpressing tumors.(11-13) Thus, 
biomarkers can play an important role in selecting the right patient for the right drug. 
Biomarkers
Types of biomarkers
According to the Biomarkers Definitions Working Group, a biomarker is a characteristic 
that is objectively measured and evaluated as an indicator of normal biological processes, 
pathogenic processes, or pharmacologic responses to a therapeutic intervention.
(14) There are different types of biomarkers: 1) diagnostic biomarkers that can help in 
disease diagnosis, 2) prognostic biomarkers that correlate to the prognosis of patients 
regardless of therapy, and  3) predictive biomarkers that predict outcome of a specific 
treatment. A biomarker can be solely diagnostic, predictive or prognostic, or can have 
multiple functions. For example, estrogen receptor (ER) expression in metastases of an 
unknown primary tumor can be used to identify the site of the primary tumor in case 
of metastatic breast cancer. Moreover, ER expression it is a good prognostic factor and 
predicts response to anti-estrogen treatment in breast cancer.  (15) Other examples of 
biomarkers that are currently used in clinical practice are prostate-specific antigen (PSA) for 
the detection and follow-up of prostate cancer,(16) HER2 expression for patient selection 
for trastuzumab treatment,(17) and  KRAS mutations for prediction of non-response to 
cetuximab treatment,(18) and V600E mutations in BRAF for the selection of vemurafenib 
in melanoma patients.(19)
In drug development, biomarkers that predict response to new targeted agents are 
urgently needed. Patient selection for targeted therapy is often based on receptor 
expression in biopsied tissue, for example endocrine therapy for ER positive tumors and 
trastuzumab for HER2 overexpressing tumors. However, this type of biomarkers has several 
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limitations which will be described below. Alternatively, molecular imaging with specific 
imaging probes can be used for patient selection. Targeted agents such as antibodies 
and tyrosine kinase inhibitors (TKIs) can be labeled with contrast agents to measure 
tumor drug delivery non-invasively (Figure 1). This review will describe the potential and 
limitations of using radiolabeled targeted agents as a biomarker in drug development.
 
Figure 1. A: Schematic overview of a receptor tyrosine kinase (RTK). B: Radiolabeled therapeutic antibodies 
target extracellular domain of receptor tyrosine kinases (RTKs) or their ligands. Tyrosine kinase inhibitors (TKIs) 
specifically target the intracellular domain of RTKs. 
Molecular imaging techniques 
Several types of anatomical, functional and molecular imaging techniques have been 
used, including ultrasound, magnetic resonance imaging (MRI), optical bioluminescent 
or fluorescent imaging, computed tomography (CT), and radionuclide imaging with 
positron emission tomography (PET) or single photon emission computed tomography 
(SPECT). Molecular imaging techniques aim to visualize, characterize and measure 
biological processes at the molecular and cellular level in living subjects.(20) For these 
techniques, imaging probes with high affinity for antigens or receptors expressed in the 
tumor can be labeled with a contrast agent, such as a fluorescent dye, MRI contrast agent 
or radioisotope, to image the distribution of molecular markers non-invasively. 
Molecular imaging techniques differ in several aspects, including sensitivity, resolution, 
depth penetration and the use of ionizing or nonionizing radiation for signal detection 
(Table 1). For example, MRI has a high spatial resolution and can be used to obtain 
anatomical and physiological information at the same time. However, the sensitivity is 
low, and relatively high doses of the contrast agent are required for signal detection. 
Optical imaging, on the other hand, has a very high sensitivity but the penetration depth 
of the bioluminescent and fluorescent signal is limited to only a few millimeter. Therefore, 
optical imaging cannot be used to non-invasively detect tumor lesions located in deeper 
organs. This review will focus on nuclear imaging techniques that use probes labeled 
with positron or gamma-emitting radionuclides for signal detection. The most important 
advantage of these techniques is the very high sensitivity (especially for PET) which allows 
imaging even at very low amounts of the imaging probe. Therefore, only a tracer dose 
of imaging probe is required, which is preferred to avoid pharmacological effects and 
saturation of binding sites.
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In drug development, molecular imaging can play an important role. Radiolabeled 
therapeutic antibodies, chemotherapeutic drugs, or tyrosine kinase inhibitors can be 
used to non-invasively determine target expression and accessibility of all tumor lesions. 
Examples that have been used in clinical studies are 89Zr-trastuzumab, 111In-bevacizumab, 
11C-docetaxel, and 11C-erlotinib. (21-24) These agents may allow tailored patient selection 
for specific clinical trials. In addition, radiolabeled therapeutics can provide information 
about the pharmacokinetics, optimal dosing for tumor targeting and targeting of critical 
normal tissues. This can be used to further optimize the dosing and timing of targeted 
treatment. 
Table 1. Comparison different imaging methods
Method Advantages Disadvantages
PET •	 High sensitivity (requires only a 
tracer dose of imaging agent)
•	 Quantitative
•	 Relative low spatial 
resolution
•	 PET cyclotron or generator 
needed
•	 Advanced radiolabeling
•	 Radiation exposure
•	 Limited availability
SPECT •	 Availability of different imaging 
agents 
•	 Detection of multiple imaging 
agents at the same time
•	 More widely available than PET
•	 Relative low spatial 
resolution
•	 Radiation exposure
•	 Quantification more 
challenging than PET 
(attenuation correction)
CT •	 High spatial resolution
•	 Anatomic imaging
•	 Limited molecular 
applications
•	 Limited soft tissue resolution
•	 Radiation exposure
MRI •	 High soft tissue resolution
•	 Combines anatomical and 
functional imaging
•	 Relative low sensitivity 
(requires high dose of 
imaging agent)
•	 Long scan time
Ultrasound •	 Real time
•	 Low costs
•	 Limited spatial resolution
•	 Mostly anatomic
•	 Limited imaging depth
Optical 
bioluminescence/
fluorescent 
imaging
•	 High sensitivity
•	 Low costs
•	 Relatively high throughput
•	 Relative low resolution
•	 Limited penetration of 
fluorescent dye in tissue 
(surface weighted)
Molecular imaging compared to conventional biomarkers
Biomarkers can be obtained by an invasive procedure where for example, a sample of blood 
or a biopsy from tumor or normal tissue is obtained from a patient. This sample can be used 
to analyze several biomarkers with different techniques, including immunohistochemistry 
or ELISA for protein expression, fluorescent in-situ hybridization (FISH) or gene-expression 
arrays for mRNA expression, and DNA sequencing to detect point mutations, deletions, 
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copy number variations and other genetic alterations. However, a tumor biopsy is obtained 
by an invasive procedure and is preferably not repeated frequently. A more accessible 
source for biomarkers is blood. Samples can easily and repeatedly be obtained and 
different types of biomarkers can be analyzed, including blood chemistries, metabolites, 
proteins, nucleic acids and circulating tumors cells. However, blood-based biomarkers do 
not directly measure target expression in the tumor and may therefore not accurately 
reflect the molecular processes occurring in tumor lesions. 
A drawback of molecular imaging techniques is that only one marker can be studied 
at a time, while on a single tumor biopsy or blood sample multiple biomarkers can be 
analyzed. On the other hand, molecular imaging with radiolabeled drugs also has several 
important advantages (Table 2). First, they allow measurement of receptor expression 
of whole tumors and their metastases, thereby avoiding sampling errors and thus 
misinterpretation due to intratumoral and interlesional heterogeneity. Second, they allow 
monitoring of expression during the course of disease, without the need for repeated 
invasive biopsies. This is of clinical importance since receptor expression can change 
during the course of disease, due to disease progression and/or the effects of treatment. 
Third, in vivo imaging techniques also take into account the in vivo target accessibility after 
systemic administration. Several factors may determine whether therapeutic agents will 
reach the tumor cells, such as blood vessel density, vascular permeability and intratumoral 
interstitial fluid pressure.(25, 26) If target accessibility is low, therapeutic agents cannot 
reach the tumor and may be ineffective, despite adequate expression of receptors on the 
tumor cells as determined immunohistochemically. In the next section we will discuss in 
more detail which factors affect the tumor targeting of radiolabeled drugs. 
Table 2. Different sources of biomarkers
Method Advantages Disadvantages
Molecular 
imaging
•	 Non-invasive and allows for 
serial assessment in time
•	 Overcomes the problem of 
tumor heterogeneity within and 
between tumor lesions
•	 Takes target availability into 
account
•	 Only one marker per scan
•	 Requires extensive tracer 
validation before clinical use
•	 Limited availability compared 
to e.g. immunohistochemistry
Tumor biopsy •	 Multiple markers can be 
examined on one biopsy
•	 Several types of biomarkers can 
be analyzed (protein, RNA, DNA)
•	 Easy applicable in multiple 
centers
•	 Sampling error due to 
heterogeneity within a tumor 
and between a tumor
•	 Invasive, thus not preferred for 
repeated assessment
Blood/plasma •	 Easy access
•	 Allows repeated analysis
•	 Different types of biomarkers 
can be analyzed (blood 
chemistries, proteins, RNA, DNA, 
circulating tumor cells)
•	 No necessarily representative 
for processes occurring in the 
tumor
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Factors affecting imaging of drug delivery
In general it is believed that radiolabeled drugs can be used to measure the expression 
of their respective antigen. However, the correlation between antigen expression and 
radiotracer uptake is not always straight forward. For example, no correlation was found 
between EGFR expression in tumors and EGFR expression measured by immunoPET 
with 89Zr-cetuximab.(27) Also, in sarcoma xenografts no correlation was found between 
IGF-1R expression as measured by immunoSPECT with radiolabeled R1507 (anti-IGF-1R 
antibody) and immunohistochemistry or western blot (Figure 2). However, interestingly, 
tumor targeting of R1507 did correlate with response to IGF-1R targeted therapy. OS-1 
xenografts, which are IGF-1R positive and highly response to IGF-1R targeted therapy, 
showed specific accumulation throughout the whole tumor. EW-5 xenografts, also IGF-
1R positive but only modestly responsive to anti-IGF-1R therapy, showed a lower and 
more heterogeneous uptake of R1507. Two IGF-1R therapy resistant xenografts, EW-8 
(IGF-1R positive) and OS-33 (IGF-1R negative), showed significantly less tumor targeting 
of radiolabeled R1507. (28) This illustrates that radionuclide imaging may potentially be 
more effective in predicting response to treatment than conventional methods such as 
immunohistochemistry.
Figure 2. ImmunoSPECT/
CT scans of mice with OS-1, 
EW-5, EW-8 and OS-33 bone 
sarcoma xenografts. Uptake 
of radiolabeled R1507 showed 
no correlation with IGF-1R 
expression as measured 
immunohistochemistry but 
was an independent predictor 
of response to IGF-1R targeted 
therapy. (adapted from (28))
A few clinical studies have assessed the correlation between radiotracer uptake and antigen 
or receptor expression. Some of them reported a very high correlation, such as for 16-α-[18F] 
fluoro-17-β-estradiol (18F-FES) uptake and ER expression. In primary and metastatic breast 
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cancer, the uptake of this tracer correlated strongly with ER expression as measured by 
immunohistochemistry.(29-32) However, for most tracers this correlation is less clear. For 
instance, Steffens et al. have studied the correlation between the radiolabeled antibody 
cG250 (131I-cG250) and the expression of its respective antigen CAIX.(33) They have shown 
that high antigen expression was a prerequisite for high antibody uptake. However, 
autoradiography of these tumors showed a very heterogeneous distribution of 131I-cG250 
within in the tumor, despite a clear homogeneous antigen expression. Therefore, regional 
differences in antibody uptake within a tumor cannot be explained by antigen expression 
alone. 
Another example is 89Zr-trastuzumab to image HER2 expression. PET was able to visualize 
the majority of tumor lesions in patients with HER2-positive breast cancer. However, in 
half of the patients, PET scans showed no uptake in one or more tumors lesions that were 
previously identified with conventional imaging.(21) A potential explanation may be lack 
of HER2 expression in these metastatic lesions. Although all patients were diagnosed with 
at least one HER2-positive lesion, this was not evaluated for all tumor lesions since this 
would have required multiple invasive biopsies. (34, 35) This highlights the difficulty of 
proper characterization of new radiotracers in clinical studies. 
Clearly, antigen expression is not the only factor responsible for the accumulation of a 
drug in a tumor. In the next section we will discuss the role of the type of drug, localization 
of the antigen, in vivo accessibility of the antigen, enhanced permeability and retention 
(EPR) effect, receptor internalization, and tracer dose and timing of imaging in molecular 
imaging of drug delivery. 
Type of drug
The two main classes of targeted drugs in oncology are antibodies and TKIs. They differ 
in several aspects that need to be taken into account when developing a molecular 
imaging method.(36) First of all, antibodies are large molecules (approximately 150,000 
Da) which are administrated intravenously and have a long circulatory half-life. Therefore, 
several days between injection and scanning are required to obtain high-contrast images. 
TKIs on the other hand, are small molecules (approximate 500 Da) and have much 
shorter half lives, which allows imaging shortly after injection of the radiolabeled drug. 
Second, antibodies cannot cross the cell membrane and bind antigens that are located 
extracellularly, for example the extracellular domain of a receptor tyrosine kinase (RTK) or 
antigen or excreted growth factors such as VEGF. TKIs easily pass the cell membrane and 
target domains located intracellularly such as the intracellular domain of a RTK (Figure 1). 
Third, the two agents differ in specificity: antibodies can bind antigens with a very high 
specificity and affinity, while TKIs are generally less specific and cross-react with multiple 
receptors. This is a potential advantage since multiple signaling pathways can be inhibited 
using a single agent. However, it also increases the risk of toxicity. Fourth, antibodies are 
metabolically stable and the distribution of the radioactivity represents the distribution of 
the antibody. In case of TKIs, radioactive metabolites may be formed in vivo and therefore 
the biodistribution of the radiolabel may not reflect the biodistribution of the intact TKI. 
Finally, radiolabeling of TKIs is more challenging and due to the shorter half-life different 
radionuclides are used compared with antibodies. TKIs are usually labeled with short 
living positron emitting radioisotopes such as 11C (t½ = 20 min) and 
18F (t1/2 = 110 min), 
which allow for PET imaging. Antibodies are labeled with longer living isotopes such as 
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111In (t1/2 = 2.8 days), 
124I (t1/2 = 4.2 days) or 
89Zr (t½ = 3.3 days) for SPECT and PET imaging, 
respectively. 
Radionuclides and labeling procedures
Various techniques have been developed to radiolabel antibodies, peptides and 
small molecules for PET and SPECT imaging. For example, non-radioactive carbon 
or fluorine atoms can be substituted by 11C or 18F, respectively, without altering the 
chemical structure and biological properties of the molecule. Second, direct labeling 
reactions can be used for iodine radioisotopes such as 124I and 125I. Radioactive iodine is 
incorporated covalently into tyrosine residues of the radiotracer, in the presence of an 
oxidizing agent such as chloramines-T or iodogen. A drawback of this technique is that 
radioiodination is not site-specific and can also occur at the binding site of the antibody 
or peptide, which can result in reduced immunoreactivity. In addition, iodine is a non-
residualizing radionuclide, which implies that upon internalization of the radiotracer, the 
radioiodinated amino acid residues will be rapidly excreted out of the cell (see also section 
3.5). This may result in reduced tumor-background ratios and, therefore, radioiodinated 
tracer may be less suitable to visualize internalizing targets. Radiometals, such as 111In, 
89Zr, 68Ga, and also Al18F, can be stable coupled to a peptide or antibody by a metal 
chelator. The most widely used chelators are diethylenetriaminepentaacetic acid (DTPA) 
and N,N’,N’’,N’’’-tetraazacyclododecane-N,N’,N’’,N’’’-tetraacetic acid (DOTA), or derivatives 
of these compounds. The coupling of the chelator to the antibody or peptide is often 
not site-specific and may alter the immunoreactivity of the tracer. However, an important 
advantage of these tracers is that the radionuclide-chelator complex is trapped inside the 
cell after binding and internalization of the tracer. This results in enhanced accumulation 
and retention in the tumor, and will improve tumor-background contrast. In general, 
these chelates are also very stable. However, in blood, transchelation may occur of the 
radionuclide to serum proteins such as transferring. (37, 38)
Localization of the antigen
Tumor-associated antigens can be expressed in various locations within the tumor, such as 
tumor cell cytoplasm, nucleus, cell membrane, extracellular matrix or blood vessels. Most 
conventional techniques to analyze antigen expression on a tumor biopsy do not take into 
account where the antigen is located. For example, ELISA measures the total expression of 
a protein in a tumor homogenate and methods such as qPCR analyze mRNA expression, 
which not necessarily correlates with protein expression. Immunohistochemistry has the 
potential to discriminate between different locations of the antigen but is only semi-
quantitative. For in vivo targeting of these antigens, the location plays an important role. 
For example, antibodies cannot penetrate tumor cells and therefore only target antigens 
that are expressed on the cell surface or in the extracellular matrix, while TKIs can also 
target receptors  located intracellularly (Figure 1). Moreover, some antigens such as VEGF-
121 (an isoform of VEGF-A) are excreted by tumors cells and are freely diffusible. Their 
function can be neutralized by binding of bevacizumab, however, this does not result in 
the accumulation of radiolabeled bevacizumab in the tumor.(39)
In vivo accessibility 
In vivo accessibility of the receptor for the targeting agent can affect the accumulation of 
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radiolabeled drugs in the tumor. For example, poor tumor vascularization, low vascular 
permeability, and high intratumoral interstitial fluid pressure may prevent effective 
tumor targeting especially of high molecular weight drugs such as antibodies, despite 
adequate antigen expression. There are several examples from literature to illustrate this. 
For example, bevacizumab treatment of breast and ovarian cancer xenografts in mice 
resulted in significantly reduced tumor targeting of radiolabeled cetuximab, R1507 (anti-
IGF-1R) and trastuzumab, while the expression of EGFR and IGF-1R remained unaltered and 
HER2 was only slightly decreased.(40-42) The discrepancy between receptor expression 
and tracer uptake was most likely caused by the reduced vascular density caused by 
bevacizumab treatment, which limited the delivery of cetuximab, R1507 and trastuzumab 
to the tumor.(40-42)
Also in patients this may be a relevant issue, since the vascularization of each tumor 
lesion is different, depending on tumor type and localization, and can be affected by 
treatment (e.g. anti-angiogenic therapy). This was illustrated in a study by Desar et al. who 
performed 111In-bevacizumab scintigraphy in  renal cell cancer patients that were treated 
neoadjuvantly with the VEGFR inhibitor sorafenib . (43) Sorafenib treatment significantly 
reduced tumor uptake of 111In-bevacizumab compared to the pre-treatment scan (Figure 
3). Immunohistochemical analysis of the tumor sample revealed that the decrease in 
tumor uptake was most likely due to destruction of the tumor neovasculature, whereas 
VEGF-A expression did not change. A similar effect has been observed for patients with 
non-small cell lung cancer. Bevacizumab treatment reduced tumor perfusion and net 
influx rate of 11C-docetaxel within 5 hours after bevacizumab administration, and these 
effects persisted after 4 days. (23)
Figure 3. Anterior and posterior 111In-bevacizumab scintigraphy at baseline (A) and after four weeks of treatment 
with sorafenib (B). Decrease of 111In-bevacizumab uptake, more enhanced in central parts of tumor, is shown 
(arrows). (Reprinted from(43))
Enhanced permeability and retention (EPR) effect
Another factor that should be taken into account is the non-specific accumulation of 
macromolecules in tumors due to the EPR effect. Macromolecules larger than 40 kDa 
selectively leak out from tumor vessels and accumulate in tumor tissue and not in normal 
tissue. This effect is caused by the abnormal architecture of tumor vasculature, including 
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for example defective endothelial cells with wide fenestrations, irregular vascular 
alignment and lack of a smooth muscle layer. In addition, tumor tissues usually lacks 
effective lymphatic drainage and produce vascular mediators such as bradykinin, nitric 
oxide, prostaglandins and VEGF, that further enhance the extravasation and accumulation 
of macromolecules into tumor tissue.(44) The EPR effect can cause high molecular weight 
drugs, such as antibodies and antibody fragments, to accumulate in tumor tissue even 
in the absence of the antigen. This has been illustrated in several preclinical studies. For 
example, the non-specific tumor accumulation the antibodies R1507 and cetuximab was 
20-30% of the total accumulation.(45, 46) Similarly, the uptake of a non-specific control 
antibody in IGF-1R expressing breast cancer xenografts was 20-30% of the anti-IGF-1R 
antibody uptake.(47) Moreover, the accumulation of 89Zr-trastuzumab in HER2-negative 
tumors was approximately 20% of the uptake in HER2-positive tumors.(48) Clinical studies 
have suggested that this effect also occurs in patients.(49) For example, radiolabeled 
bevacizumab has been shown to accumulate in tumors even in the absence of VEGF-A 
expression.(22) Therefore, the EPR effect may lower the sensitivity of molecular imaging 
of biomarkers with large macromolecules. 
Receptor internalization
Some tumor-associated receptors, for example IGF-1R, EGFR and HER2, are internalized 
upon binding of the drug.(45, 46, 50) Following internalization, the tracer can be degraded 
and in case of a residualizing radionuclide (such as the radiometals 111In or 89Zr), the 
radionuclide-chelator complex is trapped inside the cell, while the receptor itself can be 
degraded or re-expressed on the cell membrane. This plays a role in, for example, in HER2 
targeting.(50, 51) Rudnick et al. have shown that the accumulation of  111In-trastuzumab 
in HER2-expressing xenografts is significantly higher, compared to 125I-trastuzumab.(51) 
Binding of radiolabeled trastuzumab to HER2 results in activity at the tyrosine kinase 
domain, which in turn triggers internalization of the receptor-antibody complex into 
lysosomes.(52, 53) Within the lysosome, the radiolabeled antibody is degraded and the 
radioisotope is released. The radioiodine is eliminated from  the cells, while the 111In-
chelator complex is trapped. The receptor itself can also be degraded, or recycled back to 
the tumor cell membrane.(52, 53)   If this turnover is rapid, the accumulation of the tracer 
does not solely reflect membranous receptor expression, but also the internalization rate 
and re-expression rate of the receptor.
Protein dose and expression of target in normal tissue
Next to properties of the tumor (e.g. receptor expression, tumor vascularization and 
receptor internalization kinetics), tumor uptake of a radiolabeled drug can be affected 
by the tracer protein dose and timing of imaging. Usually a low tracer dose is preferred to 
avoid induction of a pharmacological effect and to prevent saturation of the receptors in 
vivo. However, this is not ideal for all targets. For example, in case of the anti-HER2 Affibody 
molecule it has been shown that a higher tracer doses improves the discrimination 
between high and low HER2-expressing xenografts. (54) Also, clinical studies with 89Zr-
labeled trastuzumab have shown the importance of using the optimal tracer dose. At 
low tracer doses, 89Zr-trastuzumab accumulated mainly in the liver and resulted in a 
pronounced intestinal excretion. As a result, 89Zr-trastuzumab cleared rapidly from blood, 
and tumor uptake was low. Increasing the dose of  89Zr-trastuzumab resulted in lower 
hepatic uptake and enhanced tumor targeting. This dose-dependent clearance is most 
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likely due to the presence of extracellular HER2 domains in the circulation caused by 
shedding of (part of ) the receptor by tumor cells.(55) 
Optimization of protein dose is also an important issue when the antigen is expressed 
on healthy tissue. For example, growth factor receptors such as EGFR and IGF-1R are 
expressed not only on tumor cells, but also in normal organs such as liver, salivary gland 
or pancreas.(20, 56) If the injected tracer dose is low, these organs can serve as a sink and 
bind high amounts of the radiotracer, thereby preventing the tracer from reaching to the 
tumor cells. Increasing the tracer dose can potentially saturate the receptors on healthy 
organs, since their expression is often relatively low compared to the tumor. This will result 
in increased uptake of the tracer in the tumor and improved imaging contrast between 
tumor and normal organs.(20, 56) This phenomenon can be illustrated by tracers targeting 
EGFR. Preclinical studies with the anti-EGFR Affibody molecule ZEGFR:2377 have shown a clear 
dose dependent increase of tumor uptake, which is most likely due to saturation of EGFR 
in the liver.(56) Similar results have been obtained with a radiolabeled anti-EGFR antibody 
225 in patients. Divgi et al. showed that at least 20 mg of the antibody was required to 
image EGFR-expressing squamous cell carcinoma of the lung, while lower doses resulted 
mainly in liver uptake.(57) Of note, preclinical studies with  cetuximab (chimeric variant of 
225)  did not show receptor-mediated uptake in the liver, or a dose dependent increase 
in tumor uptake. This is most likely due to the fact that cetuximab does not cross-react 
with murine IGF-1R and only recognizes human EGFR expressed on human xenografts. 
Therefore, animal studies do not always accurately predict the distribution of the 
radiotracers  in human beings. 
Discussion
An ideal biomarker of drug delivery should fulfill several criteria. First of all, the outcome 
of the scan needs to have an impact on clinical decision making. For example, it should 
predict whether a patient is likely to respond to a certain therapy. Moreover, it should have 
an added value compared to existing techniques. Second, the imaging method should 
be safe. And third, the technique needs to be feasible in clinical practice, widely available, 
and affordable. 
Drug delivery and response to treatment
Although molecular imaging of drug delivery clearly has potential for patient selection 
for targeted therapy, only a limited number of studies have determined whether tracer 
uptake indeed is predictive for response to therapy. For instance, in case of IGF-1R targeted 
therapy it has been shown that the uptake of 111In-R1507 measured by immunoSPECT/CT 
in sarcoma xenografts was predictive for response to treatment with this targeting agent, 
whereas conventional methods such as immunohistochemistry and western blot were 
not (Figure 2).(28)  However, no clinical studies have been carried out to confirm these 
results in patients. Another preclinical example is [18F]F-PEG6-IPQA, a radiolabeled EGFR 
TKI. High uptake of this tracer correlated with favorable responses to EGFR TKIs, whereas 
lack of uptake predicted resistance.(58) Radiolabeled EGFR TKIs have also been tested in 
clinical studies. (24, 59, 60) One of these studies prospectively enrolled patients with non-
small cell lung cancer in an erlotinib trial.(24) Pretreatment tracer uptake of 11C-labeled 
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EGFR TKI correlated strongly with overall survival and progression free survival after 
treatment with erlotinib. These results suggest that this tracer can potentially be used to 
identify patients that are likely to respond to EGFR TKIs. However, for most other targeted 
therapies (e.g. trastuzumab and anti-angiogenic therapy) the correlation between tracer 
uptake and response to treatment is less clear, or has not yet been investigated.(61, 62) 
Safety and feasibility of molecular imaging in clinical practice
To bring radionuclide imaging into clinical practice, some specific issues need to be 
considered. First of all there are a couple of safety issues. SPECT/CT and PET/CT scans do 
add to radiation exposure, especially when relative long-living radionuclides are being 
used in combination with slow clearing tracers, such as 89Zr-labeled antibodies for PET. In 
case of repetitive imaging, these scans cause a substantial radiation dose. This may not 
be a relevant risk for patients with advanced cancer or patients who have been exposed 
to radiotherapy, but radiation exposure should be kept as low as possible in case of (non-
radiotherapy based) curative treatment. 
A second important factor that determines the success of radiotracers in clinical practice is 
the feasibility and availability. Before a new radiotracer can be studied in patients, it needs 
to be produced in a current good manufacturing practice (cGMP) compliant way. Quality 
aspects, e.g. radiochemical purity, purification, stability, and storage, needs to be carefully 
documented. Not every hospital has the facility for radiolabeling according to cGMP. 
Moreover, the availability of the radionuclides may be limited to centers with a cyclotron. 
However, nowadays, 89Zr is produced commercially, and because of its longer half life, can 
be shipped to other hospitals. Also, tracers can be labeled with 89Zr at specialized centers, 
and further distributed to other hospitals. Another improvement is the availability of 
68Ge/68Ga-generators with a long life-span, which allows continuous availability of 68Ga 
in several hospitals. A limitation that still needs to be overcome is the relative high costs 
that are involved in radionuclide imaging. Currently, the development and production of 
radiotracers is expensive, which limits the translation to the clinical setting. 
Directions for future research
Up to now, most imaging studies have been performed in preclinical models and much 
time and effort is spent to characterize and optimize these tracers, while only very few 
have been translated into the clinic. Therefore, only limited information is available about 
sensitivity and specificity in patients. Moreover, the correlation between drug delivery 
and treatment response and survival in patients is unknown. This is understandable since 
the clinical development of radiotracers is expensive and time consuming. However, 
especially in drug development, this technique might be of great value and research 
should focus on bringing promising tracers into the clinic, preferable in an early stage of 
drug development in order to test their potential role as a biomarker in a structured way. 
Examples of drugs which currently being tested in early clinical trials and which could 
potentially benefit from molecular imaging are agents targeting HER3, hepatocyte 
growth factor receptor (HGFR), and PD-1 or PD-L1. HER3 and HGFR are RTK that are over-
expressed on different cancer types. Phase I trials with anti-HER3 antibodies have shown 
encouraging results in patients with solid tumors,(63) while phase I trials with agents 
targeting the HGFR have shown to be active in lung cancer.(64) Radionuclide imaging 
using anti-HER3 or anti-HGFR antibodies may enable patient selection for this type of 
Chapter 10
10
172
therapy. Another potential target is PD-L1. PD-L1 is expressed on tumor cells and plays 
an immunosuppressive role in the tumor microenvironment. Upon binding of PD-L1 to its 
receptor PD-1, T-cell function is inhibited. Antibodies that block the interaction between 
PD-1 and PD-L1 have shown remarkable antitumor activity.(65) However, not all patients 
respond to these antibodies and expression of PD-L1 seems to be required for anti-tumor 
activity.(66) Therefore, in vivo imaging with radiolabeled anti-PD-L1 antibodies can 
be used for the detection of PD-L1 expression and accessibility and may allow patient 
selection of PD-L1 targeted therapy. 
Conclusion
Currently, patient selection for targeted therapy is often based on receptor expression 
or mutation analysis determined on tumor biopsies. Although this has been shown to 
be successful for certain targeted therapies, it also has a couple of disadvantages: 1) it 
requires an invasive procedure to obtain tumor material, 2) misinterpretation may 
occur due to intratumoral an interlesional heterogeneity and 3) target accessibility is 
not taken into account. Molecular imaging may overcome these problems by using 
radiolabeled agents that measure drug delivery noninvasively. In this way, all factors 
that affect drug delivery, such as antigen expression, tumor vascularization, vascular 
permeability, intratumoral interstitial fluid pressure and the EPR effect are taken into 
account. Moreover, molecular imaging can measure drug delivery of whole tumors and 
their metastases, thereby avoiding misinterpretation due to heterogeneous expression. 
Therefore, molecular imaging is potentially more predictive for response to treatment 
than traditional biomarkers that determine mutation status or antigen expression only.
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Summary
During the last decades, several monoclonal antibodies (mAbs) and tyrosine kinase 
inhibitors (TKIs) that target receptor tyrosine kinases (RTKs) and their ligands have been 
developed for cancer treatment. However, only a limited number of these agents have 
been shown to significantly improve outcome of patients and it is difficult to predict 
beforehand which patients will benefit from treatment. Therefore, accurate methods 
for patient selection and response monitoring are required to maximize the chances for 
effective treatment and to minimize the exposure of patients to ineffective therapeutics 
agents. Furthermore, a combination of the different targeted agents may be used to 
further improve survival of cancer patients. Finding a rationale to choose a particular 
combination of these therapeutic agents is challenging. Finally, timing and sequencing of 
the different agents may be important, if not crucial. This thesis describes the development 
of new radiotracers which may be used as tools for patient selection. 
The first part of this thesis focuses on the insulin like growth factor 1 receptor (IGF-1R). IGF-
1R is expressed on different cancer types and is a potential target for cancer treatment. 
Patients with cancer lesions that express IGF-1R can potentially benefit from treatment 
with anti-IGF-1R antibodies. The aim of the first studies was to develop a non-invasive 
imaging method to measure IGF-1R expression. Therefore, the humanized anti-IGF-1R 
antibody R1507 was radiolabeled with iodine-125 (125I), indium-111 (111In) or zirconium-89 
(89Zr) and was characterized in vitro and in vivo using the triple negative, IGF-1R expressing 
breast cancer cell line SUM149 (chapter 3). It was shown that radiolabeled R1507 had a 
high affinity for IGF-1R (Kd = 0.6 nM) and was slowly internalized. In vivo, 
111In-R1507 and 
89Zr-R1507 specifically and efficiently accumulated in subcutaneous SUM149 xenografts 
in mice, while the accumulation of 125I-R1507 was less efficient. Moreover, SPECT and PET 
using 111In-R1507 and 89Zr-R1507, respectively, could clearly visualize the subcutaneous 
IGF-1R expressing xenografts. However, optimal contrast was only reached at later 
time points after injection (≥ 3 days), which was due to the slow clearance of intact 
antibodies from the circulation. To accelerate the targeting of IGF-1R, R1507 F(ab’)2 and 
Fab fragments were produced (chapter 4). The in vitro and in vivo characteristics of these 
111In-labeled antibody fragments were compared to those of intact R1507 IgG. In vitro, 
the affinity of 111In-labeled F(ab’)2 was similar to that of 
111In-IgG, while the affinity of 111In-
Fab was significantly lower (Kd: 0.7 nM, 0.6 nM, and 3.0 nM, respectively). Biodistribution 
studies in mice with subcutaneous SUM149 xenografts showed that the absolute tumor 
uptake of 111In-F(ab’)2 was significantly lower than that of intact IgG. However, due to the 
faster clearance of antibody fragments from the circulation, tumor-to-blood ratios were 
significantly higher for 111In-F(ab’)2, while no specific targeting was observed for 
111In-Fab. 
IGF-1R-expressing xenografts could be clearly visualized with 111In-F(ab’)2 SPECT/CT as 
early as 6 h post injection, while with R1507 IgG, the tumor could be visualized after 24 h. 
This shows that targeting and imaging of IGF-1R can be significantly improved by using 
111In-F(ab’)2 fragments.
The expression of IGF-1R can change during conventional breast cancer treatment and 
may play a role in resistance to conventional therapies. Therefore, in chapter 5 and 6, 
the dynamics of IGF-1R expression during conventional breast cancer treatment were 
studied and monitored with 111In-R1507 immunoSPECT/CT. Mice with subcutaneous 
MCF-7 xenografts were treated with either estradiol or tamoxifen and IGF-1R expression 
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was measured by immunohistochemistry and by immunoSPECT/CT. Estradiol treatment 
resulted in enhanced expression of IGF-1R, which could be measured by immunoSPECT/
CT. In contrast, tamoxifen therapy resulted in down-regulation of IGF-1R expression, 
whereas, this down-regulation could not be measured by immunoSPECT/CT. This suggests 
that next to expression levels, other factors may also influence the antibody accumulation 
in the tumor, for example microvascular density, vascular permeability or intratumoral 
interstitial pressure. 
We and others showed in preclinical studies that IGF-1R expression can change during 
conventional breast cancer therapy and that IGF-1R may be involved in developing 
resistance to these therapies. The modulation of IGF-1R in tumors in patients during 
therapy is largely unknown. Therefore, IGF-1R expression was studied in 22 human breast 
tumors from patients who were treated preoperatively for 2 to 6 weeks with tamoxifen, 
anastrozole or fulvestrant. IGF-1R expression was determined immunohistochemically on 
a biopsy at the time of diagnosis (pretreatment) and on surgical resection material (post 
treatment). Down-regulation in IGF-1R expression was detectable in 9 out of 22 patients 
(p = 0.003). These results show that anti-estrogen treatment can cause a significant 
reduction in membranous IGF-1R expression. This can occur within a few weeks after start 
of endocrine treatment. Based on these results, a combination of anti-IGF-1R antibodies 
with anti-estrogen therapy appears not be a rational treatment strategy. 
In chapter 6, the effects of neoadjuvant treatment on IGF-1R expression were further 
explored and it was determined whether changes in expression were associated with 
survival. Paraffin embedded tumor material was collected from pretreatment biopsies 
and from samples obtained at surgical resection of 62 breast cancer patients who were 
treated with neoadjuvant chemotherapy or endocrine therapy. IGF-1R, ER, PR and HER2 
expression were determined immunohistochemically. before and after treatment and 
correlated to overall survival. High membranous IGF-1R expression at diagnosis proved 
to be significantly correlated with ER positivity, low tumor stage (stage I/II) and longer 
overall survival (p < 0.05). After neoadjuvant treatment, membranous IGF-1R expression 
remained the same in 41 (65%) patients, was upregulated in 11 (18%) patients and was 
downregulated in 11 (18%) patients. Most importantly, changes in membranous IGF-1R 
expression were significantly associated with overall survival (log-rank test: p = 0.013, 
multivariate cox-regression: p = 0.086). Mean overall survival time for upregulation, no 
change, and down-regulation in IGF-1R expression was 3.0 ± 0.5 years, 7.3 ± 1.0 years 
and 15.0 ± 1.8 years, respectively. This shows that IGF-1R expression may change during 
neoadjuvant treatment. Also, upregulation of IGF-1R expression after neoadjuvant 
treatment seems to be a poor prognostic factor in breast cancer patients, providing the 
rationale for incorporating anti-IGF-1R drugs in the management of this subcategory of 
patients.
In chapter 7, the development of a new radiotracer to image human epidermal growth 
factor receptor 2 (HER2) expression was described. HER2 is overexpressed in approximately 
20% of all breast carcinomas and is associated with a poor prognosis. Patients with HER2 
expressing breast or gastric tumors benefit from treatment with the anti-HER2 antibody 
trastuzumab. HER2 expression can be measured non-invasively by using radiolabeled 
affibody molecules. Affibody molecules are small (7 kDa) proteins with high targeting 
affinity. Their small size allows rapid extravasation in tumors and rapid clearance from the 
blood, resulting in high-contrast imaging within several hours after injection. The Affibody 
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molecule ZHER2:2395, which is directed against HER2, was radiolabeled with fluorine-18 (
18F), 
based on the complexation of Al18F by NOTA.  18F-ZHER2:2395 had a high affinity for HER2 
(Kd: 6.5 nM) and showed specific accumulation in HER2 overexpressing subcutaneous 
xenografts in mice. Moreover, PET/CT visualized these xenografts with high contrast as 
early as 1 h post injection.  This was the first time Affibody molecules were radiolabeled 
with 18F based on the complexation of Al18F by NOTA. Further research is warranted to 
study whether this tracer can be used to select patients for HER2-targeted therapy in the 
clinical setting.
Chapter 8 and 9 focussed on the combination of bevacizumab (anti-VEGF) and cetuximab 
(anti-EGFR) treatment. Bevacizumab  and cetuximab are currently approved for the 
treatment of certain tumor types. However, when combined, they do not improve the 
survival of colon cancer patients. The effect of bevacizumab and cetuximab on tumor 
growth, EGFR and VEGF expression, microvascular density, perfusion and antibody 
targeting to the tumor was studied in mice with subcutenaous SUM149 tumors. First, mice 
were treated with a single dose of bevacizumab. This resulted in significantly reduced 
tumor targeting of 111In-cetuximab, while EGFR expression remained unaltered and the 
microvascular density in the tumor was reduced. Next, mice were treated with cetuximab. 
This also significantly reduced the targeting of 111In-bevacizumab to these tumors, while 
VEGF expression in the tumors was unaltered. An irrelevant control antibody (111In-
hLL2) also showed significantly reduced tumor targeting after cetuximab pretreatment. 
This suggested that physiological factors of the tumor, such as vascular permeability 
and intratumural interstitial pressure, played a role in the reduction of tumor targeting 
of bevacizumab. In summary, these results can partly explain why the combination 
of bevacizumab and cetuximab does not improve therapeutic efficacy. Moreover, the 
findings emphasize the importance of identifying rational combinations of the targeting 
agents, and the optimal timing and sequencing of these agents. 
Future perspectives
This thesis has described the development of several new radiotracers for PET and SPECT 
which showed promising results in mouse models for breast and colorectal cancer. 
However, none of these tracers have been translated to the clinical setting yet. An imaging 
biomarker in the clinic should fullfil several criteria. First of all, the outcome of the scan 
needs to impact on clinical decision making. For example, it should predict the likelihood 
of an individual patient to respond to a certain therapy and it should have added value as 
compared to existing techniques. Second, the imaging method should be safe. And third, 
the technique needs to be feasible in clinical practice, widely available, and affordable. 
In case of radiolabeled R1507, preclinical studies have shown that tumor uptake can 
predict response to IGF-1R targeted therapy. (1) Moreover, studies with other 111In-labeled 
antibodies have shown the safety and feasibility of using this type of radiotracers in clinical 
practice. (2-4) However, large phase II/III trials with IGF-1R targeting agents failed to show 
a clear benefit which has led to the discontinuation of several studies investigating the 
efficacy of anti-IGF-1R treatment strategies, including R1507.(5-7) Of note, these trials 
were conducted in large, but unselected patient population, while early phase I/II trials 
did show meaningful single-agent responses in specific subgroups of patients. (8-
10) Therefore, it is of crucial importance to develop biomarkers that can identify these 
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patients. SPECT/CT using 111In-R1507 can potentially play a role in patient selection for 
IGF-1R targeted therapy. However, unless clinical programs with these agents will be 
restarted, it is unlikely that 111In-R1507 SPECT/CT will be translated into the clinic in the 
near future.
In case of anti-HER2 affibody molecules, a small clinical study has been performed which 
showed that HER2-overexpressing tumors can be visualized with 111In- and 68Ga-labeled 
Affibody molecules.(11) However, the technique to label Affibody molecules with 18F 
based on the complexation of Al18F by NOTA is relatively new and this tracer has not been 
tested in patients yet. Recently, a paper was published that for the first time applied the 
Al18F technique to label a dimeric RGD peptide for PET imaging of αvβ3 expression of lung 
cancer in patients(12). Therefore, future studies are warranted to explore the feasibility 
of 18F-labeled Affibody molecules in the clinic. One important issue that needs to be 
taken into account is that molecular imaging should also have added value compared 
to existing techniques for patient selection. In case of HER2 targeted therapy, it has 
already been shown that HER2-overexpression as measured by immunohistochemistry or 
FISH is predictive for response to anti-HER2 therapy. Clinical studies with HER2-targeted 
radiotracers have shown the feasibility of using these tracers in patients. However, clinical 
trials still have to prove that PET imaging is predictive for response to HER2-targeted 
therapy, and that it has added value compared to existing techniques. Of note, HER2-
imaging can potentially play an important role in for example those patients with 
(multiple) metastases that cannot be biopsied.
In the last part of this thesis the effect of cetuximab was studied on tumor targeting of 
radiolabeled bevacizumab and vice versa. Here, the aim was not to develop a new tracer 
for patient selection for targeted therapy, but the tracers were used to study how these 
agents interact with each other in order to determine the optimal combination of these 
agents. These studies showed that antibodies can influence each other’s tumor targeting 
and potentially affect each other’s therapeutic efficacy. This can be due to interactions 
between the signaling pathways involved as was shown for VEGF expression, which was 
reduced by cetuximab treatment. Alternatively, it can be a more general mechanism such 
as the destruction of the tumor vasculature by bevacizumab. These studies show that 
radionuclide imaging can aid in identifying rational combinations of the targeting agents, 
and the optimal timing and sequencing of these agents.   
In summary, preclinical studies have shown the potential value of radionuclide imaging 
for patient selection for targeted therapy and to optimize combinations of targeted 
agents. However, translation of preclinical data into the clinic remains a challenge and 
the correlation between imaging and treatment response and survival in patients is yet 
to be determined. Considering the potential role of molecular imaging, especially in drug 
development, it is of importance that future research focuses on bringing promising 
tracers into the clinic, preferably in an early stage of drug development in order to test 
their potential role as a biomarker.
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Samenvatting
De afgelopen jaren zijn er verschillende zogenaamde doelgerichte behandelingen 
(“targeted therapies”) tegen kanker ontwikkeld. Deze zijn onder te verdelen in monoclonale 
antilichamen en tyrosine kinase remmers (TKIs). Antilichamen (antistoffen) zijn gericht 
tegen eiwitstructuren, die zich aan de buitenkant van de tumorcel bevinden. TKIs zijn 
daarentegen gericht tegen eiwitstructuren, die zich intracellulair bevinden. Antilichamen 
en TKIs kunnen de functies van deze eiwitten blokkeren, waardoor de tumorgroei geremd 
wordt. Helaas resulteert slechts een beperkt aantal van deze behandelingen in een 
significante overlevingswinst. Het is daarbij ook nog eens moeilijk om van te voren te 
voorspellen welke patiënten baat zullen hebben bij een behandeling met deze nieuwe 
middelen. Daarom is het van belang om methoden te ontwikkelen om patiënten te 
selecteren, die goed zullen reageren op een bepaalde therapie. Op deze manier wordt de 
kans op een effectieve behandeling gemaximaliseerd en  kan tevens worden voorkomen 
dat patiënten worden behandeld met middelen die voor hun geen nut hebben, terwijl 
ze daar wel de bijwerkingen van ondervinden.  Naast de selectie van de juiste patiënten 
is het van belang om de werkzaamheid te verbeteren door bijvoorbeeld gebruik te 
maken van een combinatie van verschillende geneesmiddelen. Het vinden van de juiste 
combinaties en de optimale timing van twee middelen is echter moeilijk. In dit proefschrift 
beschrijven we de ontwikkeling van nieuwe radiotracers. Een radiotracer is een radioactief 
gelabelde verbinding, die in dit geval gericht is tegen eiwitten, die specifiek voorkomen 
op tumorcellen. Deze verbindingen kunnen gebruikt kunnen worden om patiënten te 
selecteren voor doelgerichte behandelingen en om te bepalen hoe de verschillende 
behandelmethoden elkaar beïnvloeden. 
De eerste hoofdstukken van dit proefschrift beschrijven het onderzoek gericht op de 
insulin-like growth factor 1 receptor (IGF-1R). IGF-1R is aanwezig op de membraan van 
verschillende soorten tumorcellen. Antilichamen gericht tegen deze receptor kunnen 
mogelijk gebruikt worden voor de behandeling van patiënten met kanker. Het doel van 
het onderzoek in hoofdstuk 3 en 4 was om een beeldvormende techniek te ontwikkelen 
waarmee op een niet-invasieve manier, zonder gebruik te maken van bijvoorbeeld 
tumorbiopten, de aanwezigheid van IGF-1R op de celmembraan kan worden gemeten. 
Hiervoor is gebruik gemaakt van het gehumaniseerde monoclonale antilichaam R1507 
en de borstkankercellijn SUM149, die IGF-1R tot expressie brengt. Het antilichaam werd 
radioactief gelabeld met jodium-125 (125I), indium-111 (111In) en zirconium-89 (89Zr). 
Radioactief gelabeld R1507 had een hoge affiniteit voor IGF-1R (Kd = 0.6 nM) en werd 
langzaam geïnternaliseerd door SUM149 cellen. In muizen werden 111In-R1507 en 89Zr-
R1507 efficiënt en specifiek opgenomen in onderhuids geïmplanteerde  SUM149 tumoren. 
De opname van 125I-R1507 in de tumor bleek significant lager. De tumoren konden 
duidelijk gevisualiseerd worden met behulp van een SPECT en PET-scanner. Echter, door 
de langzame klaring van antilichamen uit de circulatie was het contrast tussen de tumor 
en normale organen pas optimaal op latere tijdstippen (≥ 3 dagen na injectie). 
Om de accumulatie van anti-IGF-1R radiotracers in de tumor te versnellen werden kleinere 
antilichaam fragmenten ontwikkeld (F(ab’)2 en Fab fragmenten). In vitro was de affiniteit 
van 111In-F(ab’)2 vergelijkbaar met het intacte 
111In-R1507 antilichaam (IgG), terwijl de 
affiniteit van 111In-Fab significant lager was. In muizen was de absolute tumor opname van 
het 111In-R1507 IgG het hoogst. Door de snellere klaring van de F(ab’)2 fragmenten waren 
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de tumor-bloed ratio’s van 111In-F(ab’)2 echter significant hoger. De opname van
 111In-Fab in 
SUM149 tumoren was niet specifiek voor de IGF-1R. Met behulp van 111In-F(ab’)2 SPECT/CT 
kon de expressie van IGF-1R op de tumoren al na 6 uur zichtbaar gemaakt worden, terwijl 
dit met 111In-R1507 IgG pas na 24 uur mogelijk was. Hieruit werd geconcludeeerd, dat het 
mogelijk is om IGF-1R expressie te visualiseren met behulp van radioactief gelabeld R1507 
IgG of F(ab’)2. Indien het van belang is om snel na injectie van de radiotracer een scan te 
maken kan gebruik gemaakt worden van 111In-F(ab’)2. 
In hoofdstuk 5 en 6 werd de verandering van IGF-1R expressie van borsttumoren 
onderzocht tijdens behandeling met hormonen of chemotherapie. Dit is van belang omdat 
IGF-1R mogelijk betrokken is bij het ontwikkelen van resistentie tegen conventionele 
behandelmethoden. Daarnaast kan de timing van IGF-1R therapie verbeterd worden 
wanneer meer bekend is over de expressie tijdens conventionele therapieën. Muizen met 
onderhuids geïmplanteerde tumoren die een  receptor voor vrouwelijk hormoon – de 
oestrogeen receptor (ER) – tot expressie brachten, werden behandeld met vrouwelijk 
hormoon (estradiol) of met anti-hormonale therapie (tamoxifen). De expressie van IGF-1R 
werd gemeten met immunohistochemie en 111In-R1507 SPECT/CT. Estradiol behandeling 
leidde tot verhoogde expressie van IGF-1R in de tumor en dit was meetbaar met 111In-
R1507 SPECT/CT. Behandeling met tamoxifen leidde tot een verlaagde expressie van IGF-
1R op de tumorcelmembraan. Dit was echter niet meetbaar met 111In-R1507 SPECT/CT. 
Waarschijnlijk is IGF-1R expressie dus niet de enige factor die bepaalt in welke mate R1507 
wordt opgenomen in de tumor. Fysiologische factoren van de tumor zoals de dichtheid 
en permeabiliteit van bloedvaten en de interstitiële vloeistofdruk in de tumor spelen 
mogelijk ook een rol. 
Omdat er weinig informatie bekend is over de verandering van IGF-1R expressie in 
tumoren van patiënten met borstkanker is in hoofdstuk 5 ook de IGF-1R expressie van 
22 humane borsttumoren onderzocht voor en na hormonale therapie. Patiënten in deze 
studie werden gedurende 2 tot 6 weken behandeld met verschillende vormen van anti-
hormonale therapie (tamoxifen, anastrozole of fulvestrant). De expressie van IGF-1R werd 
bepaald met behulp van immunohistochemie op coupes van het biopt ten tijde van 
diagnose (voor start therapie) en op het chirurgische resectie materiaal (na therapie). In 9 
van de 22 tumoren werd een verlaging van de IGF-1R expressie gemeten. Deze resultaten 
laten zien dat hormoontherapie kan leiden tot een verlaagde expressie van IGF-1R en dat 
dit effect al binnen enkele weken kan optreden. Op basis van deze resultaten lijkt het niet 
zinvol om de patiënten waarbij de IGF-1R expressie omlaag gaat te behandelen met anti-
IGF-1R therapie.
In hoofdstuk 6 is nader onderzocht wat de effecten van neoadjuvante hormoontherapie 
en chemotherapie zijn op IGF-1R expressie. Tevens werd bepaald of veranderingen 
in expressie geassocieerd zijn met de overleving van patiënten met borstkanker. Op 
tumor materiaal verkregen voor de start van de behandeling met chemotherapie of 
hormoontherapie (biopt ten tijde van diagnose) en na behandeling (chirurgische resectie 
materiaal) werd de expressie van IGF-1R bepaald met behulp van immunohistochemie. 
Statistische analyses toonden aan dat een hoge IGF-1R expressie ten tijde van diagnose 
gecorreleerd was met ER expressie, laag tumor stadium (I/II) en een lange overleving 
(p < 0.05). Na neoadjuvante therapie was de expressie van IGF-1R onveranderd in 41 
(65%) patiënten, verhoogd in 11 (18%) patiënten en verlaagd in 11 (18%) patiënten. 
Veranderingen in IGF-1R expressie waren significant geassocieerd met overleving: als 
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de expressie van IGF-1R toenam onder invloed van de behandeling, leefden  patiënten 
gemiddeld korter dan als de expressie van IGF-1R gelijk bleef of afnam De gemiddelde 
overleving voor een verhoogde, onveranderde en verlaagde IGF-1R expressie was 
respectievelijk 3 jaar, 7 jaar en 15 jaar. Deze studie laat zien dat in tumoren van patiënten 
de IGF-1R expressie inderdaad kan veranderen tijdens neoadjuvante therapie en dat deze 
verandering de overleving van patiënten met borstkanker kan voorspellen. Daarnaast is 
de patiëntengroep  bij wie de IGF-1R verhoogd is tijdens neoadjuvante therapie mogelijk 
de subpopulatie, die baat kan hebben bij de behandeling met anti-IGF-1R antilichamen. 
Hoofdstuk 7 beschrijft de ontwikkeling van een nieuwe radiotracer om de expressie van 
de human epidermal growth factor 2 (HER2) te visualiseren. HER2 komt tot overexpressie 
op gemiddeld 20% van alle borsttumoren. Patiënten met borstkanker die HER2 tot 
overexpressie brengen, hebben een significant slechtere overleving in vergelijking met 
patiënten met een HER2 negatieve tumor. De overleving van patiënten met een HER2 
positieve tumor kan echter verlengd worden door behandeling met een antilichaam 
gericht tegen de HER2 receptor: trastuzumab. 
Het doel van het onderzoek in hoofdstuk 7 was het ontwikkelen van een nieuwe radiotracer 
om de expressie van HER2 op een niet-invasieve wijze te kunnen bepalen. Hiertoe werden 
anti-HER2 Affibody moleculen (ZHER2:2395), gelabeld met fluor-18 (
18F). Affibody moleculen 
zijn kleine eiwitten (7 kDa) met een zeer hoge affiniteit voor antigenen die tot expressie 
komen op tumorcellen. Ze worden zeer snel (binnen één uur) opgenomen in de tumor. 
Om Affibody moleculen te labelen met 18F werd gebruikt gemaakt van een nieuwe 
labelingstechniek waarbij het aluminiumfluoride (Al18F) gecomplexeerd werd door de 
metaalchelator NOTA.  ZHER2:2395 gelabeld met 
18F  had een hoge affiniteit voor HER2  en 
werd  specifiek opgenomen in tumoren die HER2 tot overexpressie brachten. Met behulp 
van PET/CT konden HER2 positieve tumoren binnen 1 uur na injectie van de radiotracer 
zichtbaar gemaakt worden. Vervolgonderzoek moet uitwijzen of deze radiotracer gebruikt 
kan worden om patiënten te selecteren voor anti-HER2 therapie. 
Hoofdstuk 8 en 9 beschrijven het onderzoek naar de effecten van de combinatie van 
bevacizumab- en cetuximab behandeling. Bevacizumab is een antilichaam gericht 
tegen vascular endothelial growth factor (VEGF), een groeifactor die de vorming van 
nieuwe bloedvaten stimuleert. Behandeling met bevacizumab remt de vorming van 
nieuwe bloedvaten en kan op deze manier de tumorgroei remmen. Cetuximab is een 
antilichaam gericht tegen de epidermal growth factor receptor (EGFR). EGFR is een eiwit 
dat voorkomt op de membraan van verschillende type kankercellen en de celdeling kan 
stimuleren. Cetuximab blokkeert de functie van EGFR waardoor de tumorgroei geremd 
wordt. Bevacizumab en cetuximab worden momenteel bijvoorbeeld gebruikt voor de 
behandeling van patiënten met colorectale tumoren. Ondanks dat de toevoeging van 
deze afzonderlijke middelen aan chemotherapie kan leiden tot een overlevingswinst, 
bleek in eerdere studies dat de combinatie van deze twee therapieën niet effectiever is, 
integendeel zelfs. 
Het doel van hoofdstuk 8 en 9 was om verklaringen te vinden voor het gebrek aan 
effectiviteit van de combinatie therapie. Hiertoe werden muizen met tumoren die 
EGFR en VEGF tot expressie brachten behandeld met bevacizumab, cetuximab en de 
combinatie van beide antilichamen. Vervolgens hebben we onderzocht wat het effect van 
de behandeling was op tumorgroei, EGFR en VEGF expressie, vaatdichtheid en perfusie. 
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Daarnaast hebben we onderzocht of bevacizumab en cetuximab nog steeds in dezelfde 
mate werden opgenomen in de behandelde tumoren ten opzichte van onbehandelde 
tumoren.  Bevacizumab behandeling leidde tot een significant verminderde opname 
van cetuximab in de tumor, terwijl de expressie van EGFR niet veranderde. Echter, de 
vaatdichtheid bleek ook significant verminderd. Dit toont aan dat bevacizumab de 
bloedvatvoorziening van de tumor kan veranderen waardoor andere antilichamen de 
tumor niet meer goed kunnen bereiken en daardoor mogelijk minder effectief zijn. Het 
tweede experiment liet het omgekeerde zien: behandeling met cetuximab kan leiden tot 
een significant verminderde opname van bevacizumab in de tumor. Daarnaast was de 
opname van een irrelevant controle antilichaam in de tumor ook significant verminderd. 
Hieruit werd geconcludeerd, dat cetuximab de opname van bevacizumab in de tumor kan 
verminderen en dat dit waarschijnlijk verklaard kan worden door fysiologische factoren 
van tumoren, zoals vasculaire permeabiliteit en intratumorale interstitiële vloeistofdruk. 
Deze resultaten laten zien dat het identificeren van combinaties van antilichamen om de 
behandeling van patiënten met kanker te verbeteren niet eenvoudig is en dat zorgvuldig 
onderzocht moet worden wat het effect van de ene behandeling is op de effectiviteit van 
andere behandeling.
Toekomstperspectief
In dit proefschrift wordt de ontwikkeling van verschillende radiotracers beschreven, 
waarmee in de toekomst patiënten mogelijk beter geselecteerd kunnen worden voor 
bepaalde targeted therapieën. Echter, tot op heden zijn deze radiotracers nog niet 
onderzocht in klinische studies. Voordat een radiotracer in de kliniek gebruikt kan worden 
moet deze aan verschillende voorwaarden voldoen. Ten eerste moet de uitkomst van de 
scan met de radiotracer relevant zijn voor de klinische besluitvorming.  Bijvoorbeeld een 
positieve scan moet het effect van behandeling kunnen voorspellen. Ook is het belangrijk 
dat de beeldvormende techniek veilig, uitvoerbaar, breed beschikbaar en betaalbaar is. 
Voor veel radiotracers is het voorlopig nog een uitdaging om aan al deze voorwaarden te 
voldoen. Niettemin kunnen deze beeldvormende technieken een belangrijke rol spelen 
in de selectie van de juiste patiënt voor de juiste therapie. Daarom is van belang dat 
nieuwe radiotracers in de kliniek getest worden, bij voorkeur in een vroeg stadium tijdens 
de ontwikkeling van nieuwe therapieën, zodat een mogelijke rol van deze radiotracer op 
een gestructureerde manier bepaald kan worden.
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Dankwoord
Ik kijk met heel veel plezier terug op mijn promotie onderzoek, en dat is op de eerste 
plaats te danken aan de mensen met wie ik heb samengewerkt. Ik vind het dan ook een 
eer dat ik nu de kans krijg om een aantal van jullie hier persoonlijk te noemen.
Allereerst wil ik mijn promotor en co-promotor Prof. dr. Otto Boerman en Prof. dr. Hanneke 
van Laarhoven bedanken. Beste Otto, ik ben erg blij dat je me de kans hebt gegeven om 
mijn promotie onderzoek in jouw groep uit te voeren. Ik ben begonnen als student in het 
‘aquarium’ en ik vond het toen al heel bijzonder dat jouw deur altijd voor iedereen open 
staat. Je bent niet alleen geïnteresseerd in onderzoeksresultaten, maar ook oprecht in alle 
onderzoekers binnen jouw groep. Daardoor heb ik onze samenwerking als heel prettig 
ervaren. Je staat altijd open voor discussie, bent razendsnel met het becommentariseren 
van mijn stukken, en bovenal altijd enthousiast. Ik ben blij dat ik de komende jaren in 
jouw onderzoeksgroep kan blijven werken.
Beste Hanneke, je bent de afgelopen jaren een voorbeeld voor mij geweest. Ik vind het 
knap dat je ondanks het grote aantal onderzoekers die je begeleidt, altijd precies weet 
waar ik mee bezig ben. Je bent altijd erg kritisch ten opzicht van mijn onderzoeksresulten 
en manuscripten, maar dat heb ik juist als prettig ervaren omdat ik er heel veel van heb 
kunnen leren. Je enthousiasme, onverwachte invalshoeken, en sociale karakter maken dat 
ik graag met je samenwerk. 
Prof. dr. Wim Oyen en Prof. dr. Winette van der Graaf, beste Wim en Winette, bedankt voor 
jullie begeleiding tijdens mijn promotie onderzoek. Jullie wisten mijn onderzoek altijd in 
het grotere, klinische, perspectief te zetten. Wim, ik ben blij dat je, je samen met Otto hebt 
ingezet zodat ik de komende jaren onderzoek kan blijven doen op onze afdeling. 
Beste Janneke, als er iemand is die een mooi plekje in dit dankwoord verdient dan ben 
jij het! Daarom sta je 13 juni ook naast mij als paranimf. Je bent ontzettend betrokken 
bij het onderzoek en haalt altijd alles uit de kast voor de beste resultaten. We hebben de 
afgelopen jaren veel van elkaar geleerd. Ik van jouw protocollen en nauwkeurige manier 
van werken, en jij van mij, soms wat meer relaxte houding. Met name hoofdstuk 5 is tot 
stand gekomen door jouw doorzettingsvermogen. En buiten de goede samenwerking 
hebben we ook ontzettend veel plezier gehad in het lab. Ik hoop dat we de komende tijd 
nog veel zullen samenwerken!
Gerben, bedankt voor je hulp met de Zr-89 labelingen en voor het feit dat je altijd kalm 
blijft als de rest gestresst raakt. Lieke, we zijn samen als student begonnen op de Nucleaire 
Geneeskunde en ik ben blij dat je nog steeds mijn collega bent. Ik kijk er naar uit om 
straks jouw artikelen op pubmed te lezen. Danny, bedankt voor je hulp bij de FLT studies, 
daardoor had ik mijn handen vrij om aan mijn artikelen te schrijven. De andere analisten, 
Annemarie, Desiree, Cathelijne, Rian en Hanneke, bedankt dat jullie altijd bereid zijn om 
bij te springen als het nodig is. En bovenal, bedankt voor de gezelligheid!
Daarnaast mijn collega (ex)promovendi: Maarten, Stijn, Tessa, Wietske, Dennis, Willem, 
Gabie, Rafke, Inge, Stefanie, Selen, Wael, Anouk, Susanne, Jonathan, Bianca, Emmy, 
Cheng, Alexander, bedankt voor de mooie tijd, voor alle kantoor praat, vrijdagavonden 
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in de Aesculaaf, filmavonden, mooie congressen, etentjes, slechte grappen, het delen van 
frustraties als het onderzoek tegen zit, en natuurlijk voor jullie hulp bij talloze projecten! 
Sommige van jullie zijn al gepromoveerd, knap gedaan! De rest wil ik veel succes wensen 
met het schrijven van hun proefschrift. Ik kijk uit naar jullie feestjes.
Peter, bedankt voor een mooie samenwerking in hoofdstuk 7 en voor het feit dat je altijd 
bereid bent om mee te denken met mijn onderzoeksprojecten. Floor, Samantha, Mark en 
Maarten, ik ben blij dat jullie me op weg helpen naar mijn bestaan als post-doc. Ik kan nog 
veel van jullie leren.
Mijn fietsmaatjes, Peter, Tessa, Stijn, Gerben en Wietske, ik ben blij dat jullie begrijpen 
dat er op een zonnige lente dag niet altijd gewerkt moet worden maar dat we soms ook 
de heuvels rondom Nijmegen moeten verkennen. Of zelfs verderop, in de Ardennen, 
Sauerland en Vancouver. Hopelijk gaan we dat in de toekomst nog vaak doen!
Bianca, Henk, Iris, Kitty en Nicole, bedankt voor jullie hulp op het PRIME. Jullie zijn een kei 
in jullie vak en zorgen ervoor dat wij zoveel mogelijk resultaten uit onze dierexperimenten 
kunnen halen. Jullie flexibiliteit en inzet is echt ongelovelijk. En buiten dat, zijn jullie 
hartstikke leuk om mee samen te werken en dat maakt dat ik altijd met plezier naar PRIME 
toe ga om mijn experimenten uit te voeren. Bedankt! 
Collega’s van het secretariaat Nucleaire Geneeskunde en Medische Oncologie, in het 
bijzonder Marie-Louise en Jacqueline, bedankt voor jullie hulp. 
Van de afdeling Experimentele Urologie wil ik Kees, Mirjam, Jeannette, Dorien, Maureen 
en Tilly  bedanken voor de gastvrijheid op de celkweek en het immunolab, en natuurlijk 
voor jullie advies en de gezelligheid. 
Emmy, Melissa en Yvonne, het “IGF-1R clubje”, bedankt voor de fijne samenwerking. 
De afdeling Nucleaire Geneeskunde bestaat niet alleen uit research, en ik wil dan ook alle 
laboranten, medewerkers van het hotlab, artsen en stafleden bedenken voor de mooie 
tijd die ik heb gehad tijdens mijn promotie onderzoek. Ook alle medewerkers van de 
afdeling Medische Oncologie, bedankt voor jullie input vanuit het klinisch perspectief 
tijdens de mijn onderzoekspresentaties. 
Prof. dr. Fred Sweep en Anneke Geurts-Moespot, bedankt voor jullie hulp bij de VEGF 
en cetuximab bepalingen uit hoofdstuk 9 en voor jullie input bij het schrijven van het 
manuscript. 
Tijdens mijn onderzoek heb ik veel hulp gehad van studenten: Erwin, Marc, Wilbert, 
Sami en Mallory, bedankt! Wilbert, je F(ab’)2 fragmenten hebben geleidt tot twee mooie 
publicaties. Bovenal, was de periode dat jij hier stage liep erg gezellig!  Mallory, ik ken 
weinig studenten die zo betrokken zijn bij hun onderzoek als jij, bedankt voor de grote 
hoeveelheid werk die je hebt verzet voor hoofdstuk 9. Hopelijk leidt dit binnenkort tot 
een mooie publicatie.
Sunny moon: Herold, Peter, Monique, Marius, Joost en Astrid, bedankt dat ik deel mocht zijn 
van jullie Alpe d’HuZes team. Jullie hebben me laten zien waarom wij als wetenschappers 
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elke dag het lab in duiken. Onderzoek doen naar kanker is ontzettend belangrijk, en voor 
mij is 7 juni 2012 is een dag om nooit vergeten!
Mijn studievriendinnen, Monica, Willemijn en Wandana, jullie weten allebei als geen ander 
hoe het is om te promoveren. Ik vond het altijd super fijn om ervaringen met jullie uit te 
wisselen. Wie weet volgen er nog mooie samenwerkingen in de toekomst. 
Anke en Danielle, ik ben blij dat we na ons wedstrijd seizoen nog zo goed contact hebben. 
Bedankt voor de leuke fietstochten en etentjes, waarbij jullie altijd naar verhalen over mijn 
onderzoek moesten luisteren. 
Anne, Eva, en Mieke, 10 jaar geleden hebben we elkaar in de roeiboot leren kennen. 
Roeien doen we niet meer samen, maar gelukkig gaan we nog regelmatig op ‘Pantarei 
date’. Eva, bedankt voor alle avonden in de kroeg waar je me vroeg “wanneer is je boekje 
nou eindelijk eens af, goed is goed genoeg”. Bij deze! Ik kijk uit naar de komende avonden 
met speciaal biertjes in de kroeg.  
Lieve Martijn, ik heb ontzettend veel bewondering voor wat jij bereikt hebt de afgelopen 
jaren. We hebben wat meegemaakt samen en ik ben blij dat het nu zo goed met je gaat. 
Ik ben heel trots dat jij mijn paranimf wil zijn! Lieve Linda, de tijd dat je mijn kleine zusje 
was is wel voorbij. Ik ben blij dat je in Nijmegen woont, trots dat je, je studie zo goed hebt 
afgerond en ik wil je heel veel succes wensen met je eigen promotie onderzoek. Over een 
paar jaar staan we er weer, maar dan is het jouw feestje. 
Lieve pap en mam, zonder jullie had ik hier niet gestaan! Ondanks dat jullie zelf niet 
gestudeerd hebben, hebben jullie mij van kinds af aan gemotiveerd om goed mijn best te 
doen op school zodat ik naar de universiteit kon gaan. Ik weet dat het voor jullie niet altijd 
makkelijk was om twee studerende dochters te hebben, en dat jullie de afgelopen jaren 
onze opleiding voorop hebben gesteld. Daarvoor ben ik jullie heel erg dankbaar. 
Henk en Annie, Joost, Annemiek, Alieke en Jolijn, ik ben blij met zo’n lieve schoonfamilie! 
Fijn dat jullie er vandaag bij zijn. 
Lieve Vincent, je weet dat ik het cliché vind om je hier te bedanken. Maar als geen ander 
begrijp je dat het onderzoek voor mij heel belangrijk is en je klaagt nooit wanneer ik weer 
eens op zaterdagochtend een bezoekje aan het lab breng. Je staat altijd voor me klaar, als 
er iets te vieren is, maar ook als dingen tegen zitten. Ik ben heel blij met wat we samen in 
Nijmegen hebben opgebouwd en ik wil hier graag met jou blijven. 
